Effects of anti-osteoporosis drugs on human mast cells. by Lee, Hoi Ying. & Chinese University of Hong Kong Graduate School. Division of Pharmacology.
Effects of Anti-osteoporosis Drugs on Human Mast Cells 
LEE，Hoi Ying 
AThesis Submitted in Partial Fulfillment 




The Chinese University ofHong Kong 
September 2010 
(•、 -u 
, ^ ^ ^ ^ i X ^ ^ ^ . 
/ v ^ > �兵給 ,圖 ^ ^ ^ 
/ / / ~A,A\ s ( 2 7 AUb 201Z m m ] - - J 
i^5>v^L ;^V\Ys\sTEW^NjS J^^  ^ ^ ^ ^ 
Thesis/ Assessment Committee 
Professor Lam Fu Yuen Francis (Chair) 
Professor Lau Hang Yung Alaster (Thesis Supervisor) 
Professor Ko Wing Hung (Committee Member) 
Professor Lung Kin Yum Mary Agnes (External Examiner) 
"； (. 
Abstract 
Mast cells are granulated ceUs that exist in different parts of the body. Mast cells are 
the major effector in immune system, especially in the response of inflammation 
through the release of mediators after activation. Accumulation and activation ofmast 
cells were observed at sites of bone remodeling. Clinical observation also showed 
accumulation of mast cells in patients with osteoporosis, which is characterized by 
imbalance bone remodeling. The regulation of bone remodeling is believed to be 
mediated through different local factors like cytokines and histamine which can be 
produced by activated mast cells. In vitro studies demonstrated that histamine could 
stimulate osteoclasts mediated bone resorption. Different studies have showed that 
mast cells may be involved in the development of osteoporosis. 
In our study, we used human primary mast cells cultured from buffy coat and mast 
cell line LAD2 cells as models of human mast cells. We found that the female sex 
steroids, estradiol, did not induce basal histamine release from human mast cells. The 
selective estrogen receptor modulators (SERMs), raloxifene and tamoxifen induced 
basal histamine release only from LAD2 cells at 10"¾. Histamine release from 
anti-IgE activated HCMC was inhibited only after 30 minutes treatment with 10'^ M 
estradiol but similar effect was not observed after treatment with SERMs. Activation 
ofhuman mast cells by compound 48/80 was not affected by treatment with estradiol 
and SERMs. The release ofTNF-a from anti-IgE activated mast cells was potentiated 
by estradiol, but both SERMs exerted an opposite inhibiting effect. High 
concentration of SERMs however enhanced TNF-a release from substance P 
activated mast cells. The gene expression of estrogen receptors and various bone 
i 
remodeling molecules were not affected by treatment with 10"^ M estradiol. 
Our studies also found that the anti-osteoporosis Chinese herbal formulation ELP and 
its herbal constituents, Herba Epimedii (HEP), Fructus Ligustri Lucidi (FLL) and 
Fructus Psoraleae (FP) inhibited histamine release from compound 48/80 activated 
human mast cells in a dose-dependent manner. Further solvent extraction ofHEP and 
FLL showed that all fractions demonstrated dose-dependent suppression on basic 
secretagogues mediated mast cell degranulation, which suggested that the active 
compounds mediated the inhibition might be contained in different fractions. TNF-a 
released from substance P activated human mast cells was prominently suppressed by 
increasing concentration of ELP, and its herbal constituents. ELP, HEP and FLL 
produced gradual reduction of calcium influx in activated mast cells, and only 
500p,g/ml HEP could produced a significant reduction (p<0.05). Our results suggested 
that the anti-osteoporosis Chinese herbal medicine may regulate pathways involved 
with the activation of mast cells by basic secretagogues. 
Based on our study, estradiol and SERMs did not produce a prominently effect on 
regulation of mast cell activity. With the proven effect of estradiol and SERMs on 
treatment of osteoporosis, it may suggest the clinical actions of these drugs may not 
involve mast cell activity. The anti-osteoporosis Chinese herbal medicines effectively 
regulated mast cell activity with a possible interaction with basic secretagogues 
activation pathway. The interaction between mast cells and anti-osteoporosis drug 
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- Chapter 1. Introduction 
1 Introduction 
1.1 Human mast cells and its activation 
Mast cells are a member of the immune system. They are originated from CD34+ 
pluripotent stem cells in the bone marrow which circulate in the peripheral blood as 
precursors until they are stimulated by stem cell factor (SCF) and other local factors 
to tum into mature mast cells. Mast cells are granulated cells which contain a wide 
variety of mediators stored inside the granules. Some of them are synthesized upon 
activation. These mediators include preformed mediators like histamine, serotonin, 
heparin and protease; newly synthesized mediators such as eicosanoids, chemokines 
and cytokines. The release of mediators can trigger different responses in the body 
and serve as amplifying signals to induce more actions locally. The functions of 
pro-inflammatory mediators of mast cell are summarized in Table 1.1 (Brown et al., 
2008; Metcalfe, 2008; Moller et al., 1991; Pundir et aL). 
The classical pathway of mast cell activation is through the crosslinking of the high 
affinity IgE receptors (FcsRI). Dendritic cells and other antigen presenting cells 
phagocytosed allergen and presented fragment of allergen to interact with naive T 
cells. Naive T cells acquire the characteristics of T helper 2 (Th2) cells in the 
presence of cytokines. Th2 cells then stimulate the immunoglobulin class-switch 
recombination o f B cells and IgE antibody is largely produced. The IgE antibody then 
binds to FceRI on mast cells. When the allergen invades the body again, it binds to 
and crosslinks IgE molecules on mast cells, leading to activation of the cells (Galli et 
al.，2008b). Subsequently, granules in the cytoplasm are exocytosed to release stored 
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mediators to the extracellular region. The induction of cascades of intracellular 
signaling events involving the recruitment ofLyn and Syk tyrosine kinases enhances 
the gene expressions and the production of de novo synthesized cytokines and 
chemokines (Figure 1.1). It is a typical observation of immune response in 
inflammatory and allergic reactions (Galli et aL, 2008a; Gilfillan et al., 2006). 
Mast cells can also be activated in an FceRI-independent manner (Figure 1.1). 
Reports have proved that basic secretagogues bind directly to GTP-binding proteins 
(G proteins) and trigger the degranulation of mast cells (Aridor et al., 1990; MousH et 
al., 1990). Basic secretagogues are a large set ofcationic endogenous and exogenous 
peptides and drugs, such as substance P, anaphylatoxin C3a and compound 48/80. It 
is showed that exposure of cells to pertussis toxin (PTX) prior to the stimulation of 
compound 48/80 or substance P could reduce the histamine release (Aridor et al., 
1990). The interaction of basic secretagogues with PTX-sensitive Gi2 and Gi3 
proteins is the first step to initiate the activation of mast cells. The dissociated Py 
subunit from Gi protein triggers the signal transduction of two downstream signaling 
pathways. In one hand it stimulates phospholipase Cp (PLCP) to elicit exocytosis of 
stored mediators; on the other hand, it activates phosphatidylinositol 3-kinase (PI3K) 
and induction ofsequential activatioa ofarachidonic acid metaboHsm and the release 
ofnewly synthesized lipid mediators (Ferry et aL, 2002; Ferry et al., 2001). 
1.2 Role of mast cells in inflammation 
Mast cell is widely distributed in different tissues and it is one ofthe innate immune 
cells to deal with the invasion of antigens. The involvement of mast cells in innate 
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imrmmity is based on the activation of mast cells through Ig-E-dependent or 
IgE-independent pathways and the subsequent release of mediators, which in tum 
induce the inflammatory responses. The mediators released from activated mast cells 
are always termed as "pro-inflammatory" because they can induce diverse features of 
inflammation. These mediators are major effectors to induce systemic effects in the 
inflamed tissues. 
Histamine is a potent vasodilator that increases vascular cell permeability via the 
activation of Hi histamine receptor on endothelial cells. The production of nitric 
oxide in tum stimulates guanylate cyclase which increases generation of cyclic 
guanosine monophosphate (cGMP) in the endothelial cells (Beyak et aI., 1995; Izumi 
et al., 1995). The increasing level of cGMP reduces the intracellular calcium 
concentration and leads to smooth muscles relaxation. It results in fluid infiltration 
and allows more immune cells to reach the site of inflammation and contributes to the 
swelling and edema of tissues (Simons, 2003). 
Lipid mediators are newly synthesized from the metabolism of arachidonic acid 
released from membrane phospholipids by phospholipase A in the activated mast cells. 
Leukotrienes are synthesized via thq action of 5-lipoxygenase while prostaglandins 
are synthesized by the action of cyclooxygenase. LTB4 and LTC4, PGD2 and PGE2 are 
the major eicosanoids produced in mast cells (Metcalfe, 2008). Many systemic effects 
in inflammation are the actions of eicosanoids produced by mast cells. 
Cysteinyl-leukotrienes (LTC4, LTD4 and LTE4) work similarly as histamine, which is 
also a vasodilator and can increase the rate of plasma extravasation with a potency 
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1000 time of that of histamine. LTB4 is responsible for initiating leukocytes 
recruitment and assists the immune cells to adhere to endothelium of venules, and 
hence transits to the late-phase of inflammation (Hedqvist et al., 2000). In vivo 
experiment found that histamine can synergise the inflammatory action of LTB4. 
Histamine up-regulates the sensitivity of endothelial cells to cysteinyl-LTs and 
promotes LTB4-induced leukocytes adhesion via a blood flow-dependent increscent in 
leukocyte rolling (Raud et al., 1994). Nevertheless, leukotrienes directly induce 
bronchial smooth muscle contraction, which is the major symptom of airway 
inflammation (Ogawa et al.，2006). 
Prostaglandin production from activated mast cells is another indication of 
inflammation. Direct PGD2 inhalation induces bronchoconstriction with 10-fold 
potency ofthat ofhistamine. At the same time, it can also enhance the responsiveness 
ofbronchial smooth muscle on the action ofhistamine (Boyce, 2005). Apart from the 
action on vasodilatation to increase the inflammatory response, PGD2 can also 
enhance leukocytes extravasation by different chemotactic mediators. PGD2 acts 
through DP receptor and chemoattractant receptor-homologous molecules expressed 
on T helper-2 cells (CRTH2). Effect of vasodilatation and the relaxation of smooth 
muscles are mediated through the activation of DP receptors, with the prove of 
DP-specific agonists which induce the mentioned actions (Wright et al., 1998). 
Certain immune cells express CRTH2, including Th2 cells, eosinophils and basophils. 
Upon activation of CRTH2, PGD2 induces calcium mobilization and chemotaxis in 
Th2 cells. The activation ofCRTH2 also mediates the PGD2-dependent cell migration 
ofeosinophils and basophils (Hirai et al.’ 2001). The inflammatory action induced by 
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PGD2 is mediated first via the action ofDP receptors to induce vasodilatation locally 
and enhance leukocyte extravasation, then the chemotactic migration of various 
inflammatory cells via the CRTH2 with the help of chemokines (Sallusto et al., 
1998). 
Production ofcytokines and chemokines from activated mast cells contributes to the 
progression oflate-phase response in inflammation. Various cytokines, growth factors 
and chemokines are produced from mast cells right after activation or up till few 
hours afterwards, with differential functions ofthe secreted mediators (Bradding et al., 
1996). Small amount of stored tumor necrosis factor-a (TNF-a) is released after 
activation while a lot more is synthesized after activation. It is a pro-inflammatory 
cytokine through direct induction of bronchial vasoconstriction and increased 
production of other cytokines indirectly (Wagner, 2000). Mast cell-mediated TNF-a 
production is important in the proliferation ofT-cell lineage through direct interaction 
(Nakae et aL, 2005). IL-3, IL-5 and chemokines promote the recruitment of innate 
immune cells (e.g. neutrophils, basophils and eosinophils) and the activation ofthem, 
those immune cells take actions to eliminate invading antigen (Galli et cd., 2008b). 
The activities oflate-phase reaction of inflammation are contributed by the actions of 
resident mast cells and the circulating leukocytes that recruited to the site of 
inflammation. 
1.3 Mast cell heterogeneity 
Mast cells are classified into two subpopulations in rodent based on their 
phenotypical, biochemical, functional properties. The initial identification of mast 
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cells in rodents was based on fDcation property and histochemical stains. Since they 
also located in different tissue, their nomenclature is based on their location. 
Connective tissue mast cells (CTMCs) and mucosal mast cells (MMCs) show 
opposite response in formalin fixation; CTMCs are sensitive to formalin and MMCs 
are not. Their histochemical differences are associated with majority of heparin 
proteoglycans for CTMCs but limited amount ofheparin are found in MMCs. MMCs 
contain chondroitin sulphate proteoglycans which have less negative charges to 
heparin which results in differential staining properties of two subpopulation of 
rodent mast cells. CTMCs and MMCs show different mediator contents and cellular 
responses. CTMCs contain more histamine and produce more PGD2. MMCs are low 
in histamine content and generate cysteinyl-LTs as the major Upid metabolites 
(Gurish et aL, 2001). Both CTMCs and MMCs can be activated through 
IgE-dependent mechanisms for releasing mediators. However, the activation of mast 
cell by basic secretagogues is varied in different subtypes. CTMCs can be 
successfully activated by compound 48/80 but similar observation was not seen in 
MMCs. It was found that rodent MMCs and CTMCs could be activated by calcium 
ionophore and substance P (Irani et al., 1989). 
Human mast cells are also classified into subpopulations based on differences in 
neutral protease content. MCci cells contain tryptase and chymase; they are 
predominantly located in the skin and intestinal submucosa. MCi cells only contain 
tryptase and predominant in the lung alveoli, nasal epithelial mucosa and intestinal 
muscosa (Lrani et al., 1989). However, both types of mast cells can be found in most 
tissues and thus increases the complexity in determining the difference ofthem based 
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on the location alone. Reviews have summarized different responses ofactivated mast 
cells based on the variation in secretagogues and anti-allergic agents (Forsythe et al., 
2000; Irani et al., 1989). Mast cells isolated from skin were responsive to stimulation 
of immunological and wide range of non-conventional stimulants such as calcium 
ionophore A23187, polycationic molecules compound 48/80 and the neuropeptide 
substance R However, apart from the positive result from anti-IgE and A23187 
stimulated activation, lung mast cells are unresponsive towards the polycationic 
stimulants. MCxc and MCi are found to respond differently towards the treatment of 
common inhibitors ofdegranulation. For example, sodium cromoglycate (SCG) could 
significantly inhibition anti-IgE mediated histamine and PGD2 release from human 
lung mast cell (MGr cells as the majority) while skin mast cells (MCic cells as the 
predominant type) were unresponsive to SCG (Okayama et al., 1992). 
1.4 Interaction of bone and immune system 
Bone and immune system are two important systems in human body which appear to 
be individual system without connection. However, studies of the pathophysiology of 
some bone-associated diseases like rheumatoid arthritis (RA) have revealed the 
interplay ofbone and immune system. The cytokine IL-17 produced by T-helper cells 
has been demonstrated to stimulate.the production of receptor activator of nuclear 
factor-KB ligand (RANKL) from synovial fibroblasts and osteoblasts, which in tum 
promotes the osteoclastogenesis in the synovium. IL-17 also promotes the production 
ofother inflammatory cytokines like IL-6, IL-1 and TNF from synovial macrophages. 
These cytokines increase additional production of RANKL and induce more 
osteoclastogenesis that happen in inflamed synovium (Takayanagi, 2009). 
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Apart from the cross-taLc of bone and immune system observed through the role of 
IL-17 in the development ofRA, there are more interactions between the two systems. 
Osteoclasts share the common origin with the myeloid precursor cells that give rise to 
macrophages and myeloid dendritic cells. Osteoblasts are the regulators of 
hematopoietic stem cell (HSC) niche from which all blood and immune cells derive. 
The bone marrow is considered as the storage organ of lymphoid cells. Last but not 
the least, various cytokines, chemokines and growth factors can regulate fiinctions 
and activities ofboth immunity and bone remodeling (Lee et al.，2008; Lorenzo et aL, 
2008). The interaction ofthese two complex systems provides a clue for explaining 
the pathophysiology ofvarious kinds ofbone diseases which are also regulated by the 
action ofcytokines and other mediators produced in immune response. 
1.5 Introduction of bone system 
Bone is a living connective tissue which is always changing in size and shape. It 
forms the framework ofhuman in keeping the body in an upright posture and gives 
support and protection for body structures. It is also the reservoir of calcium and 
phosphorus in the body in the form of hydroxapatite ([Ca3(PO4)2]Ca(OH)2). The 
skeleton is also the extracellular storage of ions like magnesium, sodium, citrate and 
bicarbonate in the body. The bone system can be divided into two major systems: the 
- long bones such as femur and the flat bones like the skull. Long bones are responsible 
for lifting up the muscles in the correct position and aid the locomotion while the flat 
bones are the protecting shell ofimportant organs like brain, heart and lungs (Datta et 
al., 2008; Raisz，1999a). 
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Bones are formed and developed during fetal state till the end of adolescence by a 
modeling process. The mineralized tissues are deposited to lengthen and thicken the 
bones. It promotes the enlargement of body shape and allows the expansion of 
different organs during growth. Bone modeling is soon dominated by a remodeling 
process after the end ofsecond decade oflife. Bone remodeling occurs throughout the 
life and predominant in adulthood. Contrasting to the modeling process, bone 
remodeling is a replacement ofbone tissue in the same site. After the bone is resorbed, 
bone cells are then laid on same site to begin the formation ofmineralized bone. Bone 
turnover keeps the serum calcium and phosphorus in a homeostatic level in response 
to the intake ofminerals from daily diets (Broadus, 1996; Kanis，1994). 
1.6 Bone remodeUng 
The health ofbone is carefully regulated by well-balanced bone turnover. About 10% 
oftotal bone is being replaced annually in adult. Bone remodeling happens in specific 
unit called "basic multi-cellular unit" (BMU). They are the dynamic structure located 
on cortical and also trabecular bones. The resorption is initiated by signals that lead to 
degradation of unmineralized osteoid by inactive osteoblasts that line on top of the 
mineralized bone surface (Figure 1.2). Inactive osteoblasts by then increase the 
expressions of RANKL and macrophage colony-stimulating factor (M-CSF). The 
.expression ofdecoy receptor ofRANK, osteoprotegerin (OPG) by osteoblasts is also 
decreased in order to promote the interaction between RANK on osteoclasts and 
RANKL on osteoblasts. 
When osteoclasts are recruited to the surface ofbone, osteoblasts are retracted from 
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bone surface. Osteoclasts can then gain access to the mineralized bone to begin 
resorption process. The multinuclear osteoclasts attach to the bone matrix through 
vitronection receptors (avp3) and develop a ruffled border. The hydroxyapatite 
crystals are dissolved with the help of proton pumps and chloride channels in the 
ruffle membrane. The matrix is further degraded by the proteolytic enzyme cathepsin 
K. Subsequent to the cleaning up of matrix, osteoblast precursor cells will be 
recruited to the resorption lacunae and differentiated into active osteoblasts. They 
facilitate the laying down oforganic matrix and the following deposition ofminerals 
onto the lacunae. After filling up the lacunae with minerals and a line ofosteoblasts, 
bone has completed a cycle ofbone remodeling (Everts et al, 2002; Lemer, 2006). 
1.7 Regulation of bone remodeling 
It is now clear that RANKL/RANK/OPG system based on the interaction between 
osteoclasts and osteoblasts is the major regulatory system in bone remodeling 
(Hasegawa et al., 2002; Haynes et al., 2001; Hofbauer et al., 2004). M-CSF and 
RANKL produced and expressed by osteoblasts are essential for the development, 
activation and survival of osteoclasts. Osteoblasts also secrete OPG, the decoy 
soluble receptor of RANKL, to counteract the differentiation and activation of 
osteoclasts. There are different reports demonstrated that over-expression ofOPG or 
.depletion of RANKL can induce osteopetrosis in mice and patients with 
postmenopausal osteoporosis (Khosla, 2001; Mizuno et aL, 1998; Raisz, 2005). 
This regulatory system is influenced by mechanical stress, systemic hormones and 
local factors to keep the balance of RANKL and OPG in the correct rate of bone 
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remodeling. Osteocytes are postulated to convert mechanical stimuli to metabolic 
signal and therefore initiate bone turnover. It is found that increased mechanical strain 
can inhibit RANKL and up-regulate OPG production from osteoblasts. Hence 
osteoclastogenesis is suppressed and bone mass is increased through the stimulation 
ofosteocytes (Hadjidakis et aL, 2006; Robling et al., 2006). 
Calcium-regulating hormones maintain calcium homeostasis through modulation of 
bone turnover. Parathyroid hormone (PTH) and 1,25-dihydroxy-vitamin D can 
stimulate bone resorption but reverse the effect on bone at high concentration. 
Reviews also mentioned other systemic hormones in regulating bone turnover, like 
growth hormone, thyroid hormone and glucocorticoids (GCs). Estrogen also plays a 
crucial role in controlling the activities and development of different bone cells. This 
sex hormone may inhibit the production of local factors such as interleukins (IL)-1, 
IL-6 and PGE2which promote bone resorption (Li et al., 1998; Raisz，1999a; Rubin 
et al., 2002). 
The local factors including cytokines and growth factors that can either act as 
stimulator or inhibitor in the regulation of bone remodeling. Insulin growth factor-I 
(IGF-I) and transforming growth factor-p (TGF-P) from extracellular matrix can 
stimulate the recruitment and activation of osteoblasts in the remodeling site. They 
are termed as "coupling factor" to link bone resorption and bone formation. Members 
ofILs, TNF and their receptors are indentified as regulator of remodeling. IL-1, 
IL-6 and TNF-a directly act on osteoclasts to regulate osteoclastogenesis and 
modulate the production of RANKL. These cytokines work by interacting with 
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osteoclasts and osteoblasts in regulating their recruitment, differentiation, activation 
and activity differently (Lorenzo et al., 2008; Manolagas et aL, 1995; Raisz, 1999a; 
Sanchez et al, 2009). 
1.8 Introduction of Osteoporosis 
Osteoporosis is a common degenerative disease in many developed countries after the 
improvement of life expectancy. According to the statistic of World Health 
Organization, osteoporosis is a disease with increasing concerns in the coming decade. 
It is the major cause ofhospitalization of elderly in western society. Bone fractures 
are common symptoms of osteoporosis, which always occur in long bones, hip and 
spinal cord. The fracture is akeady the alerting signal ofosteoporosis since the bone 
density has akeady lost to a dangerous level. In many cases, patients lose mobility 
permanently after series of bone fractures. The extent of osteoporosis is defmed by 
the bone mineral density (BMD) ofthe patient. Patients with a BMD lies 2..5 standard 
deviation or more below that ofaverage young healthy women (i.e. T-scores< -2.5 SD) 
are diagnosed as having osteoporosis. Currently, dual X-ray absorptiometry (DXA) is 
a validation technology to measure BMD in patients (WHO, 2004). 
Osteoporosis is characterized by a reduction of bone mass in skeleton and bone 
strength, associated with the increased fragility and risk of fractures. The loss of 
mineral from bone matrix and hence the deterioration of micro-architecture in bone 
increase the fragility of the bones. The fractures commonly occur in long bones like 
forearm, vertebra body and femoral neck. These are the bones that always suffered 
from strong mechanical stress after falling. The loss ofbone mass is contributed by (i) 
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failure to reach an optimal peak bone mass in young adulthood, (ii) excessive 
resorption of bone after peak mass being achieved, or (iii) an impaired bone 
formation response during remodeHng. These factors can work alone or contribute 
together to increase the risk of fractures (Francis et al., 1998; Raisz, 2005; Raisz, 
1999a). 
1.9 Pathophysiology of osteoporosis 
The most common types of osteoporosis are age-related osteoporosis in both gender 
and postmenopausal osteoporosis in women. Bone loss due to aging is a normal 
process which begins from 65-year-old in men and from 50 in women (Rizzoli et al., 
1999). The gradual loss of bone is contributed by the age-related mechanism like 
cumulative effects of calcium and vitamin deficiency. It stimulates resorption process 
through the action of parathyroid hormone in order to induce calcium ion release 
from bone. Also, the amount ofbone formed in each remodeling cycle decrease with 
age since the supply of osteoblasts is reduced. All age-related factors cause an 
accumulation of micro-damages of bone but in contrast, less mineralized bone is 
formed. It leads to reduction in the stiffiiess ofbone. The strength of bone is reduced 
and pores appear inside the bone and hence the micro-architecture is distorted 
(Manolagas et al, 1995; Seeman, 2003). 
Women experienced an additional bone loss after menopause. The withdrawal of 
estrogen influences the activity of bone remodeHng by interacting directly with 
different bone cells or indirectly to regulate the production of local factors. Estrogen 
promotes the differentiation and activation of osteoblast progenitors to initiate the 
resorption process. The sex hormone maintains the production of OPG to tightly 
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regulate the RANKL/OPG ratio so that the resorption and formation of bone is 
balanced. The reduction of estrogen after menopause induces a decrease of OPG 
secretion by osteoblasts (Hofbauer et al., 1999). With the increase ratio of 
RANKL/OPG in BMU, more osteoclastogenesis is initiated (Marini et al., 2008). 
Subsequently, more mature osteoclasts are recruited to the resorption sites. Estrogen 
deficiency leads to increasing survival of osteoclasts but at the same time promotes 
apoptosis of osteoblasts. Therefore, the rate of bone formation cannot compensate 
that ofresorption as less osteoblast is available for the completion ofbone remodeUng 
(Krum et al，2008; Lemer, 2006; Robinson et al，1997). 
Estrogen is a key regulator in the production of various cytokines and growth factors 
that modulate bone remodeling. Estrogen is the suppressor in the production ofIL- l , 
IL-6 and TNF-a from osteoblasts. These cytokines can act as autocrine to promote the 
production ofM-CSF and expression ofRANKL from osteoblasts. At the same time, 
they stimulate the activation and differentiation of osteoclasts (Atkins et al, 2000). 
Furthermore, there are various reports demonstrated that the elevation of these 
bone-resorbing cytokine production in female after menopause or ovariectomized 
mice (Bismar et al., 1995; Lerner, 2006; Masiukiewicz et al.’ 2000; Passeri et al, 
1993). They suggested that estrogen deficiency is a major contributor in inducing the 
imbalanced bone remodeling in menopausal osteoporosis. 
1.10 Pharmacological interventions in osteoporosis 
It is clear that osteoporosis is a disease with imbalanced bone remodeling with high 
bone turnover rate. The excessive bone loss is due to high bone resorption rate or low 
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bone formation rate or the combination of both. Therefore, the treatment of 
osteoporosis are targeting on Hmiting the resorption (antiresorptive therapy) or 
promoting the formation (anabolic therapy). 
The bone density is maintained if less bone resorption occurs. The antiresorptive 
treatment is focus on reducing bone resorption before the bone loses large amount of 
bone matrix. The traditional hormone replacement therapy (HRT) can improve the 
bone density and reduce the risk of fractures. However, a report from the Women's 
Health Initiative (WHI) trial revealed that HRT can also increase the risk of breast 
cancer, venous thromboembolism and cardiovascular disease. HRT is no longer 
recommended as treatment of osteoporosis (Cauley et aL, 2003). Since the 
unfavorable impact ofHRT outweighs its skeletal benefit, compound that mimic the 
effect ofestrogen is considered. Selective estrogen-receptor modulators (SERMs) act 
as agonists of estrogen-receptors in some tissues but as antagonists in others. 
Raloxifene is currently the only SERMs approved by FDA in the United States for the 
treatment of postmenopausal osteoporosis. It acts as estrogen-receptor agonist on 
bone and receptor antagonist on breast. Raloxifene increases the BMD and reduces 
bone turnover markers; furthermore, it reduces the risk ofvertebral fractures for over 
30%. Large-scale clinical studies haye demonstrated that raloxifene does not induce 
adverse effect similar to the use ofestrogen in HRT; therefore, raloxifene is approved 
as a prevention and treatment of postmenopausal osteoporosis (Borges et al., 2006; 
Kanis et al., 2008; Lewiecki, 2009). 
Biophosphonates are the stable analogues ofpyrophosphate which have high afiTmity 
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to hydroxapatite in bone. They accumulate in bone matrix with a long halflife. They 
workthrough inhibiting the function ofosteoclast and inducing apoptosis ofthe bone 
resorbing cells. Studies have found that biophosphonates can effectively increase 
BMD and reduce bone turnover markers. Both vertebral and non-vertebral fractures 
are prevented by intravenous or orally administrated biophosphonates therapy in 
many clinical studies. The promising effect and long period of efficacy make 
biophosphonates the most potent antiresorptive agents available worldwide (Borges et 
al., 2006; Kanis et al., 2008; Lewiecki, 2009; Suzuki et al., 2008). 
In order to improve the specificity of action ofanti-resorptive agent on targeting bone 
cells, new intervention is being investigated. Cathepsin K inhibitor and monoclonal 
RANKL antibodies are produced to focus on specific steps in bone resorption so that 
bone formation is retained and affected in the least extent. Cathepsin K is selectively 
expressed by osteoclasts and it is a cystein protease which degrades bone matrix 
protein such as collagen. Stoch et aL (2009) have revealed a promising effect of 
cathepsin K inhibitor from a phase I study. BMD from postmenopausal women were 
suppressed significantly by oral administration of cathepsin K inhibitor. 
RANK-RANKL interaction between.osteoclasts and osteoblasts is the key step in the 
progression of bone remodeling. It initiates the maturation and differentiation of 
osteoclasts to start bone resorption. OPG produced by osteoblasts is the decoy 
receptor to counteract and balance the RANK-RANKL interaction. Denosumab is a 
human monoclonal antibody that binds selectively to RANKL with high afFmity, 
which mimics the effect ofOPG on RANKL. Based on some phase II clinical studies, 
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this antibody has akeady given a promising effect on increasing BMD in 
postmenopausal women. It can be used in combination with anabolic agent to 
enhance the therapeutic effect (Lewiecki, 2009; Pageau, 2009). 
Since bone remodeling is a coupling process, the inhibition of bone resorption will 
eventually suppress the rate of bone formation. Anabolic agent is being used to 
promote the formation ofnew bone in spite of the loss ofbone. Parathyroid hormone 
is a calcium-regulating hormone as mentioned before. It stimulates activity of 
osteoclasts and osteoblasts to enhance bone turnover and therefore facilitate calcium 
release from bone during calcium homeostasis. However, from the effect observed in 
case of primary hyperparathyroidism, it suggests that this hormone may participate 
also in anabolic activity ofbone turnover. Subcutaneous daily injection ofteriparatide 
(human recombinant parathyroid hormone 1-34) has enhancing effect in bone 
formation and increasing BMD. It also reduces the risk of fracture by at least 35% as 
observed in clinical studies. Although the dual effects of parathyroid hormone on 
bone is still unclear, teriparatide is the only anabolic agent approved by FDA in the 
United States (Pettway et al., 2008; Rubin et al., 2002). 
Herbal medicines are also used in treatment of osteoporosis. Putnam et al. (2007) has 
summarized the therapeutic effects of single herbs or combination of herbs on bone 
protection. Some single herbs like sage and rosemary can inhibit bone resorption with 
as little as one gram per day in rat diet. Different in vivo and in vitro studies have 
demonstrated the use ofherbal formulations in various regions can effectively protect 
bone loss or improve BMD after menopause. The effect of single component from the 
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formulation is used to further prove the active components that participate in the 
antiosteoporosis effects. For example, flavonoid compound icariin from Herha 
Epimedii (HEP) and oleanolic acid from Fructus Ligustri Lucidi (FFL) are the active 
compound that show beneficial effects on bone metabolism in vivo and in vitro 
studies (Zhang et al, 2009; Zhang et aL, 2008). 
1.11 Involvement of mast cells in bone metabolism 
As early in 1985，McKerma and Frame have summarized the observations on the 
mast cells and bone based upon animal models with calcium deficient diet and 
clinical observation of patient with systemic mastocytosis (McKenna et aL, 1985). 
The study of mast cells involvement in bone metabolism began with systemic 
mastocytosis. It is a condition characterized by mast cell infiltration ofbone marrow 
and tissues in the absence of identified circulating bone marrow-derived progenitors. 
The overproduction of mast cell was the result of activating mutations in the SCF 
receptor, KIT. Scattered alterations and circumscribed lesions were observed in ribs, 
skull and pelvis of patients. Histomorphometry analysis of the skeletal tissue of 
patients showed increased bone turnover in regions of mast cell accumulation 
(Chiappetta et al., 2006; Metcalfe, 2008). 
Apart from the clinical observation, animal models were also used to demonstrate the 
role of mast cells in bone remodeling. Silberstein et al. (1991) used mast cell 
deficient mice to determine whether the absence of mast cell affect bone histology 
and activity. They found that mast cell deficient mice had a delayed onset of 
activation phase of osteoclasts recruitment at BMU, a shortened duration of bone 
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formation and less bone matrix was synthesized. Rat undergone ovariectomy (OVX) 
is a standard model to illustrate the phenotype of postmenopausal osteoporosis. There 
was significant increment in the rate of bone remodeling and decrement in bone 
volume in rats 14 days after surgery (Thompson et al., 1995). The number of bone 
marrow mast cell in OVX rats was 7 times of that in sham-operated rats. The 
accumulation of mast cell was maximal during the phase of rapid bone loss (Lesclous 
et aL, 2001; Lesclous et aL, 1999). Different pieces of evidence have led to the 
hypothesis that mast cells may be responsible for regulating the accelerated bone 
turnover. 
The release of mediators from mast cell activation may also provide evidence on the 
involvement ofmast cells in bone remodeling. Mast cell activation and degranulation 
was observed in the early induction of bone resorption (Fouilloux et al., 2006). 
Histamine receptors are expressed in osteoblastic cell line and histamine could induce 
expression of RANKL mRNA in the osteoblasts in a dose-dependent manner. 
Histamine induces osteoclastogenesis in the co-culture of bone marrow cells with 
osteoblastic cell line in the presence of vitamin D3 (Deyama et al., 2002). The 
importance of histamine in bone remodeling is proven in another way. Histidine 
decarboxylase (HDC) catalyzes the production of histamine from histidine. HDC 
.knockout mice (HDC"-) showed an increased bone formation rate when compared 
with the wild type mice. The knockout mice have higher BMD in cortical and 
trabecular bones. Furthermore, HD&' mice protected bone loss induced by OVX. 
The histological examination of bone tissue of OVX knockout mice revealed the 
increase in the amount of mineralized tissue and bone volume when compared with 
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sham-operated HDC" '^ mice or wild type mice (Fitzpatrick et al, 2003). It suggested 
histamine regulate the activity of osteoclasts and hence the bone remodeling. Apart 
from histamine, cytokines that modulate bone turnover such as IL-1, IL-6, TNF-a and 
TGF-P are produced by activated mast cells (Moller et al., 1998). As mentioned in 
previous sections, cytokines modulate bone turnover through interaction with 
osteoclasts and osteoblasts. Some act as bone resorbing cytokines which stimulate 
destructive bone resorption like IL-1, 11-6 and TNF-a, while some promote bone 
formation through activation of osteoblasts like TGF-P (Marcelli et aL, 1990; Raisz, 
1999a). 
1.12 Aim of study 
There are different pieces of evidence demonstrated the involvement ofthe mast cells 
and its mediators in the regulation ofbone metabolism. Bone remodeling is regulated 
through different local factors which can be produced by activated mast cells. Since 
osteoporosis is a bone disease characterized with imbalanced bone resorption and 
bone formation, it is suspected that mast cells or the mediators released may also be 
involved in the pathophysiology of osteoporosis through the regulation ofbone cells 
activities. As estrogen is rapidly diminished after menopause and it results in the 
subsequent bone loss in postmenopausal osteoporosis, it is hypothesized that estrogen 
may regulate bone remodeling through modulating the activity of mast cell activity. 
Based on results that histamine can induce osteoclastogenesis, it is suspected that 
mast cell may be one of the effectors in regulating the release of histamine so as to 
regulate bone remodeling. Zaitsu et al have demonstrated the release of histamine 
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and leukotriene C4 (LTC4) from human mast cell cell-Une (HMC-1) and primary 
cultures ofbone marrow-derived mast cells (BMMCs) from mice after the incubation 
of physiological concentration of estradiol (Zaitsu et al, 2007). Estrogen can regulate 
the release of cytokines which mediated by elevation of calcium influx and activation 
of protein kinase C. It was demonstrated that estradiol could suppress the phorbol 
ester and ionophore induced production ofIL-6, IL-ip and TNF-a from mast cell line 
HMC-1 (Kim et al, 2001). 
We try to elucidate the involvement of estrogen in regulating the activity of mast cells 
by means of studying mediator release. Primary human cultured mast cells (HCMC) 
derived from CD34+ progenitor cells in peripheral blood and human mast cell 
line-line LAD2 were used as human mast cells model since they represent different 
subtypes of human mast cells. HCMC are demonstrated to be tryptase-positive in 
protease staining (Wang et al., 2006b) and resemble human lung mast cells (Saito et 
al., 1995). LAD2 cells are a cell line originated from the bone marrow mast cells o f a 
male patient with mast cell sarcoma-leukemia, which reported to be 
tryptase-chymase-positive in protease staining (Kirshenbaum et al., 2003). They were 
used to evaluate the effect of estradiol and some selective estrogen receptor 
modulators on histamine and other mediator released from mast cells induced by 
different secretagogues. 
Since there are increasing use of Chinese herbal medicine in the treatment ofdifferent 
disease including osteoporosis, the effect of an anti-osteoporosis herbal formulation 
and the individual herbs on human mast cells are also examined in this study. This 
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herbal formulation has proven to produce anti-osteoporosis effect on rat by 
preservation ofBMD after OVX (Sun et al,, 2008). We investigated if the release of 
mediators from mast cells were modulated after incubation with the anti-osteoporosis 
herbal formulation or individual component herbs. Different partitions of the herbal 
constituents in the formulation after solvent extractions were also used to elucidate 
which fractions are more potent in regulating the mast cell activity. 
？ 
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Table 1.1: Summary of pro-inflammatory mediators of mast cells 
Class mediators Biological effects 
= = = = = ^ = = ^ ^ ^ = = = = = = ^ = = ^ = ^ = = = = = = = 
Preformed Histamine, heparin, Increase vascular permeability, 
mediators seretonin contract smooth muscles 
Serine protease Chymase, tryptase Protein degradation, remodeling 
tissue matrix 
Cytokines IL-4, IL-13 Stimulate and amplify Th2-cell 
response 
IL-3, IL-5, GM-CSF Promote eosinophils, granulocytes 
and monocytes production and 
stimulation 
IL-6, TNF stimulate cytokines production, 
promote inflammation 
Chemokines CCL2, CCL3, CL4, Chemoattraction and tissue 
CXCL1，CXCL2, infiltration of leukocytes 
CXCL3, CXCL10 
Lipid mediators Prostaglandin D2, E2 Cause smooth muscle 
^ Leukotriene B4, C4 contraction, increase 
vascular permeability, 
stimulate mucus secretion 
Platelet-activating Leukocytes chemotaxis, platelet 
factor aggregation 
Abbreviation: CCL, chemokine (C-C motif) ligand; CXCL, chemokine (C-X-C motif) 
ligand; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL, interleukin; 
Th2, type 2 T-helper cell; TNF, tumor necrosis factor 
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Figure 1.1: The activation pathways of human mast cell. Antigens crosslink 
IgE-bound high affmity receptors for IgE (FcsRI) lead to the recruitment and 
activation of Lyn and Syk tyrosine kinase. The phosphorylation of adaptor protein, 
linker for activation of T cells (LAT) by the tyrosine kinases subsequently activate 
phospholipase Cy (PLCy) pathway. Degranulation is followed by the activation of 
protein kinase C (PKC) and increased intracellular calcium concentration (Ca�+). The 
activation of small G-protein, Ras, is mediated through different adaptor signaling 
-molecules in mast cells and then triggers the signal transduction in mitogen-activated 
protein kinase (MAPK) pathways, which leads to generation of eicosanoids and 
production of cytokines. Meanwhile, mast cell activation can also be mediated 
through IgE-independent pathway. Basic secretagogues directly bind to the 
intracellular G-protein. The Py subunit from G-protein activates PLCp and lead to 
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degranulation through activation of PKC and increasing calcium mobilization. Also, 
the Py subunit trigger the activation of PI3-K and induce the downstream signaling 
pathway including PKC and PTK to start the generation of eicosanoids and cytokine 
production through activation of transcription factors. Abbreviations: DAG, 
diacylglycerol; GTP, guanosine triphosphate; IP3, inositol trisphosphate; PI3-K, 
phosphoinositide 3-kinase; PIP2, phosphatidylinositol-4,5-bisphosphate; PIP3, 
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Chapter 2. Materials and Methods 
2 Materials and Methods 
2.1 Materials 
Chemicals and reagents used in current study and brand names are listed below in 
table format (abbreviations in brackets). 
Human buffy coat 
Mature primary human cultured mast cells (HCMC) were derived from CD34+ 
progenitors isolated from fresh buffy coat. Fresh buffy coat of less than 24 hours old 
was prepared by Hong Kong Red Cross and collected at the Hong Kong Red Cross 
Headquarter Donor Centre. 
LAD2 cell line 
LAD2 cell line was kindly donated as live culture by Dr. Arnold S. Kirshenbaum 
" (Laboratory of Alleric Diseases, National Institute of Allergy and Infectious Diseases, 
National institutes ofHealth, Bethesda, MD 20892-1881, USA). 
Chinese herbal medicines 
The lyopliilized powder ofELP formulation, Herba Epimedii (HEP), Fructus Ligustri 
Lucidi (FLL) and Fructus Psoraleae (FP) and the fractions of individual herbs after 
solvent extractions were gifts from Dr. Chan B.C.L (Institute of Chinese Medicine, 
The Chinese University ofHong Kong, HKSAR). In brief, raw herbs ofHEP, FLL 
and FP in a weight ratio of 5:4:1 were boiled under reflux in large scale extractor until 
the decoction became pale. The decoction was then concentrated under reduced 
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pressure and then dried using a spray dryer. Individual smashed herbs of HEP and 
FLL were boiled for 60 minutes and filtered twice. Part of the extracts ofboth herbs 
were frozen and lyophilized to dryness. The dried fraction was labeled as crude 
fraction. The remaining extract was concentrated and partition with dichloromethane. 
The aqueous layer after first partition was subject to partition with ethyl acetate and 
n-butanol in sequential order. The solvent layers obtained were termed as 
dichloromethane (DCM) fraction, ethyl acetate (EA) fraction and butanol fraction. 
The water residue left after partition with solvent was collected and terms as water 
residue. All partitions collected were evaporated under reduced pressure to dryness. 
Smashed raw FP herb was boiled under reflex twice. The extract was subject to 
ethanol extraction. The ethanol extract was filtered and centrifoged. Supernatant was 
collected and evaporated under reduced pressure. The concentrated supernatant was 
frozen and lyophilized to give dry powder extract. 
Human mast cells culture 
命 2-Mercapto ethano 1 Gibco 
® 
Albumin solution from bovine serum, 35% (BSA) Gibco 
CD34 MicroBead kit, human Miltenyi Biotech 
Citrate-dextrose solution Sigma-Aldrich 
Fetal bovine serum {FBS), heat inactivated Invitrogen 
Ficoll-Paque PLUS GE healthcare 
Insulin-transferrin-selenium Gibco® 
Iscove's modified Dulbecco's medium (IMDM) Invitrogen 
L-Glutamine Gibco® 
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StemPro-34 SFM Consisting of Basal Medium & Gibco® 
Nutrient Supplement 
SuperMACSII Magnetic cell separator Miltenyi Biotech 
MACS LS separation columns Miltenyi Biotech 
Penicillin-streptomycin Gibco® 
Recombinant human interleukin-3 (IL-3) PeproTech Asia 
Recombinant human interleukin-6 (IL-6) PeproTech Asia 
Recombinant human stem cell factor (SCF) PeproTech Asia 
Serum-free methylcellulose medium StemCell Technologies — 
Immunostaining 
25mm circular coverslips Menzel-Glaser 
Cy2-conjugated goat Anti-rabbit IgG secondary Jackson ImmunoResearch 
antibodies 
Cytospin 3 SHANDON 
Entellan® Merck KGaA 
Giemsa's solution Merck KGaA 
Glycerol Sigma-Aldrich 
May-Grunwald's solution - Merck KGaA 
.Mayer ' s hematoxylin DakoA/S 
Mouse anti-human mast cell chymase monoclonal Chemicon (Millipore) 
antibody 
Mouse anti-human mast cell tryptase monoclonal Chemicon (Millipore) 
antibody 
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Normal goat serum Jackson ImmunoResearch 
Polysine white adhesion slides Menzel-Glaser 
Paraformaldehyde S igma-Aldrich 
Rabbit anti-human estrogen receptor alpha AfFmity BioReagents 
polyclonal antibody 
Rabbit anti-human estrogen receptor beta Affinity BioReagents 
polyclonal antibody 
VESTASTAESr® ABC-AP Kit Vector Laboratories 
VESTASTAlLN® ABC-AP substrate Kit Vector Laboratories 
Mast cell secretagogues 
Compound 48/80 Sigma-Aldrich 
Goat anti-human immunoglobulin E antibody Sigma-Aldrich 
(e-chain specific) (Anti-IgE) 
Substance P Sigma-Aldrich 
Estrogen and selective estrogen receptor modulators (SERMs) 
17p-estradiol Sigma-Aldrich 
Raloxifene hydrochloride � Sigma-Aldrich 
Tamoxifen citrate Sigma-Aldrich 
Functional assays on mediator release 
AutoAnalyzer 3 Bran-Leubbe 
BenchMark Plus™ microplate spectrophotometer Bio-Rad 
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Brij 35 solution Sigma-Aldrich 
Butanol Lab scan 
Glycine Sigma-Aldrich 
Heptane Lab scan 
Human Immunoglobulin E (IgE), myeloma Calbiochem 
Methanol Mallinckrodt 
4-Nitrophenyl N-acetyl-P-D-glucosaminide Sigma-Aldrich 
OptEIA™ - Human TNF ELISA Set BD Bioscience 
Ortho-phthaldialdehyde (OPT) Sigma-Aldrich 
Perchloric acid Mallinckrodt 
Sulphuric acid (H2SO4) Merck KGaA 
TMB Substrate Reagent Set BD Bioscience 
Reverse transcriptase polymerase chain reaction (RT-PCR) 
Agarose Invitrogen 
Bio-Rad ChemDoc XRS System Bio-Rad 
Chloroform BDH 
Diethyl pyrocarbonate (DEPC) Sigma 
DNase 1, amplication grade - Invitrogen 
dNTPs mix Invitrogen 
GelRed nucleic acid stain Biotium 
Isopropanol Invitrogen 
Microseal® 'B' film Bio-Rad 
Mitsubishi P93D thermal printer Mitsubishi 
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MyCycler Thermal Cycler Bio-Rad 
OUgo (dT)i2-i8 Invitrogen 
Paired primers for estrogen receptors, various bone Invitrogen 
remodeling molecules 
Platinum® Taq DNA polymerase Invitrogen 
Qiagen RNeasy mini kit Qiagen 
RNaseOUT™ recombinant ribonuclease inhibitor Invitrogen 
SmartSpec™ Plus Spectrophotometer Bio-Rad 
SUPERSCRIPT™ II RNAse H reverse Invitrogen 
transcriptase 
TRIZOL reagent Invitrogen 
Calcium mobilization studies 
22mm circular cover slip Menzel-Glaser 
CCD camera (model RET-2000RV-F-M-12-C) Qimaging 
Lambda-10-3 filter wheel Sutter Instruments 
Fura-2-acetoxymethyl ester (Fura-2AM) Invitrogen 
Immersion oil Stemcell 
Lambda 10-3 filter wheel - Sutter Instruments 
Olympus inverted 1X51 microscope Olympus America Inc 
40X Olympus oil objective lens (Uapo/340, Olympus America Inc 
40XA.35 oil iris) 
SlideBook™ software version 4.2 Olympus America Inc 
Temperature controlled chamber Life Science Resources 
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Xenon light source Olympus America Inc 
Buffers preparation 
Phosphate-Buffered Saline (PBS), NaCl 137mM 
p H 7 . 4 Na2HPO4 8.1mM 
KC1 2.7mM 
KH2PO4 1.4mM 
Magnetic cell separation (MACS) PBS supplemented with 0.5% BSA 
buffer，pH 7.4 and 2 mM Citrate-dextrose solution 
Full HEPES buffer with human NaCl 137mM 
albumin (FHB/HA), pH 7.4 Glucose 5.56mM 
HEPES 12 mM 
KC1 2.7 mM 
NaH2PO4 0 . 4 m M 
CaCl2 1 m M 
MgCl2 1 m M 
Human albumin (HA) 0.03% 
Assay diluents used in TNF-a assay, PBS supplemented with 2.5% BSA 
pH 7.0 � 
Wash buffer used in TNF-a assay, PBS supplemented with 0.05% 
pH 7.0 Tween-20 
Tris-buffer used in immuno- Tris-HCl 50 mM 
fluoroscence staining, pH 7.4 
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2.2 Methods 
2.2.1 Human mast cells culture 
Mature primary human cultured mast cells (HCMC) were derived from progenitors 
isolated from fresh buffy coat. Freshly prepared buffy coat cells were first diluted 
with same volume of PBS and then layered gently on top of Ficoll-Paque solution. 
After centrifugation (400 x g, 30 min), the interface containing mononuclear cells 
was collected and washed with PBS. CD34+ progenitor cells were magnetically 
labeled with CD34 Microbeads and loaded onto a MACS LS column which is placed 
in the magnetic field of a SuperMACSII Magnetic cell separator. The magnetically 
labeled CD34+ cells are retained within the column while the unlabeled cells run 
through. After removing the column from the magnetic field, the magnetically labeled 
CD34+ cells were eluted as the positively selected cell fraction. Isolated progenitors 
were first cultured with SCF (200ng/ml) and IL-6 (50ng/ml) and in serum free 
methylcellulose for 6 weeks with IL-3 (lng/ml) added in the first two weeks only and 
then cultured in Iscove's modified Dulbecco's medium (IMDM) supplemented with 
1% insulin-transferrin-selenium, 5xlO'^M 2-mercaptoethanol, 5% foetal bovine serum 
(FBS), 1% penicillin-streptomycin, 0.1% BSA, SCF (lOOng/ml), IL-6 (50ng/ml) for 
6 - 8 weeks. 
LAD2 cell Hne (LAD for Laboratory of Allergic Diseases) is a gift from Dr. 
Kirshenbaum and was established from different bone marrow aspirates obtained 
from a male patient during the diagnosis of mast cell sarcoma-leukemia 
(Kirshenbaum et al., 2003). The cell line was cultured in StemPro-34 serum-free 
growth medium with nutrient supplement, 1% penicillin-streptomycin, 2mM 
L-glutamine, lOOng/ml SCF and 50ng/ml IL-6. Cells were kept in a density of less 
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than 0.5 x 10^ per ml ofmedium. 
2.2.2 Human mast cells characterization 
HCMC were characterized with May Grunwald-Giemsa staining of cytoplasmic 
granules as well as immunocytochemical staining of human mast cell tryptase, 
chymase employing monoclonal anti-human tryptase, anti-human chymase antibody 
and the Universal LSAB™ 2 kit from Dako as instructed by the manufacturer. For 
May Grunwald-Giemsa staining, cell smears (6 - 8 x 10^  cells) were prepared by 
cytocentrifugation (250 x g) onto poly-L-lysine coated glass slides using a Shandon 
Cytospin 3 and were subsequently stained with 0.25% of May-Gruenwald's solution 
for 10 min followed by a further 20 min incubation after diluting the solution with 
equal volume of 0.1 M PBS (pH 6.4). The smears were then rinsed under running 
water and stained with 0.1% of Giemsa's solution for 30 min. The smears were rinsed 
again the running water and fmally covered with a coverslip using aqueous mounting 
medium. 
Staining for tryptase and chymase protein expression in mast cells was performed by 
the immunocytochemical staining. Cytocentrifuged smears were fixed in Carnoy's 
fixative (60% ethanol, 30% chloroform, 10% glacial acetic acid) for 90 second, 
air-dried and then incubated with 1/1000 dilution of anti-human mast cell tryptase or 
chymase monoclonal antibodies overnight at 4°C in a humidified chamber. The 
smears were then washed with PBS and subjected to sequential 30 minutes incubation 
at room temperature with biotinylated secondary antibody solution and 
VECTASTATN ABC-AP reagent with washing in between. Finally, immunoreactivity 
was detected by incubating the slides with freshly prepared aUcaline phosphatase 
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substrate solution for 20 一 30 minutes. The smears were counterstained in Mayer's 
hematoxylin and finally covered with a coverslip using aqueous mounting medium. 
All images of staining were taken by Zeiss Axioskop Microscope at 400 x 
magnification. 
2.2.3 Histamine release assay 
HCMC after 12^ -^14^ ^ week of cultures or LAD2 cells were incubated with human 
myeloma IgE (0.5^g/ml) overnight at 31�C in IMDM in a 5% CO2 incubator. 
Sensitized cells were washed with Full HEPES Buffer with human albumin (FHB/HA) 
and were resuspended in pre-warmed buffer. Pre-warmed HCMC suspension was 
aliquoted into polystyrene test tubes (1 一 1.5 x 10^ cells/tube) and then incubated with 
drugs and/or secretagogues at 37°C. Cells incubated with buffer alone served as 
control for spontaneous histamine release. Reactions were stopped by addition of 
ice-cold buffer followed immediately by centrifugation at 180 x g for 5 min at 4°C. 
Cell pellets and supernatants were separated by transferring the supernatant in each 
tube to a new tube. Cell pellets were resuspended with distilled water and 30% 
perchloric acid was added to both the supematants and cell lysates prior to measuring 
the histamine contents spectrofluorometrically with a Bran+Luebbe AutoAnalyzer 3. 
Results were expressed as a percentage of total cellular histamine release [Histamine 
release (%)] 
Histamine release (%) 二 Histamine level in supernatant X 100% 
Histamine level in supernatant + in cell pellets 
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The spontaneous histamine release levels of HCMC before and after sensitization 
with myeloma IgE were comparable and were less than 5% of total cellular 
histamine. 
2.2.4 Immunofluorescence staining of estrogen receptors 
Expression of estrogen receptors were detected by immunofluorescence staining. 
HCMC were collected and washed with PBS. Cell smears (6 — 8 x 103 cells) were 
prepared by cytocentrifiigation (250 x g) onto poly-L-lysine coated glass slides using 
a Shandon Cytospin 3 system. The smears were immediately fDced in 4% 
paraformaldehyde and the cytospin sections were incubated with mouse anti-human 
estrogen receptors antibodies at 1/250 dilution and probed with Cy2-conjugated goat 
anti-mouse IgG secondary antibodies at same dilution. Fluorescent images were 
captured either with a Zeiss Ax fluorescent microscope. Sections that were incubated 
with normal mouse IgG only were used as negative control. 
2.2.5 Reverse Transcriptase Polymerase Chain Reaction 
RNA was extracted from all the samples using the Qiagen RNeasy mini kit and was 
quantified by measuring the ratio of A26Onm/A28Onm. The total RNA (0.5^ig) was then 
reverse transcribed to cDNA in the presence of SUPERSCRIPT™ II reverse 
transcriptase (200U/^il), 0.5mM dNTPs mix, Oligo (dT)12-i8 (500^g/ml), RNase 
inhibitor (40U/p,l) and reverse transcriptase (RT) buffer. The RT mixture was 
incubated for 50 minutes at 42°C followed by 15 minutes at 70�C. RT product was 
subjected to PCR amplification in the presence of a mixture containing PCR buffer, 
lmM 0fMgCl2,0.2mM ofdNTPs, lU ofPlatinum® Taq DNA polymerase and paired 
primers for different genes to be analyzed (100 nM for each primer). Sequence of 
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oligonucleotide primers are listed in Table 2.1. The PCR conditions were as follows: 
denaturation for 60s at 95 °C, annealing for 30s at temperature indicated in Table 1 for 
different primers and extension for 60s at 72 °C, followed by 10 minutes at 72 °C for 
fmal extension. Sequences were amplified in 35 cycles using a MyCycler Thermal 
Cycler. PCR products were resolved on 1% agarose gel with GelRed nucleic acid 
stain and visualized by Bio-Rad ChemDoc XRS System. 
2.2.6 TNF measurement 
HCMC and LAD2 cells were placed in 96 wells plate (1 x 10^ HCMC or 1 x 10^  
LAD2 cells per well). Drugs were added to the sensitized HCMC and incubation in 
5% CO2 incubator at 37 °C for 8 hours. Supematants were measured using human 
TNF ELISA kit. Briefly, an antibody specific for human TNF was coated in the 96 
well ELISA plate. Free TNF was sandwiched between the coated antibody and a 
biotinylated secondary antibody that was added afterward. A streptavidin-HRP 
conjugate that was specific for the biotinylated antibody was used for colour 
development with the substrate solution. A standard curve was created for each 
ELISA plate at the same time as sample measurement. The plates were measured for 
absorbance at 450 nm (with reference on absorbance 570 nm) in BenchMark Plus™ 
microplate spectrophotometer. Results were expressed as net TNF release per million 
cells (pg/106 cell). 
2.2.7 Calcium mobiUzation studies of mast cells 
Sensitized LAD2 cells were loaded with 2^iM Fura2 AM for 30 minutes at 37°C. 
Cells were left for 15 minutes for the complete hydrolysis of the ester to free acid and 
then washed twice with buffer. Fura2 loaded cells were placed on a circular cover slip 
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fixed in the temperature controlled chamber and equilibrated at 37°C until over 90% 
ofthe cells were morphologically intact and slightly attached to the cover slip. During 
the measurement, cells were excited using a xenon light source and filter wheel for 30 
ms, cyclically at 340 nm and 380 nm through a 40X Olympus oil objective lens in 
Olympus inverted 1X51 microscope. Fluorescence at 510 nm emission was detected 
with a cooled CCD camera. Ca^^ fluorescence images obtained at 20s intervals were 
stored on the hard disc of a computer, and then the fluorescence ratio of340 to 380 
nm was measured to calculate the [Ca^^]i. All analyses were carried out using a 
computer-based fluorescence image analysis system, SlideBookTM software version 
4. 
2.2.8 Statistical analysis 
All results are expressed as mean 士 standard error of mean (SEM) values for n 
independent mast cell cultures from one set of isolation of progenitor cells or each 
sub-culture ofLAD2 cells. The statistical significance was analyzed using analysis of 
variance (ANOVA) or paired t-test for paired data, depending on the set ofdata being 
compared. Values were considered significantly different at p<0.05 when compared 
with control set-up. 
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Table 2.1: Sequence of oligonucleotide primers of estrogen receptors and 
various bone remodeUng molecules 
Primer Sequence 5’ ^ 3, Expected 
product size 
ER-a Sense: 668bp 
GTG GGAATG ATG AAA GGT GG 
Anti-sense 
TCC AGA GAC TTC AGG GTG CT 
ER-P Sense: 528bp 
TGAAAAGGAAGG TTA GTG GGAACC 
Anti-sense 
TGG TCA GGG ACA TCA TCA TGG 
OPG Sense: 470bp 
TGC AGT ACG TCA AGC AGG AG 
Anti-sense: 
TGA GCT GTG TTG CCG TTT TA 
RANK Sense: 500bp 
CCT GGA CCAACT GTA CCT TC 
Anti-sense: 
TTC CTC TAT CTC GGT CTT GC 
RANKL Sense: 475bp 
AGA GAAAGC GAT GGT GGA TG 
Anti-sense: 
ATC CAG TAA GGA GGG GTT GG 
GAPDH Sense: 595bp 
CCA CCC ATG GCAAAT TCC ATG GCA 
Anti-sense: -
TCAAGA CGG CAG GTC AGG TCC ACC 
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3 Effects of estrogen and selective estrogen receptor 
modulators (SERMs) on mediators release from 
human mast cells 
3.1 Introduction 
Estrogen is a steroid hormone in human body that regulates growth, differentiation 
and function of a broad range of target tissues. Estrogen is the primary sex hormone 
in female for regulating the functions of the reproductive system by promoting the 
growth and differentiation of reproductive tissues. It also regulates the metabolism of 
other tissues such as brain (McCarthy, 2009), cardiovascular system (Farhat et aL, 
1996) and bone (JiUca, 1998). 
Estrogen exerts various effects through the activation of estrogen receptors, estrogen 
receptor (ER)-a and ER-p. ERs belong to the nuclear receptor (NR) superfamily, 
which are ligand-regulated transcription factor. Conventional activation of estrogen 
receptor is mediated via the binding of estrogen to receptors in the nucleus, followed 
by the dimerization of receptors and bind to estrogen-response elements (ERE) in the 
promoter of target genes (Nilsson et al., 2001). The regulation of target gene 
transcription via the action of estrogen can be ERE-independent. Steroid-receptor 
complex directly binds to other transcription factors and regulates gene transcription. 
Study by Pfeilschifter (2002) demonstrated that down-regulation of nuclear factor-KB 
proteins (NF-KB) and activation protein-1 (AP-1) were mediated by the 
ERE-independent genomic action of the estrogen-ER complex and resulted in 
suppressing production of IL-6 and TNF-a. The binding of activator to promoter of 
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IL-6 gene was inhibited by estrogen-ER complex and the transcription of cytokine 
was blocked. Estrogen-ER complex inhibited the expression of Jun and suppressing 
the Jun N-terminal kinase pathway, hence AP-1 was down-regulated and TNF-a 
transcription was blocked. 
Many studies demonstrated the rapid activation of signaling pathways such as 
mobilization of intracellular calcium (Improta-Brears et al, 1999), stimulation of 
adenylate cyclase (Aronica et aL，1994) and phospholipase C (PLC) activation (Le 
Mellay et al, 1997) were regulated by estrogen. These actions are possibly not 
regulated through the transcription of gene and synthesis of target protein due to the 
rapid onset of activations. These non-genomic actions of estrogen are believed to be 
activated through the binding of membrane-bound ER (mER). The activation ofmER 
has been extensively studied in breast cancer cells. Bai's review (2009) reported the 
regulations of estrogen on mER activation and the subsequent actions of various 
signaling pathways like mitogen-activated protein kinase (MAPK) and 
phosphoinositol 3-kinase (PI3K) signaling pathways. The rapid signal transduction 
from estrogen-mER complex is often interacted with signaling molecules in pathways 
of G-protein coupled receptor, ion channel and protein kinases (Jacob et al., 2006). 
Estrogen supports the survival of breast cancer cells in a non-genomic fashion. The 
apoptosis induced by chemotherapy or irradiation treatment of human breast cancer 
cell line MCF-7 was prevented by estradiol (Razandi et al., 2000). The signal 
transduction of c-Jun N-terminal kinase (JNK) pathway was inhibited by estradiol 
reducing phosphorylation ofBcl-2 protein and blockage of caspase activity. 
Studies also suggested that there is cross-taUc between non-genomic action of mER 
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and the genomic responses (Bjornstrom et al., 2005; Jacob et al., 2006; Levin, 2005). 
The activation ofmembrane signaling pathways always result in activation oftarget 
gene transcription. The well-know examples ofconvergence ofnon-genomic actionto 
genomic action are the activation of NF-KB and AP-1. Apart from the 
ERE-independent genomic activation of NF-KB and AP-1 gene transcription by 
estrogen-ER complex (Pfeilschifter et al., 2002), transcriptional activity can also be 
initiated by PI3-K-mediated {Romashkova et al., 1999) and MAPK-mediated 
phosphorylation (Karin, 1995) respectively. The activation ofPI3-K/Akt pathway via 
estradiolpromotes the expression ofNF-KB binding gene (Kawagoe et aL, 2003). It is 
found that the up-regulation of PI3-K>'Akt pathway by estradiol was in an ER-a 
dependent manner (Lee et al, 2005). Estradiol also up-regulates MAPK signaling 
pathway and promotes the AP-l-DNA binding activity and enhance transcription. The 
action of estradiol was mediated through both ER-a and ER-P (Bjomstrom et al., 
2004). Therefore, the regulation of transcription mediated by ER is composed oftwo 
distinct mechanisms: protein-protein interaction in nucleus via nuclear receptor and 
activation ofsignal transduction through membrane-bound receptor. 
Estrogen functions as a systemic regulator to bone metabolism. The production of 
cytokines and arachidonate metabolites from the microenvironment in bone 
metabolism is regulated by estrogen. The drastic depletion of estrogen after 
menopause is a major cause of the postmenopausal osteoporosis. Deficiency of 
estrogen can increase Hfespan of osteoclasts and increase number of osteoblasts to 
support the survival of osteoclasts through RANK7RANKL interaction (Lerner, 
2006). It is found that estrogen modulates the production of cytokines, especially the 
bone resorbing cytokines like IL-1, IL-6 and TNF-a, and hence the regulation ofbone 
43 
‘ Chapter 3. Effects of estrogen and SERMs on 
mediators release from human mast cells 
remodeling. Girasole et al. (1992) has revealed that estradiol inhibited the 
production of IL-1, IL-6 and TNF-a in mouse bone marrow stromal cell line and 
osteoblasts. The promotion of bone resorbing cytokine production was observed in 
postmenopausal osteoporosis patients (Zheng et al., 1997). The resultant promotion in 
RANKL production following the augment of bone-resorbing cytokines from 
microenvironment causes maturation of more osteoclasts and the subsequent 
osteoclastogenesis. Estrogen also regulates the metabolism of arachidonic acid in 
bone cells. Prostaglandin (PG) E2 is a multifunctional regulator to bone turnover. It 
modulates the rate ofbone turnover through different prostaglandin receptors. There 
are four PGE2 receptors being identified (EP1-EP4). The bone resorption induced by 
PGE2 via the binding 0fER4 was proved with the formation of osteoclasts-like cells 
in mouse marrow cultures (Ono et aL, 1998). PGE2 can also stimulate bone formation. 
Woodiel et al. (1996) found that the anabolic effect 0fPGE2 was mediated by EP2 
receptor that stimulated adenylate cyclase and protein kinase A (PKA) activation. The 
effects 0fPGE2 on bone are depended on the receptors being bound. The production 
ofPGs from bone cells is regulated by estrogen and cytokines (Hikiji et al., 2008; 
Raisz, 1999b). Human osteoblasts increased PGE2 production by treatment of 
estradiol and cultured with transforming growth factor-^ (TGF-p) and TNF-a 
(Secreto et al, 2003). However, clinical observation showed that postmenopausal 
osteoporosis patients have higher level of urinary prostaglandins (PGE2 and PGF2a) 
and the use ofhormone replacement therapy (HRT) reversed the effect (Akgul et al., 
1998). The contradictory effects of estrogen on the production and functions ofPGs 
on bone metabolism remain unclear and further investigation is needed to elucidate 
the role ofPGs in bone metabolism. 
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The regulation ofestrogen in bone remodeling can be also reflected by the expression 
of RANKL/OPG ratio in osteoblasts (Cheung et al., 2003). Interaction between 
RANKL from osteoblasts with RANK from osteoclasts promotes bone resorption. 
The decoy receptor ofRANKL is OPG, which is also produced by osteoblasts. OPG 
interacts with RANK can decrease the amount of RANK-RANKL interaction and 
therefore the rate of bone resorption is regulated (Haynes et al., 2001). With the 
balancing effect ofRANKL and OPG on interacting with RANK, the expressions of 
RANKL and OPG mRNA in cells provide useM information on revealing the 
mechanism of regulation by estrogen. In vivo study suggested that RANKL/OPG 
ratio was decrease after treatment of estrogen in OVX mice. Those mice also 
demonstrated improvement on the mineral content in trabecular bone (Lindberg et al., 
2001). 
The importance of estrogen during lifetime and its effects on bones suggested that 
estrogen should be supplemented to maintain the physiological level after menopause. 
Various case-control studies and cohorts have demonstrated the effectiveness ofHRT 
in enhancing BMD and preventing bone fractures (Barrett-Connor et al., 1997; 
Cauley et al., 2003; Michaelsson et aL, 1998). However, with the side effects ofHRT 
on increasing risk ofbreast cancer and cardiovascular disease, the use of estrogen in 
the therapy ofosteoporosis was not suggested and alternatives were used to mimic the 
effect ofestrogen (Cauley et al., 2003). Selective estrogen receptor modulator (SERM) 
can reproduce the effect of estrogen on estrogen receptors at various tissues like 
breast, bone, uterus and brain. SERMs can act as agonist at special tissue while as 
antagonist at others. The selectivity of action of SERMs suggests them as prevention 
and treatment of osteoporosis. 
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Tamoxifen is a triphenylethylene compound and is the first generation SERM. It 
works as an antagonist in breast tissue but as an agonist in uterus and bone. Clinical 
observation has proven the effectiveness of tamoxifen in reducing the risk of 
ER-positive breast cancer and its recurrence (Fisher et al., 1998). It was also effective 
in the preservation ofbone mineral density in patients with breast cancer (Tiitinen et 
al., 2004). However, due to the side effects of tamoxifen such as stroke, hot flushes 
and the high risk ofdeveloping malignant condition in female genital tract, alternative 
are being introduced to improve the efficacy (Love et al.，1991; Senkus-Konefka et 
al, 2004). 
Raloxifene is a second generation SERM with benzothiophene structure. It acts as an 
antagonist in breast and uterus while as an agonist in bone (Sato et al, 1996). It is a 
better choice in comparison with tamoxifen, since raloxifene does not promote the 
uterus cancer (Fisher et al, 1998). It is the only FDA approved intervention for 
prevention and treatment of postmenopausal osteoporosis. Raloxifene has 
demonstrated a promising protective effect on bone by improving BMD and reducing 
bone fractures in a large scale 3-year randomized clinical trial (Ettinger et aL，1999). 
The withdrawal of estrogen after menopause is the major cause of postmenopausal 
osteoporosis since estrogen is a major regulator in bone metabolism. It was found that 
as low as 10"^ ^M estradiol can suppressed the proliferation of osteoblastic cell line 
(Robinson et aL, 1997). Recently, evident showed that the involvement ofhistamine 
in modulating the differentiation of osteoclasts and osteoblasts during bone tumover. 
Histamine increased the number of osteoclasts in vivo and less osteoclasts were 
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produced from cells of histamine-deficient mice (Biosse-Duplan et al., 2009). 
Histamine-deficient mice showed an increased bone formation and bone loss were 
prevented even after ovariectomy (OVX) (Fitzpatrick et aL, 2003). As the main 
storage ofhistamine in body tissues, mast cells were found to accumulate close to the 
bone surface of patient with osteoporosis or systemic mastocytosis (Chiappetta et al., 
2006; McKenna et al., 1985). Mast cell activation and degranulation were observed in 
the early stage of resorption and the number of mast cells increased in rat bone 
marrow after OVX (Fouilloux et al., 2006; Lesclous et al., 1999). Results have 
demonstrated the expression of ERs on mast cells in vascular tissues by 
inununocytochemistry fNicovani et al., 2002; Zhao et al., 2001). It suggested that 
mast cells may be an effector of estrogenic actions in bone. Various experiments have 
demonstrated that the regulation of mediators release from mast cells was affected by 
estradiol or SERMs treatment. Estrogen could activate mast cell degranulation and 
mediators release with the use of rat peritoneal mast cells (RPMC) and human mast 
cell line (HMC-1) (Vliagoftis et al., 1992; Zaitsu et aL, 2007). Tamoxifen produced 
an inhibitory effect on basic secretagogues induced histamine release from RPMC 
(Vliagoftis et al., 1992). However, the release of newly synthesized mediators from 
activated mast cells responded differently towards the treatment with estradiol. The 
release of pro-inflammatory cytokines IL-6 and TNF-a were suppressed by 
pre-treatment of 17p-estradiol in mouse bone marrow-derived mast cells and human 
mast cell line HMC-1 (Hamish et aL, 2004; Kim et al, 2001). Physiological 
concentration of estradiol potentiated the allergen-induced synthesis of LTC4. It was 
proposed that regulation of estrogen on mast cells was mediated through ER-a (Zaitsu 
et al, 2007) since the pre-treatment o f E R antagonist reverse the estrogenic action. 
Therefore, it is hypothesized that estrogen may regulate the bone turnover through 
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interaction with mast cell by modulating the release ofmediators. 
In this part ofstudies, the effect ofestrogen on mast cells was evaluated by studying 
the changes in histamine and TNF-a release induced by secretagogues under the 
pre-treatment of 17p-estradiol and the two SERMs, raloxifene and tamoxifen. Human 
mast cells cultured from peripheral blood progenitors (HCMC) and LAD2 cell line 
were used as the human mast cell models for studying the modulation of estrogenic 
compound on the activation of mast cells by anti-IgE and compound 48/80. The 
change in gene expressions in mast cells was also studied to evaluate the possible 
modulation on cells after the treatment of estrogen. 
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3.2 Materials and methods 
The materials and methods are listed in Chapter 2. 0.5|ig/ml anti-IgE was used for 
stimulation of histamine release from HCMC while 2.0^g/ml anti-IgE or O.l^g/ml 
compound 48/80 were used for stimulation ofhistamine release from LAD2 cells. All 
results were corrected for spontaneous release from human mast cells in the buffer 
alone condition, which was less than 10%. 
The concentrations of drug tested were based on previous studies and the highest 
concentration was determined by the solubility of drug in solvents. When DMSO was 
used to prepare the stock solution of drugs, the highest concentration of DMSO in 
experiments was less than 0.02%. At this concentration, DMSO did not induce and 
affect the release ofmediator from mast cells. 0.02% DMSO controls were preformed 
in parallel with the experiments when these drugs were involved. 
The results were analyzed with one-way analysis of variance (ANOVA) with 
Bonferroni's multiple comparison tests as the post-hoc analysis when comparing the 
difference between treatment groups in various concentrations with the control group. 
The expression of gene was normalized with GAPDH gene in the same set of 
experiment. Paired t-test was used to compare the different between the relative 
expression of genes in control and treatment group. The statistical significance is 
performed by comparing anti-IgE, compound 48/80 or substance P induced release in 
the presence of 17p estradiol or SERMs to the control release induced by the 
corresponding secretagogue. Differences were considered significant when p<0.05. 
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3.3 Results 
The levels ofspontaneous release ofmast cell in buffer alone were within 10% in all 
the experiments. Data are presented as percentage ofhistamine after correction for the 
spontaneous release. Cytokine release was presented as amount ofTNF-a per million 
cells _ 0 6 cells). 
3.3.1 Characterization ofhuman mast cells 
Human cultured mast cell (HCMC) derived from CD34+ progenitor cells in 
peripheral blood was characterized by staining cytoplasmic granules with May 
Grilnwald-Giemsa staining and immunocytochemical staining of mast cell tryptase 
and chymase with the use of monoclonal anti-human tryptase and anti-human 
chymase antibodies. HCMC after 12^ ^ - 14仇 week of cultures contained closely 
packed granules in cytoplasm which was stained in purple color with May 
Griinwald"Giemsa solution (Figure 3.1a). 
The phenotype of human mast cell was determined by the expression of protease 
stored in granules of mast cells. Immunocytochemical staining of granule protease 
reveals the phenotype and heterogeneity of mast cells. Mast cells contained tryptase 
are termed as MCi and they are abundant in mucosal tissues of the respiratory and 
gastrointestinal tract. Mast cells contained both chymase and tryptase are termed as 
MGrc. This type of mast cells were dominated in the connective tissue of the 
bronchial and intestinal submucosa and skin (Welle, 1997). Figure 3.1b demonstrates 
that HCMC were stained with anti-human tryptase with high intensity while granular 
chymase was poorly stained. The mast cell cultured from CD34+ progenitor cells in 
peripheral blood was MCi type, which was consistence with the prove from the 
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previous study (Wang et al., 2006b). 
3.3.2 Effect ofestrogen on mediator release from human mast cells 
3.3.2.1 Basal histamine release after treatment of estrogen 
The basal histamine release from HCMC and LAD2 cells were measured after 
incubation with 17p-estradiol for 30 minutes. The spontaneous release of histamine 
from human mast cells was within 10%. The histamine release after pre-incubation 
with 10'9 — 10"^ M 17P-estradiol was similar to the level of spontaneous release from 
HCMC incubated in buffer only. Less than 10% of total histamine was measured in 
the supernatant ofreactions of all tested concentration ofl7P-estradiol (Figure 3.2a). 
Similar results as seen in HCMC were observed from the incubation ofLAD2 cells 
with 17p-estradiol (10"^ - 10 '¾) for 30 minutes. After correcting the results for 
spontaneous release from mast cells, less than 5% of total histamine was detected 
from the supernatant of reactions (Figure 3.2b). 
There were no significant changes on basal histamine release from HCMC after 
incubation with 17p-estradiol for 24 hours (Figure 3.3a). The basal level ofhistamine 
release induced by 17p_estradiol was within 10% of total histamine content from 
HCMC, which is not significantly different from the spontaneous release ofhistamine 
from HCMC. 17p-estradiol did not induce basal histamine release from LAD2 
(Figure 3.3b). 
3.3.2.2 Histamine release induced by immunological stimulus 
Human mast cells were sensitized with myeloma IgE ovemight before the day of 
experiment. The release of histamine induced by 0.5^g/ml anti-IgE for HCMC or 
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2p,g/ml anti-IgE for LAD2 was around 30 一 40% of total histamine contents. 
Pre-incubation with 17p_estradiol for 30 minutes did not induce any significant 
changes on the pattem of histamine release induced by anti-IgE. It is found that the 
level of release was not altered until a high concentration of 17p-estradiol was used. 
10"^ M i 7 p - e s t r a d i 0 l suppressed anti-IgE induced histamine from HCMC by 11.21 士 
8.35% when compared to anti-IgE control (Figure 3.4a). LAD2 cells activated by 
anti-IgE also produced similar observations as seen in primary culture ofhuman mast 
cells. Pre-incubation of 17p-estraiol caused a gradual decrease of histamine release 
induced by 2^g/ml anti-IgE from LAD2 cells. At 10"^ M 17p-estraiol used in the 
experiment, histamine release was suppressed significantly by 35.11 士 18.62o/o 
(p<0.05) and only 13.72 士 1.08o/o of total histamine was released from cells (Figure 
3.4b). 
Estrogen exerts effect through both genomic and non-genomic action. The rapid 
non-genomic action of estrogen in human mast cell was studied by 30 minutes 
incubation time. The genomic action of estrogen was studied by 24 hour incubation of 
human mast cell with 17p-estradiol. Effect of 17p-estradiol was not obvious in 
histamine release after pre-incubation of drug for 24 hours. The level of anti-IgE 
induced histamine release from HCMC was not affected by the increasing 
concentration of 17p-estradiol (Figure 3.5a). LAD2 cells treated with 17p_estradiol 
for 24 hours exerted a suppressing effect on anti-IgE induced histamine release. A 
minimum of 9.45 士 5.50o/o inhibition was observed in pre-incubation of cells with 
10'^M i7p-estradi0l. 10'^M 17p-estradiol exerted an inhibition by 23.21 士 5.80o/o on 
anti-IgE induced histamine release after 24-hour treatment (Figure 3.5b). 
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3.3.2.3 Histamine release induced by chemical secretagogues 
LAD2 can be stimulated by basic secretagogues such as compound 48/80. The level 
of histamine release induced by 0.1|ig/ml compound 48/80 was about 50 - 60% of 
total histamine content from LAD2 throughout the studies. 
17p-estradiol pre-treated LAD2 was challenged with compound 48/80 to induce 
histamine release. 30 minutes pre-incubation of 17P-estradiol with mast cell prior to 
challenge of basic secretagogues did not affect the histamine release. The degree of 
mediator release was similar to the release in control set-up (Figure 3.6), which was 
close to 60% of total histamine content of LAD2 cells. Similarly, a longer time of 
17p-estradiol treatment did not affect histamine release induced by compound 48/80 
from LAD2 cells. There was no significant change on the induced release after the 
drug treatment in all tested concentration of 17P-estradiol after 24hour pre-incubation 
(Figure 3.7). 
3.3.3 Effect of selective estrogen receptor modulators (SERMs) on mast cell 
activity 
3.3.3.1 Basal histamine release after SERMs treatment 
Human mast cells were also incubated with the two SERMs, raloxifene and 
tamoxifen, to evaluate the effects of these compounds on human mast cells. The basal 
histamine release from HCMC was not altered by the incubation of either raloxifene 
or tamoxifen at all tested concentrations. The levels of histamine release were less 
than 10% of total histamine content in HCMC (Figure 3.8a). However, both 
raloxifene and tamoxifen at 10'^M enhanced the basal histamine release from LAD2 
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cells. 10"^M raloxifene induced a significant release of 24.94 士 7.14o/> of total 
histamine content in LAD2 cells while a higher level of basal histamine release of 
40.38 士 9.21% was observed with tamoxifen Q)<0.001) (Figure 3.8b) 
Raloxifene and tamoxifen did not induce basal histamine release from HCMC after 
24 hour pre-incubation. Figure 3.9a shows the levels ofhistamine release after either 
SERMs treatment was insignificant to the spontaneous release in buffer alone. 
However, raloxifene exerted a different effect on basal histamine release from LAD2 
cells. Low concentration of raloxifene (10'^ 一 10'^M) alone did not induce basal 
histamine release from LAD2 cells, but high concentrations of raloxifene (10"^ -
10"^M) produced significantly higher level of histamine release than the spontaneous 
level 0p<O.O5) (Figure 3.9b). 10"^M raloxifene stimulated 17.16 士 2.53o/o histamine 
released while 10"¾ raloxifene stimulated 16.02 士 3.59o/o of total histamine content 
from LAD2 cells. Incubation of tamoxifen for 24 hours with LAD2 cells did not 
produce changes on releasing pattern. Tamoxifen in all testing concentrations (10'^ 一 
10'^M) did not induce histamine released after corrected to spontaneous release 
(Figure 3.9b). 
3.3.3.2 Histamine release induced by immunological stimulus 
The pre-treatment of SERMs with HCMC produced a different effect from those 
treated with 17p_estradiol. Pre-incubation with raloxifene for 30 minutes produced an 
enhancing effect on anti-IgE induced histamine release. The mediator release 
increased with the concentration of raloxifene (Figure 3.10a). 10'^M raloxifene 
increased the anti-IgE induced histamine release from 39.81 士 3 .51� /o t  50.0 士 7.11% 
of total cellular histamine. Similar to raloxifene, tamoxifen only showed a prominent 
55 
Chapter 3. Eflfects of estrogen and SERMs on 
mediators release from human mast cells 
effect at high concentration. 10"^  to 10"^ M did not produce any effect on anti-IgE 
induced histamine release (Figure 3.10a). An inhibition of histamine release was 
observed when HCMC was pre-treated with 1 0 " ^ tamoxifen for 30 minutes through 
it was not statistically significant. 
All tested concentrations of raloxifene (10"^ 一 10"½) exerted a promoting effect on 
anti-IgE induced histamine release from LAD2 cells after 30 minutes pre-incubation, 
with a significant promoting effect observed with 1 0 " ^ and 1 0 ' ¾ (at least p<0.05). 
At the highest concentration used, the histamine release was doubled to that of 
anti-IgE control and 50.78 士 2.38o/o of total histamine was released (Figure 3.10b). 
Treatment ofLAD2 cells with tamoxifen at concentrations of 10^ to 10'^M before the 
challenge ofanti-IgE did not change the pattem ofhistamine release. However, there 
was a significant enhancement of histamine release by as much as twice of that 
production with anti-IgE was observed after incubation with 1 0 ' ¾ tamoxifen 
(p<0.001) (Figure 3.10b). 
After 24 hour pre-incubation with both SERMs, anti-IgE induced histamine release 
from HCMC was not obviously affected. The levels of induced histamine release after 
drug treatments were similar to level of histamine production by anti-IgE alone 
(Figure 3.11a). Similarly, the effects x>f long term incubation of SERMs on LAD2 
cells were also not obvious. Raloxifene at low concentration did not produce any 
effect on altering histamine release induced by immunological stimuli. There was a 
slight increase in histamine release induced by anti-IgE when 10'^M and 10"¾ 
raloxifene were used. The level of induced histamine increased from 22.19 士 5.58% 
to 33.03 士 1.12% (Figure 3.11b)，although the increment was not statistically 
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significant. All tested concentration of tamoxifen did not significantly change the 
level ofhistamine release produced by immunological activation ofhuman mast cells 
(Figure 3.11b) 
3.3.3.3 Histamine release induced by chemical secretagogues 
Raloxifene promoted compound 48/80 induced histamine release from LAD2 cells 
after 30 minutes pre-incubation. 10'^M to 10'^M raloxifene showed an average of 10 
to 15% enhancement on histamine release. 10"^M raloxifene significantly promoted 
the induced histamine release by 24.40 士 52PZo and produced release over 70% of 
total histamine content (p<0.05) (Figure 3.12). In general, all tested concentrations of 
tamoxifen slightly promoted histamine release induced by compound 48/80 afler 30 
minutes pre-incubation with mast cells (Figure 3.12). However, the promoting effect 
was not observed with significant difference. 
Incubation ofLAD2 cells with raloxifene for 24 hours before the challenge ofbasic 
secretagogues did not affect the histamine release thereafter. The changes of 
histamine release after drug treatment varied within 10% ofthe control level (Figure 
3.13). Tamoxifen also did not induce significant changes on histamine release induced 
by compound 48/80 except suppression observed with lO'^M tamoxifen (Figure 
3.13). 
3.3.4 Effect ofestradiol on TNF-a release from human mast cells 
HCMC treated with 17P-estradiol did not induce significant release of TNF-a, 
however, there was a slight promotion of TNF-a release when high concentration of 
17P-estradiol was used. The activation ofHCMC with anti-IgE produced significant 
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amount of TNF-a. When HCMC was pre-incubated with 17P_estradiol before the 
challenge of anti-IgE, the subsequent release of TNF-a was higher than mast cells 
treated with anti-IgE alone (Figure 3.14a). Although the promotion of cytokine 
release was not significant, the release reached highest level at 10'^M 17p-estradioL 
The observation of induced cytokine release from LAD2 cells was not similar to that 
from HCMC. Significant amount of TNF-a was released after the stimulation of 
LAD2 cells by substance P. Figure 3.14b shows that there was a trend of decreasing 
production ofTNF-a from substance P activated LAD2 cells. 
3.3.5 Effect of SERMs on TNE-a release from human mast cells 
Raloxifene and tamoxifen could not induce release ofTNF-a from non-activated mast 
cells. However, release ofTNF-a from activated mast cells was affected by raloxifene 
and tamoxifen. Raloxifene could suppress the anti-IgE induced cytokine release from 
HCMC significantly (at least p<0.01), with an exception at 10"^M raloxifene (Figure 
3.15a). The level ofTNF-a was mostly suppressed by 1 0 ' ^ raloxifene. 
The effect of raloxifene on substance P induced TNF-a release from LAD2 cells was 
not prominent except at high concentration (Figure 3.15b). There was no difference in 
cytokine release from LAD2 cells with or without treatment of raloxifene from 
10'^ ^M - 10'^M. There was a significant enhancement of cytokine release from 
activated mast cells after incubation with 10"^M raloxifene Q)<0.001). 
There was dose dependent inhibition on the anti-IgE induced TNF-a release after the 
treatment of tamoxifen (figure 3.16a). In general, tamoxifen inhibited substance P 
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induced cytokine release, with significant difference observed at 10"^M and 10"¾ 
tamoxifen (p<0.05). The immunological-activated TNF-a release was greatly 
suppressed with 10'^M tamoxifen ^><0.001). There was ahnost no TNF-a could be 
detected from the supernatant collected from HCMC with 10"½ tamoxifen. 
The production of TNF-a from LAD2 cells after substance P activation was only 
altered by the pre-treatment of high concentration of tamoxifen (figure 3.16b). 
Induced cytokine release from LAD2 treated with lO'^^M 一 10'^M tamoxifen was 
generally the same as from cells without drug treatment�However, the release of 
TNF-a was significantly increased after the pre-treatment of 1 0 ' ½ tamoxifen 
(p<0.001). 
3.3.6 Expression of estrogen receptors on human mast ceUs 
The expression of estrogen receptor (ER)-a and ER-P were identified by staining 
against antibodies ofERs. The fluorescence staining in figure 3.17 shows that there 
were both type of ERs expressed in HCMC. The receptors were localized in the 
cytoplasm and concentrated around the nucleus of mast cells. The existence of 
receptors was further confirmed by cloning part of mRNA of ER-a and ER-P with 
RT-PCR. It was demonstrated that ER-a and ER-P were synthesized from HCMC 
(Figure 3.18) and the expressions were obvious when compared to GAPDH control 
gene expression. However, the expressions of ER-a was not clearly shown in LAD2 
while ER-P was detected in RT-PCR (Figure 3.19). It suggested that different mast 
cell types may have different cellular expressions ofER subtypes. 
3.3.6.1 Expression of estrogen receptor after treatment of estradiol 
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The expression of estrogen receptors on human mast cell was demonstrated by 
immunofluorescence staining and through cloning of estrogen receptor products. It 
was suggested that estrogen might act through the corresponding receptor to initiate 
cellular regulation. The expression of estrogen receptor was auto-regulated by the 
level of estrogen. It is observed that ER-a expression was significantly enhanced by 
addition of estrogen in primary hypothalamic astrocyte cultures derived from mice 
(Bondar et al., 2009). Similar observation may occur in other tissues systems that 
estrogen can up-regulate the expression of estrogen receptor in order to enhance the 
regulatory effectiveness. LAD2 cells were incubated with 17p_estradiol and the level 
of ERs expression was evaluated by RT-PCR. 
LAD2 cells treated with 10"^ M 17p_estradiol for 24 hours did not have significant 
changes on ER expressions (Figure 3.20a). There was no sign ofER-a expression and 
the addition of estrogen did not induce the expression of ER-a. The expression of 
ER-p was demonstrated in the previous section (Figure 3.19). The addition of 
estrogen did not alter the expression of ER-p in LAD2 cells. Semi-quantitative 
measurement of ER-P expression on LAD2 with or without 10"^M 17p-estradiol 
showed there was no significant change on the intensity of expression level on 
receptor (Figure 3.20b). 
3.3.7 Expression ofvarious bone remodeUng molecules on human mast cells 
Several bone remodeling molecules are expressed by osteoclasts and osteoblasts and 
were the major regulators ofbone turnover. RANK is produced by osteoclasts while 
RANKL and OPG are produced by osteoblasts. The production of RANK and 
RANKL are enhanced when bone resorption is dominant in bone remodeling process, 
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less OPG is produced from osteoblasts to enhance the interaction between RANK and 
RANKL (Khosla, 2001). Apart from osteoclasts and osteoblasts that located in bone 
tissue, these bone remodeling molecules were also expressed in chondrocytes of 
cartilage and in peripheral blood mononuclear cells (PBMC) (Bashir et al., 2005; 
Ikeda et al., 2001). Bashir (2005) also found that the expression ofRANKL, RANK 
and OPG in peripheral blood mononuclear cells (PMBC) were altered after hormone 
replacement therapy. It suggested that expression ofbone remodeUng molecules may 
not be exclusively happened in bone cells, the cells nearby bone tissue may also 
expression those molecules and involved in the regulation ofbone remodeling. 
Figure 3.18 and 3.19 reveals that mRNA ofRANK and RANKL were expressed from 
the RNA extract ofHCMC and LAD2 cells. The intensity ofband ofRANK cloned 
product was high and suggested RANK was highly expressed in human mast cells. 
RANKL and OPG are both expressed in osteoblasts. However, the PCR product of 
OPG was not detected, which suggested OPG and RANKL were not necessarily 
co-expressed in same cells. 
3.3.7.1 Expression of bone remodeUng molecule after treatment of estradiol 
Gene expression levels ofRANKL, RANK and OPG ofl7p-estradiol-treated (10^^) 
LAD2 cells was compared with that of untreated human mast cells. The levels of 
expressions ofRANKL and RANK were not obviously altered by estrogen treatment 
(Figure 3.21a). The expression levels of RANK and RANKL were normalized to 
GAPDH gene and the results were showed in Figure 3.21b. The result showed no 
significant change in the expression level ofRANKL in LAD2 cells with or without 
estrogen treatment. The level of RANK expression seemed enhanced after 
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17P-eatradiol treatment, though the difference was not statistically significant. 
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3.4 Discussion 
The activation ofmast cells is triggered by cross linking ofanti-IgE on high affmity 
IgE receptors (FcsRI) or by basic secretagogues through the interaction with 
G-protein. The release ofpreformed mediators such as histamine from granules is the 
major event occurred in mast cell activation. Histamine causes contraction on smooth 
muscles and mucous production (Pmssin et al., 2003). Recent findings 
(Biosse-Duplan et aL, 2009; Deyama et al., 2002) also suggested that histamine could 
regulate the differentiation of osteoblasts in vitro. With the evidence of mast cells 
accumulation and activation in patients with osteoporosis, mast cells may play as 
regulator in development of the disease (Lesclous et al., 2001). Since estrogen also 
regulates activation of osteoblasts, mast cells may play a role by the release of 
histamine to bridge the regulation ofestrogen on osteoblasts. In this part ofstudy, the 
effect ofestrogen on histamine release from human mast cells was studied. 
Our fmding showed that 17p-estroadiol did not induce the release ofhistamine from 
human mast cells after 30 minutes or 24 hours incubation. The results were similar in 
primary culture and mast cell-cell line. It suggested that 17p-estradiol is not a 
potential secretagogue ofmast cells on activating the release ofhistamine. Estrogen 
cannot directly activate antigen pathway and basic secretagogues initiated exocytosis. 
Estrogen does not crosslink to IgE receptor and cannot initiate the subsequent 
classical activation. There was no scientific research about the direct activation of 
G-protein by estrogen and the activation of mediator release from mast cells. 
Although there are different substances that can activate mast cells, estrogen does not 
fall into either category (Lagunoffe^ aL, 1983). Similar result was observed from the 
incubation of estradiol with rat uterine mast cells for 30 minutes; histamine release 
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from mast cells was less than 10% oftotal histamine release. There was one piece of 
research which showed different result. Zaitsu et aL (2007) demonstrated that 
estradiol significantly induced basal histamine release from rat RBL-2H3 cell line. 
Indeed the level ofhistamine release after estradiol treatment in that study was not 
more than 10% and it could not reflect whether it is the spontaneous release of 
histamine from mast cells or the actual effect ofestradiol. 
It was demonstrated that estradiol suppressed anti-IgE induced histamine from 
HCMC and LAD2 cells only when the cells were treated with 10"^ M estradiol for 30 
minutes. Mast cell activation via cross-linking of IgE receptors involves the 
recruitment of Lyn and Syk protein kinase and the phosphorylation of adaptor 
molecule LAT (linker for activation of T-cells). Phosphorylated form of LAT 
subsequently activates other cytosolic adaptor molecules to transmit the signal to 
other downstream signal including phospholipase Cy (PLCy). Degranulation is 
induced by the activation ofPLCy and protein kinase C (PKC), which can increase 
the calcium mobilization (Gilfillan et aL, 2006). Estrogen may regulate the 
degranulation of mast cells through interacting with PLC/PKC pathway. The 
interaction of estrogen receptor with different cell signaHng pathway was extensively 
studied (Marino et aL, 2006). Estrogen binds to membrane bound ERs to activate 
non-genomic actions which are characterized as fast and independent from the 
regulation of transcriptional factors (Bjomstrom et aL, 2005). It is found that 
membrane bound ER-a can interact with PLCy and PKC to induce cell proliferation 
though non-genomic action ofestrogen (Li et al., 2009). The interaction ofERs with 
PLCy/PKC pathway is also related with changes on intracellular calcium 
concentration. Estradiol significantly increased the calcium influx in rat enterocytes 
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through the activation of PLC pathway (Picotto et al., 1999). Mast cell 
degranulation could be regulated by estrogen through action on PLOPKC pathway. 
However, results from our study on effect ofimmunological activation ofmast cells 
were different from similar studies performed by other research teams. Vliagofits et al. 
have found that pre-incubation with 10'^M estradiol did not enhance secretion from 
RPMCs after anti-IgE challenge (VUagoftis et al., 1992). Other results suggested that 
estradiol could enhance histamine release from rat mast cell line RBL-2H3 (Zaitsu et 
ai., 2007). The discrepancy ofresults may due to the difference in the origin ofcells. 
Both VUagoftis et al. and Zaitsu et al. used rat mast cells as the model of studies 
while we used primary human mast cell or human mast cell line as the model of 
studies. It is found that the functions ofmast cell are different based on their origin. 
The activation and production ofmediators from human mast cells can be different 
from those from rat or murine (Bischoff, 2007). The comparison ofant igen-induced 
histamine release after treatment ofestradiol done by Zaitsu could not totally reflect 
the effect ofestradiol on promoting histamine release. The difference was compared 
between the level of induced histamine release with estradiol treatment and basal 
level of histamine release with estradiol treatment. The main focus of the study 
should be the difference between the levels ofantigen induced histamine release with 
or without estradiol treatment. The level ofantigen induced histamine release with or 
without estradiol treatment from Zaitsu was different by less than 5% in 30 minutes 
treatment. This result cannot effectively demonstrate the effect of estrogen on antigen 
induced histamine release. 
Mast cell degranulation via immunological stimulus was not affected by all 
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concentrations of estradiol tested after 24 hours pre-incubation. The suppressing 
effect of 10"^ M estradiol observed after 30 minutes incubation on anti-IgE induced 
histamine release was not seen. As mentioned, estrogen produces non-genomic effect 
which is rapid and the effect can be observed within minutes or hour after activation 
ofER and subsequent signaling pathway. The rapid increment ofintracellular calcium 
in rat enterocytes was observed within 10 minutes incubation ofestradiol (Picotto et 
ai； 1999). The rapid effect on regulation ofPLC/PKC pathway by estradiol may have 
faded away after long incubation oftime. However, genomic effect ofestradiol may 
still act on mast cell to regulate cellular activity. Since the degranulation ofhistamine 
from mast cells is a rapid process, which happens within 10 - 30 minutes after the 
addition of secretagogues, long period of estradiol incubation may lose the 
non-genomic action ofestrogen regulation on mast cell degranulation. 
Compound 48/80 induced histamine release from mast cells through the activation of 
G-protein (Aridor et aL，1990). It is found that HCMC used in our study was not 
sensitive to compound 48/80 activation from previous study; LAD2 cells were 
adopted as the model for study. LAD2 cells subjected to 30 minutes or 24 hours 
incubation with estradiol did not demonstrate altered histamine release induced by 
compound 48/80. The results ofhuman model ofmast cell were different from those 
obtain when rat mast cells was used. Evidence showed that histamine release from 
basic secretagogue activated rat mast cells was suppressed after estradiol incubation 
(Cocchiara et al,, 1992; Vliagoftis et al., 1992). VUagoftis et al. (1992) demonstrated 
the release ofhistamine from compound 48/80-activated RPMCs was augmented in a 
dose-dependent manner. Report from Cocchira et aL (1992) also showed inhibitory 
effect on substance P induced histamine release from RPMCs after incubation with 
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estradiol. Despite the difference in the use of different mast cell types, the studies 
done by Vliagoftis et al. and Cocchira et al. used l^iM estradiol as the starting 
concentration. The concentration used in these studies was 10000 times higher than 
that found physiologically before ovulation in human. It suggested that the promotion 
of histamine release by estradiol may not reveal the real situation in human under 
physiological condition. The activation ofmast cells by basic secretagogues was not 
affected by the physiologically level ofestradiol (i.e. 10'^^M estradiol) suggested that 
the regulation of estrogen was not mediated via the non-immunological activation 
pathway in human mast cells. 
Selective estrogen receptor modulators (SERMs) act as agonists or antagonists on 
estrogen receptors depending on the site of different tissues (Sato et al, 1996). 
Tamoxifen and raloxifene are both agonists on bone and they effectively enhance the 
BMD in postmenopausal osteoporosis patients (Siris et al, 2002; Tiitinen et al., 
2004)，but the effect of them on other tissues are different. SERMs were used to 
examine whether they act similarly as estradiol on mast cells, hence evaluate the role 
ofSERMs on the regulation ofhistamine release from human mast cells. 
The basal levels of histamine release from HCMC were not affected by raloxifene 
and tamoxifen while that from LAD2 cells were potentiated by high concentration of 
(lO-^M) SERMs. Only raloxifene could maintain the promoting effect on LAD2 after 
24 hour incubation period and similar effect was not seen with tamoxifen. Primary 
cultured mast cell obtained from lung tissue also showed no response to tamoxifen in 
terms of basal histamine release (Duffy et al., 2003). It suggested that the action of 
SERMs on human mast cells are different depend on the subtype ofmast cells used. It 
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was observed that raloxifene and tamoxifen could induce intrinsic histamine release 
from LAD2 in our study. The induction ofbackground histamine release by SERMs 
contributed to the promoting effect on histamine release from LAD2 cells activated 
by anti-IgE or compound 48/80 (Figure 3.10 and 3.12). The promotion in the level of 
histamine release at high concentration ofSERMs treatment was the additive effect of 
background histamine release induced by SERMs and the activation of mast cell by 
secretagogues. The significant promoting effect of SERMs could not reflect the action 
of SERMs on mast cell activation. The histamine release from human mast cells via 
activation by IgE- dependent and IgE-independent pathway were not affected by 
incubation with SERMs. It suggested that SERMs did not regulate mast cells activity 
via both activation pathways. 
The release of histamine is an observation of the early event happened in activated 
mast cells. The release of cytokine is always observed few hours after activation of 
mast cells because cytokines and other lipid mediators are newly synthesized (Galli et 
al, 2008a). Activation of mast cells induced propagation of signal downstream to 
activate transcription of genes of cytokines (Gilfillan et al., 2006). Our results 
demonstrated that synthesis ofTNF-a was promoted by estradiol in anti-IgE activated 
HCMC. However, the production ofTNF-a from anti-IgE activated LAD2 cells was 
• under the detectable level, the mast cell line was activated with basic secretagogues, 
substance P. At the same time, we could compare the different in TNF-a production 
from human mast cells activated through different pathways. Effect of estradiol on 
substance P induced TNF-a from LAD2 was enhanced when low concentration of 
estradiol was used and a gradual reduction of cytokine production was observed with 
increasing concentrations of estradiol. The activation of mast cell through both 
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immunological and chemical stimulation successfully produced pro-inflammatory 
cytokine and estradiol seems to enhance the production of it. However, various 
studies demonstrated that estradiol suppressed the inflammatory cytokine expression 
and production in different tissues. The action of estrogen on suppressing cytokine 
production from macrophages was through the control of localization of 
transcriptional factors belongs to NF-KB family (Ghisletti et aL, 2005). In vitro study 
also demonstrated the estradiol reversed the stimulatory effects ofHpopolysaccharide 
(LPS) on pro-inflammatory cytokine production, including TNF-a, produced by 
human periodontal ligament cells (Shu et al, 2008). Kim et al. (2001) showed that 
cytokines production from human mast cell line (HMC-1) activated by calcium 
ionophore and phorbol ester was significantly suppressed by estradiol in a 
dose-dependent manner. There are different pieces ofevidence showing that estrogen 
can work as pro-inflammatory or anti-inflammatory regulator. The difference in the 
responses ofcytokine production from mast cells after estrogen treatment may be due 
to the dosage ofestrogen used in treatment, whether the study was done in vivo or in 
vitro, type of specimen or tissues begin examined and also the type of stimulus. 
Despite the inhibition ofgene localization ofNF-KB in macrophages by estradiol as 
demonstrated by Ghisletti et al (2005), estradiol showed up-regulation of NF-xB 
signaling in mouse splenic lymphocytes. Dai et al. (2007) revealed the possible role 
of estrogen in stimulating B cell lymphoma-3 (Bcl-3), which form transcriptional 
factor complex with p50, and in tums enhance the NF-KB transcriptional factors. 
Production ofseveral anti-inflammatory cytokine including IL-1, IL-4 and mF-y was 
promoted. Although the level ofTNF-a expression was not found to be suppressed in 
the indicated study, the report suggested that the possibility of differential regulation 
on NF-KB proteins by estrogen and the subsequent expression of various cytokines 
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since TNF-a production is also under the regulation ofNF-KB signaling (McKay et 
aL, 1999). We demonstrated that TNF-a may also be up-regulated by estrogen in our 
study with the use of human mast cell, although the exact mechanism requires more 
in depth investigation. 
The effect ofSERMs on cytokine production from anti-IgE and substance P activated 
human mast cells was different from those demonstrated by estradiol. Significant 
inhibition was observed in anti-IgE induced TNF-a production after treatment of 
raloxifene and tamoxifen. Our results also demonstrated the promotion of TNF-a 
from substance P activated mast cells after incubation with raloxifene and tamoxifen 
at high concentration. It was observed that the serum level TNF-a was increased after 
withdrawal of estrogen in postmenopausal women (Zheng et aL, 1997). Clinical 
studies demonstrated the suppression ofTNF-a production after the continuous use of 
raloxifene for 6 months (Gianni et al., 2004; Walsh et aL, 2001). It suggested there 
was down-regulation ofTNF-a production by raloxifene. Walsh et al (2001) found 
that raloxifene and estrogen exerted similar inhibitory effect on the production of 
TNF-a in the patients. It suggested that raloxifene might work through similar 
mechanism as estrogen on the production of TNF-a. The regulation of TNF-a 
production by tamoxifen was also discussed by various studies. Administration of 
tamoxifen could block the estrogen mediated TNF-a production from LPS stimulated 
mice (Zuckerman et al., 1995). It suggested that tamoxifen could down-regulate the 
action of estrogen on cytokine production. We also demonstrated suppressing effect 
on TNF-a production from anti-IgE activated human mast cells after incubation with 
raloxifene or tamoxifen. It seemed that the action of estradiol on anti-IgE induced 
TNF-a release from human mast cells was opposite to the results from raloxifene and 
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tamoxifen. SERMs can exert effect through the interaction with ERs, which is similar 
to the action ofestrogen. SERMs bind to ERto induce conformational changes of the 
receptor. The SERM-ER complex is then bound to the ERE or other promoter regions 
of target gene to initiate transcription. The activation of receptors recruits the 
co-activators or co-repressors to regulate the gene transcription (Riggs et al, 2003). 
However, the action of SERMs via ER may vary due to different factors: such as 
different types of SERMs on binding ofreceptors, the subtypes ofERs being bound 
and the recruitment ofco-regulators before transcription (Dutertre et al, 2000). These 
factors can affect the actions of SERMs on regulating ER-dependent activity. 
The action of SERMs however can also exert without the binding of ERs. The 
receptor independent actions of SERMs were observed in different in vitro studies. A 
report demonstrated the inhibitory effect oftamoxifen on TNF-a mRNA expression 
and protein production in okadaic acid cultured trnnor cell line. The report proposed 
that the action oftamoxifen on production ofTNF-a was mediated by inhibiting the 
activity of NF-KB (Suganuma et aL, 1996). There was no evident showing that 
estradiol demonstrated similar or opposite effect. Recent report suggested that the 
anti-inflammatory effect of SERMs in LPS-stimulated microglial cells was 
independent to the action of ER (Suuronen et al., 2005). It reported that IL-6 
production from LPS-stimulated rat primary microglial cells was suppressed by 
incubation with raloxifene or tamoxifen in a dose dependent manner. Similar 
observation was not seen in experiment done with estradiol. Molecular study revealed 
that raloxifene down-regulated the LPS-stimulated AP-1 activation through MAPK 
pathway in microglial cells. A recent report demonstrated that tamoxifen and 
raloxifene could effectively inhibit glutamine uptake in ER-negative cancer cells 
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through inhibition of glutamine transporter (Todorova et al.). The inhibition of 
glutamine uptake directly reduced the formation of antioxidant glutathione (GSH) 
and the apoptosis of cells. It suggested that SERMs carry other pharmacological 
effect apart from interacting with ERs. Duffy et al. (2003) suggested that the cell 
proliferation of mast cells was regulated by tamoxifen in an ER-independent manner. 
They found that the proliferation of lung mast cells was dose-dependently inhibited 
after tamoxifen incubation and they proposed that might be mediated by chloride 
channel modulation. In our study, the promotion of TNF-a release from substance P 
activated mast cells after treatment of raloxifene or tamoxifen was not seen in similar 
studies ofestradiol. It might also suggest that effect ofSERMs on regulating cytokine 
production in human mast cells may involve ER-independent mechanisms. However, 
more mechanistic studies are needed to confirm the hypothesis. 
Based on our study results, we could not clearly demonstrate the possible mechanism 
ofestradiol and SERMs on human mast cellactivity; whether there was involvement 
of ERs is still unknown. However, the mechanism of another steroid hormone on 
mast cell activity may suggest the possible clue on how estrogen works. 
Glucocorticoid (GC) is a steroid hormone and also works by binding to its receptor, 
glucocorticoid receptor (GR). The action of GC was observed in down-regulation of 
the expression ofmany mediators and cytokines that mediated inflammation (McKay 
et al., 1999). Various studies reported the inhibitory effects of GC on the release of 
stored and newly synthesized mediators from mast cells activated by immunological 
and cationic stimuli (Lippert et al, 1996; Vendelin et al., 2005; Williams et al., 1995). 
The down-regulation of mast cell activity by GC was obvious and the mechanisms of 
actions were well studied. It was found that GC effectively down-regulated the PI3-K 
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activation pathway in mast cells so that degranulation was blocked(Andrade et al., 
2004). From the study of GC on mast cells, it revealed that steroid hormone may 
regulate mast cell activity, the detailed mechanistic study of estrogen and SERMs on 
regulating human mast cells still need further investigation to complete the story. 
ERs expressions were detected in various tissues; ER-a distributed mainly in uterus, 
kidney and heart, while ER_P is expressed in ovary, lung and hematopoietic system. 
There is ER co-expression in mammary gland, bone and certain regions of the brain 
(Matthews et al., 2003). The expressions of ER-a and _p in HCMC and ER_P in 
LAD2 cells with the evident by immunofluorescence staining and the amplification of 
ER mRNA fragments by RT-PCR in our study, suggesting the possibility that estrogen 
may exert effect on mast cell activity. Similar observations were reported by other 
previous studies that mast cells located in different tissues expressed ERs, including 
mast cells obtained from respiratory tract, urinary bladder, abdominal aortic vessels 
and dura mater surrounding the central nervous system (Nicovani et al., 2002; Pang et 
al., 1995; Press et al., 1986; Rozniecki et al., 1999). However, the expression ofER-a 
was not seen after the amplification of mRNA fragment by RT-PCR. ER_P was the 
dominant type of receptor on LAD2 cells. The difference in expression of ERs in 
mast cells proposed that mast cells heterogeneity in different tissue. Acar et al. (2007) 
demonstrated that bladder mast cells from rat with induced cystitis expressed ER-p 
only while the primary cultures ofbone marrow-derived mast cells (BMMC) from the 
study by Zaitsu et al. expressed ER-a only (Zaitsu et al., 2007) . The expression of 
ERs in mast cells varies by the location where mast cells are matured. Therefore, the 
variation in ERs expression may also be an observation of mast cell heterogeneity. 
HCMC and LAD2 cells represent MCi and MOrc of human mast cells. The 
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differential expressions of ER in HCMC and LAD2 cells imply that the actions of 
estrogen may vary among different type of mast cells. The variation in the mediator 
release from human mast cells after treatment of estradiol may also be attributed by 
the difference in mast cell subtypes. Furthermore, the exact localization of ER was 
not proven in human mast cells. The membrane-bound ERs may also be involved in 
mediating non-genomic action of estrogen. Localization of ERs in human mast cells 
would be useful to define whether the regulating event observed in human mast cells 
was mediated by genomic or non-genomic action ofestrogen. 
ER expressions were under auto-regulation and the level of expression can be 
modulated by exposure to estrogen. It is found that estrogen down-regulated ER-a 
expression in breast cancer cell line MCF-7 (Pink et al., 1996). Recent study 
demonstrated that the expression of ER-P was down-regulated by estrogen with 
involvement of ER-a in various regions of brain fNomura et aL, 2003). With the 
evidence that mast cells were located proximally to bone tissues and mast cell 
activation was observed in the process ofbone resorption (Fouilloux et al., 2006), it is 
hypothesized that estrogen regulates bone metabolism may mediate through the mast 
cells activity. In our study, the expression of ERs on human mast cells suggested the 
possibility of estrogenic action on cells. The incubation of human mast cells with 
10"^ M estradiol showed no difference in the expression level ofERs. It proposed that 
expression of ERs was not regulated by estrogen in mast cells. Since the work 
between mast cells activity and estrogenic action are still unclear, further exploration 
is needed in this field to elucidate the interaction between them. 
As mentioned, mast cells located proximally to bone tissue and the activity of mast 
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cell was observed in bone resorption, role of mast cells in bone remodeling is not yet 
fully understood. Since the productions of bone remodeling molecules are the major 
target of regulation in bone metaboHsm, estrogen also regulates the production of 
RANKL, OPG and RANK from osteoclasts and osteoblasts. In our study, we 
demonstrated that human mast cells also expressed some of these bone remodeling 
molecules. RANKL and RANK were expressed in human mast cells, both the 
primary cultures and immortal cell line. There was no OPG detected from human 
mast cells. 10"^M estradiol incubation did not alter the expressions of RANKL and 
RANK from human mast cells. The result shown by our study suggested RANKL and 
RANK were not uniquely expressed in bone cells and they can be co-expressed in 
mast cells. Similar observation was shown by Bashir et al (2005) that human 
peripheral blood mononuclear cells (PBMCs) expressed RANKL, RANK and OPG 
genes. In that study, levels of these genes was down-regulated after the continuous 
treatment of estrogen or raloxifene for 12 months. Since PBMC and mast cells are 
originated from hematopoietic stem cells, which is also the progenitor of osteoclasts 
(Raisz, 1999a)，it is suspected that expression of RANK and RANKL on mast cells 
can also be regulated by estrogen if longer treatment time was used. Since the action 
of estrogen is conventionally modulating the transcription activity of target genes in 
cells, the protein expressions may take longer time to give an obvious observation. 
Apart from producing anti-inflammatory effect, the pro-long intake of GC leads to 
severe bone loss and increase the risk of osteoporosis. The major molecular effect of 
GC on bone was the disturbance on proliferation and survival of osteoblasts 
(Manolagas et al, 1999). The decrease of osteoblasts activity and promotion of 
osteoblasts apoptosis were observed in mice treated with GC continuously for 3 
months. The treated mice resulted in severe osteoporosis with low mineral content. 
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Another study revealed the inhibition of OPG production from osteoblasts by 
dexamethasone, an example of GC, through repression ofOPG gene transcription in a 
JNK-dependent manner (Kondo et aL, 2008). These destructive actions of GC on 
bone tissues were completely different from the protective effect ofestrogenic action 
on bone. Although both steroids can regulate the activity of mast cells and 
inflammatory response as reported from different studies discussed before, their role 
in regulating bone metabolism is unlikely the same. 
In our study, estradiol produced a marginal inhibiting effect on anti-IgE induced 
histamine release from human mast cells. The effect of SERMs on histamine release 
from human mast cells was not prominent. The cytokine release induced from 
anti-IgE and basic secretagogue activated mast cells was regulated differentially by 
estradiol and SERMs. We also demonstrated the differential expression of ER 
subtypes in different types of human mast cells but the expression level of ER was 
not affected by short term estradiol incubation. We proposed that mast cell activity 
was modulated by estradiol and SERMS, especially on the production ofTNF-a from 
human mast cells. However, more investigation is required to confirm whether the 
actions of estradiol and SERMs are mediated by ER or not. Further studies are needed 
to establish the interaction between anti-osteoporosis drug with mast cells, and their 
roles in bone metabolism. 
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Figure 3.1: Characterization of human culture mast cells (HCMC) after 12*^  一 
14*h week of cultures. HCMC cytoplasmic granules were stained with May 
Grtinwald"Giemsa stain (a). Granular protease tryptase and chymase were stained by 
immunocytochemical method employed anti-human tryptase and anti-human 
chymase antibodies. Anti-P-actin antibody was used as positive control (b). 
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Figure 3.2: Effect of 30 minutes incubation with 17p-estradiol on basal 
histamine release from human mast cells, (a) HCMC and (b) LAD2 cells were 
incubated with 17p-estradiol for 30 minutes to observe the basal histamine release. 
Results were corrected for corresponding spontaneous release. All values are mean 土 
SEM for 3 - 6 experiments. 
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Figure 3.3: Effect of 24 hours incubation with 17p-estradiol on basal 
histamine release from human mast cells, (a) HCMC and (b) LAD2 cells were 
incubated with 17p-estradiol for 24 hours to observe the basal histamine release. 
Results were corrected for corresponding spontaneous release. All values are mean 士 
SEM for 4 - 6 experiments. 
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Figure 3.4: Effect of 30 minutes pre-incubation with 17p_estradiol on anti-IgE 
induced histamine release from human mast cells. Sensitized (a) HCMC and (b) 
LAD2 cells were pre-incubated with 17p_estradiol for 30 minutes before challenged 
with anti-IgE for 30 minutes to stimulate histamine release. Results were corrected 
for spontaneous histamine release. All values are mean 土 SEM for 6 - 9 experiments. 
Asterisk represents statistical significant different ^><0.05) in histamine release when 
compared with that induced by anti-IgE. 
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Figure 3.5: Effect of 24 hours pre-incubation with 17p-estradiol on anti-IgE 
induced histamine release from human mast cells. Sensitized (a) HCMC and (b) 
LAD2 cells were pre-incubated with estradiol for 24 hours before challenged with 
anti-IgE for 30 more minutes. Results were corrected for spontaneous histamine 
release. All values are mean 土 SEM for 4 - 6 experiments. 
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Figure 3.6: Effect of 30 minutes pre-incubation with 17p-estradiol on 
compound 48/80 induced histamine release from human mast ceUs. LAD2 cells 
were pre-incubated with 17p-estradiol for 30 minutes before challenged with 
compound 48/80 for 30 more minutes. Results were corrected for spontaneous 
histamine release. All values are mean 士 SEM for 7-9 experiments. 
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Figure 3.7: Effect of 24 hours pre-incubation with 17p-estradiol on compound 
48/80 induced histamine release from human mast cells. LAD2 cells were 
pre-incubated with 17p-estradiol for 24 hours before challenged with compound 
48/80 for 30 more minutes. Results were corrected for spontaneous histamine release. 
All values are mean 士 SEM for 4 experiments. 
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Figure 3.8: Effect of 30 minutes incubation with SERMs on basal histamine 
release from human mast ceUs. (a) HCMC and (b) LAD2 cells were incubated with 
raloxifene ( • ) or tamoxifen (•) for 30 minutes to observe the basal histamine release. 
Results were corrected for corresponding spontaneous release. All values are mean 士 
SEM for 3 - 6 experiments. Asterisk represents statistical significant different (at 
least p<0.05) in histamine release when compared with the spontaneous release. 
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Figure 3.9: Effect of 24 hours incubation with SERMs on basal histamine 
release from human mast ceUs. (a) HCMC and (b) LAD2 cells were incubated with 
raloxifene ( • ) or tamoxifen (•) for 24 hours to observe the basal histamine release. 
Results were corrected for corresponding spontaneous release. All values are mean 土 
SEM for 4experiments. Asterisk represents statistical significant different (at least 
p<0.05) in histamine release when compared with the spontaneous release. 
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Figure 3.10: Effect of 30 minutes pre-incubation with SERMs on anti-IgE 
induced histamine release from human mast cells. Sensitized (a) HCMC and (b) 
LAD2 cells were pre-incubated with raloxifene ( • ) or tamoxifen (•) for 30 minutes 
before challenged with anti-IgE for 30 more minutes. Results were corrected for 
spontaneous histamine release. All values are mean 士 SEM for 4 - 7 experiments. 
Asterisk represents statistical significant different (at least p<0.05) in histamine 
release when compared with that induced by anti-IgE. 
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Figure 3.11: Effect of 24 hours pre-incubation with SERMs on anti-IgE 
induced histamine release from human mast cells. Sensitized (a) HCMC and (b) 
LAD2 cells were pre-incubated with raloxifene ( • ) or tamoxifen (•) for 24 hours 
before challenged with anti-IgE for 30 more minutes. Results were corrected for 
spontaneous histamine release. All values are mean 士 SEM for 4 experiments. 
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Figure 3.12: Effect of 30 minutes pre-incubation with SERMs on compound 
48/80 induced histamine release from human mast cells. LAD2 cells were 
pre-incubated with raloxifene ( • ) or tamoxifen (•) for 30 minutes before challenged 
with compound 48/80 for 30 more minutes. Results were corrected for spontaneous 
histamine release. All values are mean 士 SEM for 9 experiments. Asterisk represents 
statistical significant different (p<0.05) in histamine release when compared with that 
induced by compound 48/80. 
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Figure 3.13: Effect of 24 hours pre-incubation with SERMs on compound 48/80 
induced histamine release from human mast cells. LAD2 cells were pre-incubated 
with raloxifene ( • ) or tamoxifen (•) for 24 hours before challenged with compound 
48/80 for 30 more minutes. Results were corrected for spontaneous histamine release. 
All values are mean 士 SEM for 4 experiments. 
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Figure 3.14: Effect of 17p-estradiol on TNF-a release from human mast cells. 
Sensitized (a) HCMC and (b) LAD2 cells were pre-incubated with 17p_estradiol for 1 
hour before the challenge of anti-IgE and substance P respectively. Supernatant was 
collected 24 hours after the addition of stimulant and was analyzed for the amount of 
TNF-a contented. Results were corrected for spontaneous cytokine release. All values 
are mean 士 SEM for 4 _ 5 experiments. 
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Figure 3.15: Effect of raloxifene on TNF-a release from human mast cells. 
Sensitized (a) HCMC and (b) LAD2 cells were pre-incubated with raloxifene for 1 
hour before the challenge of anti-IgE and substance P respectively. Supernatant was 
collected 24 hours after the addition of stimulant and was analyzed for the amount of 
TNF-a contented. Results were corrected for spontaneous cytokine release. All values 
are mean 士 SEM for 3 - 4 experiments. Asterisk represents statistical significant 
different (at least p<0.05) in cytokine release when compared with that induced by 
stimulant alone. 
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Figure 3.16: Effect of tamoxifen on TNF-a release from human mast cells. 
Sensitized (a) HCMC and (b) LAD2 cells were pre-incubated with tamoxifen for 1 
hour before the challenge of anti-IgE and substance P respectively. Supernatant was 
collected 24 hours after the addition of stimulant and was analyzed for the amount of 
TNF-a contented. Results were corrected for spontaneous cytokine release. All values 
are mean 士 SEM for 3 一 4 experiments. Asterisk represents statistical significant 
different (at least p<0.05) in cytokine release when compared with that induced by 
stimulant alone. 
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Figure 3.17: Expressions of estrogen receptor-a and _p in HCMC. Estrogen 
receptor-a and _p were stained by immunofluorescence staining method with the used 
of anti-human estrogen receptor-a and _P antibodies. HCMC cell smear incubated 
with anti-IgG was employed as negative control. 
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Figure 3.18: Expressions of estrogen receptors and various bone remodeKng 
molecules on HCMC. mRNA of HCMC was analysis with RT-PCR to detect the 
expression ofERs and different bone remodeling molecules. L represents 100bp DNA 
ladder, with the brightest band represents 600bp. GAPDH was taken as positive 
control. Negative lanes are the negative control of corresponding primers (without 
addition of reverse transcriptase in the synthesis of cDNA). The expected product 
sizes of different DNA product are: ER-a, 668bp; ER-p, 528bp; RANK, 500bp; 
RANKL, 475bp; OPG, 470bp; GAPDH, 595bp. Data was the representative from 
three different RNA isolation. 
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Figure 3.19: Expressions of estrogen receptors and various bone remodeUng 
molecules on LAD2. mRNA of LAD2 was analysis with RT-PCR to detect the 
expression ofERs and different bone remodeling molecules. L represents 100bp DNA 
ladder, with the brightest band represents 600bp. GAPDH was taken as positive 
control. Negative lanes are the negative control of corresponding primers (without 
addition of reverse transcriptase in the synthesis of cDNA)�The expected product 
sizes of different DNA product are: ER-a, 668bp; ER-P, 528bp; RANK, 500bp; 
RANKL, 475bp; OPG, 470bp; GAPDH, 595bp. Data was the representative from 
three different RNA isolation. 
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Figure 3.20: Effect of estrogen on the change of expression level of estrogen 
receptors in LAD2 cells. mRNA of 10'^M 17p-estradiol treated LAD2 cells was 
analyzed with RT-PCR to detect any change in expression of estrogen receptors. L 
represents 100bp DNA ladder while the brightest band represents 600bp. Lane 1 is 
basal LAD2 cells and lane 2 is estradiol treated-LAD2 cells. The expected product 
sizes ofdifferent DNAproduct are: ER-a, 668bp; ER-p, 528bp; GAPDH, 595bp (a). 
The expression of ER-P was measured semi-quantitatively and was normalized to 
GAPDH gene expression. Expression level was presented as relative ratio of GAPDH 
gene expression (b). Data was representative from 3 individual treatments. 
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Figure 3.21: Effect of estrogen on the change of expression level of various bone 
remodeling molecules in L A D 2 cells. mRNA o f 10"^M 17p-estradiol treated LAD2 
was analyzed with RT-PCR to detect any change in the expression level o f various 
bone remodeling molecules. L represents 100bp D N A ladder while the brightest band 
represents 600bp. Lane 1 is basal LAD2 cell and lane 2 is estradiol treated-LAD2 
cells. The expected product sizes o f different D N A product are: RANK, 500bp; 
RANKL, 475bp; OPG, 470bp; GAPDH, 595bp (a). The expressions o f R A N K and 
R A N K L were measured semi-quantitatively and were normalized to GAPDH gene 
expression. Expression level was presented as relative ratio o f GAPDH gene 
Expression (b). Data was representative from 3 individual experiments. 
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4 Effects of anti-osteoporosis Chinese herbal 
medicines on activity of human mast cells 
4.1 Introduction 
The use of Chinese herbal medicines in the treatment or prevention of diseases is 
gaining popularity nowadays. Herbal medicines can be any part of the plants, in raw 
or in extracts. The herbs are extracted with water or other solvents to give collections 
of chemicals, which can include fatty acids, flavonoids, aUcaloids and others (Bent, 
2008). The use of herbs in treatment of diseases is common in Southeast Asia like 
China, Japan and Korea. This trend is influencing many Westem countries like the US 
since the herbal medicines are more effective in treatment of various diseases. The 
use of herbal medicines can also be a supplement or complementary to the westem 
medicine or as alternative therapy when the conventional medications fail in 
treatment (Winslow et al., 1998). For example, ginkgo is a common herb prescribed 
for patient with dementia to improve the memory with little side effects (Solomon et 
al, 2002). 
The use of herbal medicines in the treatment of osteoporosis has developed for long 
time in China, India and Japan. Many reports have suggested the effectiveness of 
various herbal medicines or herbal formulations in improving the health of bone in 
terms of various parameters of bone metabolism. Putman et al (2007) has listed 
numbers of the herbal formulations being tested in clinical trials or in animal studies 
with their efficacy on treatment of osteoporosis. 'Chujo-to' is an herbal formula with 
16 different herbs that has been used in Japan over a century to maintain the health of 
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women. It is found that less BMD loss in rats that had undergone ovariectomy (OVX) 
after the consumption of Chujo-to for 7 weeks (Hidaka et al., 2000). Another Chinese 
herbal prescription 'Hochu-ekki-to', which contains 10 herbs, could effectively 
protect bone loss induced by injection of gonadotropin-releasing hormone (GnRH) in 
female rats (Sakamoto et aL, 2000). 'Shen Gu' is another Chinese herbal formulation 
which is traditionally recommended for maintaining health of bone. It was revealed 
that the use of Shen Gu for 6 months can enhance mineral content and inhibit bone 
resorption in osteoporosis patients (Mingyue et al., 2005). More studies are emerging 
to fmd the underlying mechanism of herbal formulations in regulating various 
pathways in metabolism. An in vitro study demonstrated a Korean herbal preparation 
containing 10 herbs can inhibit the production of PGE2 in osteoblasts through the 
down-regulation on tyrosine kinase signaling and the transcription ofcyclooxygenase 
(COX) expressions (Jin et al., 2006). 
A newly developed herbal preparation containing three herbs has been reported with 
its preservative effect on bone mineral content in ovariectomized rats. This 
formulation (in short called ELP) contains three herbs that are commonly used for 
tonifying the ‘kidney system’ in the concept of Chinese medicines; they are Herba 
Epimedii (HEP,淫羊藿），Fmctus�Ligustri Lucidi (FLL,女貞子）and Fmctus 
Psoraleae (FP,補骨月旨)with a weight ratio of 5:4:1. The water extract of ELP 
formulation (lg/day and 0.5g/day) can effectively preserve the BMD at femoral neck 
in OVX rats (Sun et al., 2008). These three ingredients are used individually or in 
combination with other herbs to improve bone health. Both HEP and FLL were 
reported with their ability to suppress urinary calcium excretion and inhibit the 
accelerated bone turnover in OVX rats (Xie et aL, 2005; Zhang et aL, 2006). FP can 
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directly stimulate bone formation locally on bone defects mixed with matrix collagen 
(Wong et al, 2009). The promising effects of these herbs in both in vivo and in vitro 
studies suggested that they are recommended as supplementary or alternative 
therapeutic in the management of postmenopausal osteoporosis. 
Apart from the bone protective effect, the constituent herbs have various uses in 
regulation of other body functions. Herba Epimedii (HEP) is a major component in 
many herbal formulations for treatment of bone disease, including osteoporosis (Wu 
et al., 2003). It is the branch and leaf parts of Epimedium species. Shen et al. (2007) 
have analyzed the genetic, chemical and estrogenic characteristics of HER They 
found that this herb contains phytoestrogenic properties and can promote the transient 
transcription of estrogen receptor a with in vitro study. The HEP extract could elevate 
the estrogen level effectively in postmenopausal women after the treatment with HEP 
water extract for six months (Yan et al., 2008). HEP also carries anti-oxidative 
property as proven by its major fIavonoids component, icariin. It protected chemical 
induced DNA damage in a dose-dependent manner and formed intramolecular 
hydrogen bond to stabilize radical formed (Zhao et aL, 2007a). Icariin acted as 
anti-oxidant on hydrogen peroxide-induced cell damage in endothelial cells by 
reducing expression of caspase-3 protein, which is the major executor in cell 
apoptosis (Wang et al, 2005). 
Fructus Ligustri Lucidi (FLL) is the fruit of Ligustrum Lucidum Ait. This herb could 
protect the liver damage induced by acetaminophen in mice (Liu et al., 1993). FLL 
has anti-cancer effects both in-vivo and in-vitro. Oleanolic acid (OA) is the major 
component of FLL. OA showed an anti-tumor effect on the implanted tumor in 
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mouse in a dose-dependent manner (Hsu et al., 1997). Incubation ofFLL extract or 
OA alone could significantly induce the programmed cell death in leukemia cell line 
HL60 cell in a time-dependent manner (Zhang et aL, 2007). OA also exert 
anti-inflammatory effect by enhancing the production of leukocytes and suppressing 
the delayed hypersensitivity event (Liu, 1995; Raphael et aL, 2003). 
Fructus Psoraleae (FP) is the seeds ofPsoralea corylifolia. Zhang et al. evaluated the 
estrogenic potency of several Chinese herbal medicines and found that FP has similar 
activity as estrogen towards the P-galactosidase assay (Zhang et al., 2005). Recently, 
the role ofFP in central nervous system was studied. FP exerted a strong inhibition on 
dopamine uptake by dopamine transporter (DAT) expressed cells and the 
noradrenalin uptake by noradrenalin transporter QSTET) expressed cells. Behavioral 
study demonstrated that FP stimulated the activity of reserpinized mice with a 
long-lasting effect (Zhao et aL, 2007b). The idea ofFP act as DAT and NET inhibitor 
suggested the regulatory effect of FP in dopamine and noradrenalin system and FP 
may act to relieve the symptoms ofParkinson's disease and depression. 
With the increasing usage ofherbal medicines in assisting or directly in the treatment 
of different diseases like rheumatoid arthritis, many herbs are found to have 
anti-inflammatory and anti-allergy effects. Many herbal preparations or individual 
herbs have been tested with their anti-inflammatory effects on mast cells, in which it 
serves as an important effector in the development of inflammation. Different herbs 
have demonstrated suppressing effect on cytokines release from mast cells induced 
immunologically or chemically (Kang et aL, 2006; Na et aL, 2004). The effect of 
herbal medicines or formulations was done on inhibiting the expression of signaling 
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molecules in the activation pathways of mast cells. An herbal formulation used for 
reducing nasal symptoms in seasonal allergic rhinitis was done by inhibiting the 
expression ofCOX-1 protein in RPMC, hence PGD2 production was reduced (Lenon 
et al, 2007). More mechanistic studies were done to elucidate the role of herbal 
medicines in reducing symptoms of mast cells-related diseases. 
Chen et al (2005) studied the effects of several Chinese herbal medicines on 
prevention ofosteoporosis with the evaluation ofmast cell count. A decrease ofbone 
marrow mast cell count was observed in mice treated with Hachimi-jio-gan for 3 
months. It suggested proliferation of mast cells was affected by the herbs in bone 
marrow; similar mechanism may also be applied to other anti-osteoporosis herbal 
formulations or individual herbs. 
Mast cells activation is observed in the early stage ofbone resorption (Fouilloux et al, 
2006). With the in vivo evidence ELP demonstrated anti-osteoporosis effect on OVX 
rats; it is suspected the mechanism of anti-osteoporotic effect may be mediated via 
the regulation of mast cells activation and the release of mediators thereafter. In this 
study the effects ofELP on mast cell activation as reflected by histamine release and 
pro-inflammatory cytokines production were investigated to figure out the possible 
relationship between mast cells and the anti-osteoporosis formulation ELP. The 
modulation of calcium influx associated with mast cells activation by the herbs was 
also studied. Human mast cells were treated with individual constituent herbs to 
further examine the possible active components in the herbal formulation. 
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4.2 Materials and methods 
The materials and methods are listed in Chapter 2. 0.5p,g/ml anti-IgE was used for 
stimulation of histamine release from HCMC while 2.0|xg/ml anti-IgE or O.lp,g/ml 
compound 48/80 were used for stimulation ofhistamine release from LAD2 cell line. 
All results are corrected for spontaneous release in buffer. 
The herbal medicines as lyophilized powder were gifts of the Institute of Chinese 
Medicine, The Chinese University of Hong Kong. Stock solutions were prepared by 
dissolving the powder in distilled water to the concentration lOOmg/ml (except that 
ELP was provided as a stock solution of 30mg/ml). The required concentrations of 
the herbal medicine used in the studies were then diluted with FHB/HA buffer before 
the experiments. When DMSO was used to prepare drugs from certain fractions of 
herbal medicines in the studies, the highest concentration of DMSO in drug was less 
than 0.02%. Lyophilized powders of these herbal medicines were dissolved with 
DMSO to give lOOmg/ml stocks and were tother diluted into required concentrations. 
At this concentration, DMSO did not induce the release of mediator from mast cells. 
DMSO controls were preformed in parallel with the experiments when those drugs 
were involved. 
The results were analyzed with one-way analysis of variance (ANOVA) and 
Bonferroni's multiple comparison tests as the post-hoc analysis. The statistical 
significance is performed by comparing anti-IgE or compound 48/80 induced 
histamine or other mediator release in the presence of drug treatment to the control 
release induced by corresponding secretagogues. Differences were considered 
significant whenp<0.05. 
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4.3 Results 
The levels of spontaneous histamine release of mast cell in buffer alone were within 
10% through the experiments. Data are presented as percentage of histamine release 
after correction for the spontaneous release. 
4.3.1 Effect of the anti-osteoporosis Chinese herbal formulation ELP on 
histamine release from human mast cells 
Histamine release was the most observable and easiest way to reveal the sign ofmast 
cell activation. The Chinese herbal formulation ELP was reported to demonstrate 
anti-osteoporosis effect in OVX rats by retaining urinary calcium from excretion (Sun 
et al, 2008). It is observed that ELP solution alone was not a stimulus to mast cells, 
with the evident that no change in basal histamine release was observed in primary 
culture mast cells or in cell line. The basal releases were kept within 10% of total 
histamine content in cells (Figure 4.1) 
4.3.1.1 Histamine release induced by immunological stimulus 
ELP could not induce change on basal histamine release from human mast cell; 
however, it suppressed the release ofhistamine induced by anti-IgE. Figure 4.2 shows 
that pre-incubation of high concentration of ELP solution with HCMC can inhibit 
histamine release after challenge of anti-IgE. The histamine release was significantly 
inhibited by over 50% (p<0.05) and only 12.67 土 6.28% histamine was release after 
treatment with 500^ig/ml ELR The inhibitor effect was more pronounced in LAD2 
cell line (Figure 4.3a). Anti-IgE induced histamine release was gradually suppressed 
by increasing concentration ofELP solution. Significant inhibition was observed with 
as low as lOOp,g/ml ELP, which was one-fifth the concentration used to produce 
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similar effect in HCMC (p<0.001). There was only 5.63 士 1.33o/o ofhistamine release 
from the activated LAD2 cells at the highest dose of ELP used in the study 
(500|xg/ml), which is similar to the basal histamine release observed in mast cells. 
4.3.1.2 Histamine release induced by chemical secretagogues 
Activation ofmast cells was also induced by basic secretagogues for investigating the 
effect ofELP on alternative activation pathway of cells. LAD2 was susceptible to the 
activation via compound 48/80, which is a member ofbasic secretagogues (Chahdi et 
al., 2000; Ferry et aL, 2002). Histamine release induced by O.l^ig/ml compound 
48/80 alone is about 50% of total histamine content in cells. However, the induced 
histamine release was totally inhibited by the pre-treatment ofELP with LAD2 for 30 
minutes (Figure 4.3b). lO^ig/ml ELP solution could akeady exert a significant 
suppression by 66.32 士 0.69% and only 19.85 士 3.48Q/o histamine was released from 
LAD2 (p<0.001). The degree of inhibition was more potent at higher concentration of 
ELP, with only 7.04 士 3.46�/^ histamine released from cells after treatment with 
500^g/ml herbal medicine. Human mast cell is also susceptible to the activation of 
neuropeptide substance P (Mousli et al., 1989). 0.25^M of the peptide elicited a 
prominent release of histamine from LAD2 (Figure 4.3c). The pre-treatment of high 
dosage of ELP formulation could significantly inhibit the substance P induced 
histamine release by at least 30% (p<0.05). The induced release of histamine was 
suppressed in maximal by 500^g/ml ELP solution and only 19.77 士 1.74o/o of total 
histamine was released. 
4.3.2 Effect of Herba Epimedii (HEP) on histamine release from human mast 
cells 
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Human mast cells were incubated with crude HEP for 30 minutes and no change was 
observed in the basal histamine release from HCMC and LAD2 (Figure 4.4). 
4.3.2.1 Histamine release induced by immunological stimulus 
Crude HEP only exerted inhibitory effect on anti-IgE induced histamine release from 
HCMC at high concentration. Suppression was observed from 250|xg/ml crude HEP 
onwards, with a significant inhibition (p<0.001) by 80.1 士 5.7Qo/o by 500^ig/ml crude 
HEP solution (Figure 4.5). The effect of crude HEP on anti-IgE activated LAD2 was 
not obvious. The variation of histamine release after the pre-treatment of crude HEP 
was similar to that induced by anti-IgE in control (Figure 4.6a). 
4.3.2.2 Histamine release induced by chemical secretagogues 
The histamine release induced by compound 48/80 was suppressed by crude HEP in a 
dose dependent manner (Figure 4.6b). An inhibitory effect was akeady seen with 
lOp,g/ml crude HEP; histamine release was inhibited by 44.25 士 22.3P/o. The 
histamine release was suppressed in the greatest extent following pre-incubation with 
250p-g/ml crude HEP. It produced a significant inhibition by 96.0 士 0.73% and only 
2.0 士 0.15o/o histamine was release (p<0.001). The histamine release activated by 
compound 48/80 was abolished by high concentrations of crude HEP. The effect of 
HEP on histamine release induced by another cationic secretagogue demonstrated a 
similar result. Substance P induced histamine release was suppressed by high 
concentrations of crude HEP (Figure 4.6c). The significant inhibition on substance P 
induced histamine release was observed in treatment with 250fxg/ml or above crude 
HEP (at least p<0.01), the release was suppressed by over 60%. The degranulation 
was significantly suppressed by 500^g/ml HEP (p<0.001). The release was reduced 
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from 21.07 士 1.47o/o to 3.47 土 0.94Q/o oftotal histamine content. 
4.3.3 Effect of Fructus Ligustri Lucidi (FLL) on histamine release from human 
mast cells 
Crude FLL powder was dissolved in buffer and used to examine its effect on basal 
histamine release from human mast cells. FLL was not a possible stimulant ofhuman 
mast cells, as the basal levels of histamine release was not affected in cultures of 
primary mast cells and cell line (Figure 4.7). 
4.3.3.1 Histamine release induced by immunological stimulus 
Pre-treatment of HCMC with crude FLL did not alter anti-IgE induced histamine 
release (Figure 4.8). The level of histamine release was keep within the variation of 
anti-IgE control (47.47 士 1.95o/o of total histamine content). Effect of crude FLL on 
LAD2 was also not obvious (Figure 4.9a). Anti-IgE induced histamine releases from 
LAD2 after pre-incubation with crude FLL in all testing concentrations were 
insignificant to that from anti-IgE control. 
4.3.3.2 Histamine release induced by chemical secretagogues 
FLL could effectively modulate histamine release from human mast cell that were 
activated by the basic secretagogue compound 48/80 (Figure 4.9b). Crude FLL 
dose-dependently inhibited compound 48/80 induced histamine release from LAD2 
cells (at least p<0.01). The release was reduced from 51.69 士 6.28o/o to 39.49 士 9.24% 
following pre-treatment with lOp,g/ml crude FLL and was completely suppressed by 
500^g/ml crude FLL treatment. Another basic secretagogue, substance P was also 
used to study the pattem of release after treatment of crude FLL solution (Figure 4.9c). 
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There was a significant inhibition on the substance P induced histamine release by 
FLL at concentrations from 250p<g/ml (at lease p<0.01). The resultant release of 
histamine was less than 10% of total histamine content. 
4.3.4 Effect of Fructus Psoraleae (FP) on histamine release from human mast 
cells 
FP is the third Chinese herbal medicine in ELP formulation with the lowest weight 
ratio. The effect of FP on human mast cells was also studied, based on the possible 
role ofFP in activation of mast cells. It is found that high concentrations of crude FP 
can stimulate the basal histamine release from human mast cells (Figure 4.10). There 
was a significant promotion in histamine release by 500^g/ml crude FP (p<0.001) and 
similar observation was seen in the study ofLAD2 (p<0.001). There was 44.81 土 
7.55% and 20.71 士 2.9P/o oftotal histamine content being released from HCMC and 
LAD2 respectively after treatment of 500|ig/ml crude FP for 30 minutes. Therefore, 
FP is a possible stimulus to mast cell activation only ifhigh dosage is used. 
4.3.4.1 Histamine release induced by immunological stimulus 
The potentiating effect by crude FP was also observed in anti-IgE stimulated 
histamine release from HCMC (Figure 4.11). 250^ig/ml crude FP produced significant 
increase in histamine release by over 60% (p<0.05). The trend of promotion in 
anti-IgE induced histamine release by crude FP matched that on cell alone activity 
shown in Figure 4.10. A mild promoting effect was also observed in the study with 
LAD2 (Figure 4.12a). The anti-IgE induced release of histamine was promoted at 
high concentration. Interestingly, incubation with lOO i^g/ml crude FP with LAD2 
cells before the challenged of anti-IgE resulted in a moderate inhibition by less than 
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15%. 
4.3.4.2 Histamine release induced by chemical secretagogues 
Despite the promoting effect of high concentration of cmde FP on anti-IgE induced 
mast cell degranulation, it produced an inhibitory effect on mast cell activation by 
compound 48/80. Figure 4.12b shows a dose-dependent inhibition by all testing 
concentrations of crude FP except at the highest concentration (at least p<0.05). The 
release ofhistamine was dropped to the lowest when LAD2 cells were incubated with 
lOOp,g/ml or 250^g/ml crude FR The subsequent histamine release induced by 
compound 48/80 was less than 15%. The bounce of histamine release observed with 
500p,g/ml was an effect mixed with the basal induction ofhistamine release by FP and 
the resultant release of compound 48/80 activation. The resultant histamine release 
was similar to the level of that by 500p,g/ml of crude FP on non-activated LAD2 mast 
cell (Figure 4.10b). High dose ofcrude FP could have akeady abolished the histamine 
release induced by compound 48/80. However, the effect of crude FP on substance P 
induced histamine release was not similar. There was no significant different between 
the induced histamine release with the release solely induced by substance P (Figure 
4.12c). There was a slight drop of histamine release with increasing concentration of 
crude FP but the effect was not statistically significant. 
4.3.5 Effect of various partitions from solvent extraction of HEP on histamine 
release from human mast cells 
Crude HEP was extracted by dichloromethane, ethyl acetate and n-butanol 
sequentially. The basal histamine release was also checked after the incubation of 
each partition. All partitions from solvent extraction of HEP did not induce 
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significant basal histamine release from LAD2 cells (Figure 4.13). 
4.3.5.1 Histamine release induced by immunological stimulus 
The effects of various partitions of extracted HEP were different towards the 
immunological stimulation ofhuman mast cells. Dichloromethane (DCM) and ethyl 
acetate (EA) partitions ofHEP exert similar inhibitory effect as crude HEP on HCMC. 
Suppression of anti-IgE induced histamine release can be observed from lOOp-g/ml 
DCM partition of HEP onwards. The release was gradually decreased and at 
500M,g/ml DCM partition exerted a significant inhibitory effect and the release was 
reduced by 66.56 士 15.33% (p<0.01) (Figure 4.14a). There was also significant 
suppressing effect on anti-IgE induced histamine release by pre-treatment of high 
concentration ofEApartition ^)<0.05). The gradual decrease in histamine release was 
also observed in increasing EA partition treatment. The suppression effect of it was 
less than that ofDCM partition. At 500^ig/ml EA partition pre-treatment on HCMC, 
release induced by anti-IgE was suppressed by 35.69 士 5.34o/o (Figure 4.14b). After 
the solvent extraction by dichloromethane and ethyl acetate, HEP was extracted by 
butanol and the aqueous phase was also collected. Butanol partition of HEP extract 
produced enhancing effect in a range of 20 - 40% on histamine release induced by 
anti-IgE, with significant enhancements observed in majority of the concentrations 
being tested (at least p<0.05) (Figure 4.14c). The aqueous residue remained after 
butanol extraction was tested on the anti-IgE induced histamine release from HCMC. 
Figure 4.14d shows that water residue ofHEP extract did not regulate the histamine 
release induced by anti-IgE. The release was not significantly different to that induced 
in cells with anti-IgE alone. 
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Inhibitory effect was not observed with the treatment ofDCM and EA partitions on 
anti-IgE induced histamine release from LAD2 cells. DCM partition exerted a slight 
potentiating effect on the induced histamine release (Figure 4.15a)，with a maximum 
release of 37.58 士 4.16o/o of total histamine content observed with 500^ig/ml DCM 
partition. There was no significant change on histamine release induced by anti-IgE 
from LAD2 cells with all tested concentrations ofEApartition ofHEP extract (Figure 
4.15b). The butanol partition of HEP extract exerted a suppressing effect on 
immunological stimulation of LAD2 cells (Figure 4.15c). The anti-IgE induced 
degranulation was gradually decreased with increasing concentrations of butanol 
partition. There was 34.28 士 5.37o/o oftotal cellular histamine content released after 
treatment of lOp,g/ml of butanol partition, which was similar to the level of control 
set-up. The release was significantly suppressed by 250^ig/ml and 500^ig/ml butanol 
partition (p<0.01). The degranulation was reduced to less than 15% oftotal histamine 
release after pre-treatment ofbutanol partition of HER The water residue remained 
after all extraction process ofcrude HEP did not produce regulatory effect ofanti-IgE 
induced histamine release from LAD2 cells (Figure 4.15d) except at the topmost 
concentration used in the study. 500^ig/ml water residue of crude HEP exerted an 
inhibitory effect on induced histamine release. The release was reduced to 18.78 土 
4AT/o of total histamine content,, however, the difference was not statistically 
significant. 
4.3.5.2 Histamine release induced by chemical secretagogue 
Various partitions ofHEP extract were incubated with LAD2 before the challenge of 
compound 48/80. Suppressing effect exerted by DCM partitions on chemically 
induced histamine release from LAD2 was only observed at concentrations of 
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250|xg/ml or above (Figure 4.16a). Compound 48/80 induced histamine releases were 
significantly suppressed by 55% (p<0.01) and dropped from over 50% to only around 
25% oftotal histamine content was released after the incubation ofDCM partitions in 
the two top-most concentration. A gradual inhibitory effect on compound 
48/80-induced histamine release was observed with increasing concentration of EA 
partition ofHEP extract (Figure 4.16b). The inhibition was obvious from lOOp,g/ml 
EA partition, with a maximum and significant suppression by 60.72 士 10.73% 
produced by 500|ig/ml EA partition (p<0.001). The histamine release was reduced to 
22.46 士 4.78o/o oftotal content. The effect ofbutanol partition ofHEP on compound 
48/80 induced histamine release was similar to that by DCM an EA partitions (Figure 
4.16c). The significant inhibitory effect was only observed by activation of LAD2 
cells after treatment with 250^gZml or 500 i^g/ml butanol partition of crude HEP 
(p<0.001). The histamine release was reduced to less than 20% of total cellular 
histamine content. The water residue of crude HEP solvent extraction produced a 
significant dose dependent inhibitory effect on chemically activated mast cell 
histamine release (at least p<0.01) (Figure 4.16d). 30M-g/ml or above concentration of 
water residue of crude HEP suppressed the compound 48/80 induced histamine 
release from LAD2 over 50% when compare to control. 
4.3.6 Effect of various partitions from solvent extraction of FLL on histamine 
release from human mast cells 
The partitions from solvent extraction of crude FLL were used to examine their effect 
on basal activity of human mast cells. It was demonstrated that all partitions and 
water residue of crude FLL produced no significant effect on the basal activity on 
mast cells (Figure 4.17). Releases after treatments with various partitions were similar 
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to the spontaneous release of LAD2, which was within 10% of total histamine 
content. 
4.3.6.1 Histamine release induced by immunological stimulus 
Partitions obtained from solvent extraction ofFLL told another story from the crude 
extract. DCM partition produced an inhibitory effect on anti-IgE induced histamine 
release at high concentration (i.e. 100|ig/ml DCM partition and onwards). Figure 
4.18a shows that significant suppressions were observed at 250p,g/ml and 500p,g/ml 
with over 70% inhibition from the control ^)<0.01). High concentration of EA 
partition also exerted suppressing effect on histamine release from immunological 
activated mast cells (Figure 4.18b). There was slight enhancement on histamine 
release in low concentration of EA partition, however, an opposite effect was 
observed at the top dose of EA partition used in the study. 500M,g/ml EA partition of 
FLL negatively regulated the histamine release to cause a release of 19.35 士 5.02o/o of 
total content Q)<0.01). A general potentiating effect in the anti-IgE induced histamine 
release was observed in the pre-incubation of butanol fraction of FLL in HCMC 
(Figure 4.18c). The promotion in histamine release was not dose-dependent and not 
statistically significant. It was observed in all tested concentrations ofbutanol fraction. 
The water residue remained after solvent extraction was not effective on regulating 
histamine release from HCMC after activation by anti-IgE (Figure 4.18d). Anti-IgE 
induced histamine release in the presence ofthe water residue was similar to that of 
anti-IgE control, with an average release of 50% of total histamine content. 
Fractions obtained from solvent extraction affected differently toward the 
immunological activated LAD2. DCM partition above lOOp,g/ml could exert an 
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inhibition on histamine release (Figure 4.19a). DCM partition at 250^g/ml 
significantly suppressed the anti-IgE induced histamine release from LAD2 (p<0.001) 
and a release of only 0.89 士 1.29。/o of total histamine content was resulted after the 
pre-treatment of DCM partition for 30 minutes. EA partition of FLL extract also 
produced significant inhibition at high concentration (p<0.05). Figure 4.19b shows 
anti-IgE induced histamine release was suppressed in both 250p,g/ml and 500p,g/ml 
EA pre-treatment. The release of histamine was halved after incubation with 
250p,g/ml EA fraction while the release was further suppressed by over 80% to 1.24 士 
1.77% of total histamine content with 500p,g/ml EA fraction treatment. Butanol 
partition of FLL also demonstrated similar suppressing effect on histamine release 
induced by anti-IgE from LAD2 cells (Figure 4.19c). There was a trend of 
suppression in LAD2 cells after treatment with increasing concentration of butanol 
partition. Pre-treatment with 500p-g/ml of butanol partition of FLL suppressed the 
anti-IgE induced degranulation from 31.49 士 4.79o/o to 14.20 士 4.14o/o of total 
histamine content, though the difference was not significant. Figure 4.19d shows that 
water residue of extraction of crude FLL did not produce effect on induced histamine 
release from LAD2 cells. The pattem of induced histamine release was similar to that 
by LAD2 cells without drug treatment. 
4.3.6.2 Histamine release induced by chemical secretagogue 
The DCM fraction of FLL extract also exhibited a similar inhibitory pattem over the 
compound 48/80-induced histamine release from LAD2 cells (Figure 4.20a). 
Significant inhibiting effect was produced by as low as 60p-g/ml DCM fraction (at 
least p<0.01). The histamine release was gradually decreased with increasing dose of 
DCM fraction in the treatment of the cells. At the highest concentration used in the 
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Study, DCM fraction significantly suppressed the compound 48/80 induced histamine 
release by over 80% when compared to the control. There was only 9.14 士 3.0P/o 
histamine release from total content, which is a level similar to that of spontaneous 
release from mast cells in buffer alone. The suppressing effect resulted from treatment 
of EA partition was not as strong as that from DCM partition study (Figure 4.20b). 
The prominent effect was observed from lOO i^g/ml EA partition treatment on LAD2 
cells. It is observed that a gradual decrease in compound 48/80 induced histamine 
release with high dosage of EA partition, with a significant suppression resulted by 
250p,g/ml and 500^g/ml EA partition pre-treatment (at least p<0.01). Similar to the 
effect of 500p,g/ml DCM fraction on human mast cells, EA fraction at same 
concentration also abolished the compound 48/80 induced histamine release and only 
3.15 士 3.550/0 ofhistamine was released. The effect ofbutanol partition of crude FLL 
on compound 48/80 induced histamine release was only observed with high 
concentrations (Figure 4.20c). It is demonstrated that 500^ig/ml butanol partition 
could significantly reduced the histamine release to less than 10% of total cellular 
histamine content (p<0.001). A dose-dependent suppressing effect on compound 
48/80 induced histamine release from LAD2 cells was observed after treatment with 
water residue after FLL extraction (at least p<0.01) (Figure 4.20d). A prominent 
inhibitory effect on compound 48/80 induced histamine release was seen when 
30|xg/ml or above water residue ofFLL was used. The histamine release after basic 
secretagogue activation was completely blocked after treatment with 60^,g/ml water 
residue because the release was reduced to less than 10% of total histamine content. 
4.3.7 Effect of ELP and its herbal constituents on the production of cytokine 
from human mast cells 
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As described in previous chapter, cytokine was also released after the activation of 
mast cells. The release of mediators can further induce the activation of different 
regulation (Pmssin et al., 2003). TNF-a is stored in granules and newly synthesized 
after mast cell activation. The release of cytokine after pre-treatment ofELP and the 
individual herbal medicines with human mast cells was studied to observe the 
possible regulation ofherbal drugs on the production ofcytokine. TNF-a was induced 
by substance P and produced in general 2000pg per million cells. It is observed that 
the anti-osteoporosis herbal formulation ELP could effectively inhibit the release of 
TNF-a from activated human mast cell in a dose-dependent manner (Figure 4.21). 
Low dose ofELP only exert a mild inhibition on the release of cytokine. The cytokine 
release was significantly inhibited by increasing the concentration of ELP (at least 
p<0.01). At the topmost dose ofELP, the induced release ofTNF-a was completely 
abolished and the amount ofrelease was similar to that from non-activated mast cell 
alone. 
Individual herbal drugs were also pre-incubated with LAD2 before the activation by 
substance P. The effect ofHEP on the release ofTNF-a from activated mast cells was 
prominent (Figure 4.22). The use of medium and high dose of HEP significantly 
suppressed the cytokine release induced by substance P (p<0.001). Pre-treatment of 
LAD2 cells with FLL provided a less outstanding result (Figure 4.23). FLL treatment 
with various dosage could significantly suppress TNF-a release from activated mast 
cells by over 50% Q)<0.01), however, the degree of inhibition was more gentle than 
the HEP treatment. FP also produced dose-dependent inhibition on substance P 
induced cytokine release from LAD2 (Figure 4.24). Results have demonstrated that 
lOp,g/ml crude FP did not affect the substance P induced cytokine release but a 
116 
Chapter 4. Effects of anti-osteoporosis Chinese 
herbal medicines on activity of human mast cells 
significant inhibition could be seen when the concentration was ten time higher (at 
least p<0.01). The release ofcytokine was greatly inhibited by high concentration of 
ELP formulation or the individual herbal medicines in ELP. 
4.3.8 Modulation in calcium mobiUzation in activated human mast cell by ELP 
and its herbal constituents 
Calcium influx after the activation of mast cells is important to increase the 
intracellular calcium level and hence promote exocytosis of mediators (Gilfillan et 
aL, 2006). In order to investigate the possible mechanism of reduction in histamine 
release from activated mast cells, activity of calcium mobilization in LAD2 cells was 
studied. The level of calcium influx was expressed as the change of intracellular 
concentration against the basal level detected in human mast cells. O.l^ig/ml 
compound 48/80 successfiilly induced calcium influx and the entry of calcium was 
transient that only one peak was observed in the record of [Ca^^]i during experiment 
(Figure 4.25). The level of [Ca^ ]^i returned to the basal level within 500s after 
addition of compound 48/80. 
The treatment of LAD2 cells with ELP induced an inhibitory effect on compound 
48/80-induced calcium influx. Figure 4.25 demonstrates that the level of relative 
[Ca2+]i of ELP-treated LAD2 cells was lower than those untreated LAD2 cells after 
the addition of compound 48/80. LAD2 cells treated with 500^ig/ml ELP exerted the 
significant inhibitory effect on compound 48/80-induced calcium influx among the 
tested concentrations ofELP solution (p<0.05). 
I Effects of individual constituent herbs in ELP on calcium influx of LAD2 cell 
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activation were also investigated. Low concentration of HEP did not alter the pattem 
ofcalcium influx by addition of compound 48/80. Only 500^ig/ml crude HEP solution 
could exert a significant suppressing effect (p<0.05) (Figure 4.26). Figure 4.26c 
shows a smaller increment in relative [Ca^^]i from HEP-treated LAD2 cells. The 
[Ca2+]i of the treatment group returned to the basal level faster than that observed in 
the control LAD2 cells. There was a gradual decrease of calcium influx induced by 
compound 48/80 with increasing concentration ofFLL in pre-treatment (Figure 4.27). 
The pattem of [Ca^ ]^i change by pre-treatment of lOp,g/ml FLL was similar to that of 
secretagogues control. The amplitude and the duration of calcium influx was 
significantly reduced when lOO i^g/ml and 500^ig/ml crude FLL were used (at least 
p<0.05). The effect ofFP on calcium influx during activation ofLAD2 cell was not 
obvious (Figure 4.28). lO^ig/ml FP did not alter the calcium influx from LAD2 cells 
activated by compound 48/80. The amplitude of calcium influx of LAD2 cells after 
treatment of 100|xg/ml and 500^ig/ml FP was smaller than that of control set up; 
however, the changes were not prominently observed. 
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4.4 Discussion 
The use ofChinese herbal medicine in the prevention and treatment ofosteoporosis is 
very common in East Asia countries and is growing in number in Westem countries 
(Putnam et al., 2007; Winslow et al., 1998). The effect of anti-osteoporosis Chinese 
herbal formulation ELP has been demonstrated in OVX rats with a positive results 
(Sun et al., 2008). This formulation contains three herbal medicines, Herba Epimedii 
(HEP), Fructus Ligustri Lucidi (FLL) and Fructus Psoraleae (FP) with a weight ratio 
of5:4:l. The in vivo study showed that ELP was an effective anti-osteoporosis herbal 
prescription by maintaining bone mineral density. However, the detailed mechanism 
ofthis herbal prescription on regulating the pathophysiology of osteoporosis remains 
unclear. Since mast cell accumulation and activation was proven in the early stage of 
bone resorption and as a clinical observation in osteoporosis patient (Chiappetta et al., 
2006; Fouilloux et al., 2006; McKenna et al., 1985), it is proposed that this herbal 
formulation can exert its bone-protective effect via the regulation ofmast cell activity. 
In our study, we studied the effects ofELP and individual herbs in the formulation on 
the histamine release induced via different secretagogues as well as TNF-a release 
and calcium influx of human mast cells activated by basic secretagogues. These 
parameters can reflect the effects of herbal medicines on regulating exocytosis and 
production ofbone related cytokines from mast cells. 
The release of histamine from mast cells is the major sign of activation. Histamine 
release from activated mast cells can be induced by anti-IgE crosslinking to the FcsRI 
on mast cells or through the interaction of cationic secretagogues by directly 
activating cellular G-protein (Ferry et al, 2002; Gilfillan et al., 2006). The 
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anti-osteoporosis formulation ELP did not induced basal histamine release from 
HCMC and LAD2 cells, but the anti-IgE and basic secretagogues induced histamine 
release after was modulated by ELP. The inhibitory effects on histamine release 
observed from human mast cells induced by anti-IgE, compound 48/80 and substance 
P suggested the ELP could modulate histamine release mediated through both 
immunological and chemical activation pathways in human mast cells. The 
production of cytokine TNF-a from activated LAD2 cells was also dose-dependently 
suppressed by ELP solution. It suggested that ELP regulated not only cytoplasmic 
activation pathway but may also directly affect nuclear activities. The calcium 
mobilization ofLAD2 cells after challenged by compound 48/80 gave a peak within 2 
minutes after addition of secretagogue. Treatment of ELP solution in various 
concentrations with LAD2 prior to compound 48/80 challenge gave less calcium 
influx. The calcium influx from extracellular region may be modulated by ELP. Since 
degranulation in mast cells was a calcium-dependent process, the reduction of 
calcium influx after treatment of ELP solution with LAD2 cells proposed that ELP 
inhibited calcium influx and reduced the rate of degranulation in human mast cells. 
The histamine releases induced by either immunological or chemical stimuli were 
affected differently by the crude extract of the individual herbs in ELP formulation. 
Histamine releases induced by anti-IgE were not inhibited from human mast cell after 
the treatment with crude HEP, except that HCMC treated with high concentration of 
crude HEP had a significant reduction in histamine release. It proposed that only high 
concentration of crude HEP could induce prominent down-regulatory effect on 
antigen activation pathway of human mast cells. Dose-dependent inhibitory effect 
was observed on basic secretagogues activated mast cell histamine release. The 
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difference in inhibitory pattem by crude HEP suggested that the chemical activation 
of mast cells was the target of herbs. TNF-a release from LAD2 cells was 
significantly blocked by crude HEP. The nuclear activity in terms of cytokine 
production was regulated by crude HER Calcium influx was also regulated by the 
herbal medicine. There was a reduced calcium influx after challenge of compound 
48/80 when LAD2 cells were pre-incubated with crude 500p,g/ml crude HEP. 
Crude FLL exerted similar regulatory action on human mast cell as crude HER The 
only difference was that crude FLL did not modulate anti-IgE induced histamine 
release even at highest tested concentration. The dose-dependent inhibition of 
histamine and cytokine release induced by basic secretagogues was observed in 
human mast cells treated with crude FLL. Calcium influx was significantly 
suppressed by crude FLL. 
Crude FP was the only herbal medicine in the study that induced histamine release 
from human mast cells alone. Therefore, when studying the effect ofFP on histamine 
release induced by secretagogues from human mast cells in the presence of FP, the 
basal induction by crude FP should be considered. It was observed that crude FP did 
not modulate mast cell activity in terms ofhistamine release induced by anti-IgE after 
the exclusion of the basal activation of cells. However, Matsuda et aL (2007) 
demonstrated different response when the herb was extracted with different solvent. 
Matsuda et al. showed that the ethyl acetate-soluble fraction of methanolic extract of 
FP could effective inhibit the IgE-induced degranulation from RBL-2H3 cells. In our 
study, FP was extracted by ethanol and it did not exert modulation on the 
degranulation induced by immunological stimulant. The differential response of 
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histamine release from mast cells with treatment of FP suggested that solvent 
extraction of herbal medicines could lead to diverse responses in cellular activity 
since chemical compound in herbs dissolved in various solvent with different 
solubility. Suppressing effect on basic secretagogues induced mediators, both stored 
histamine and newly synthesized TNF-a release were observed in a dose-dependent 
manner. However, the calcium mobilization was not regulated by crude FP since the 
change in calcium influx with or without FP treatment was similar. 
Histamine acts through binding to histamine receptors and induces physiological 
activities. Histamine can increase the cell permeability and allow more immune cells 
to reach the inflammation site (Simmonds et al., 2008). Histamine was also identified 
as a regulator in bone resorption and the inhibition of histamine release by receptor 
antagonists could effectively reduce the rate of resorption in rats (Dobigny et al., 
1997). The production of histamine after activation of mast cells was suppressed 
where the anti-osteoporosis herbal formulation or the individual herbs was used. The 
suppression was more prominent from human mast cells that were activated by 
compound 48/80 or substance P in our study. The major difference of the 
IgE-independent activation pathway from the immunological one is the involvement 
ofG-protein activation by basic secretagogues. The identified basic secretagogues are 
polybasic compounds with shared structures such as the association of positive 
charges with hydrophobic structure; compound 48/80 contains aromatic ring while 
substance P contains a carboxyl terminus (Ferry et aL, 2002). It was found that 
compound 48/80 and substance P shared common activation pathway on mast cells 
(Lowman et al., 1988; Mousli et al., 1989). Activation of mast cells by basic 
secretagogues does not involve receptor but the direct binding to PTX-sensitive 
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G-protein induces propagation of downstream signal. The activation of PLCp 
signaling induces mast cell exocytosis while activation ofPKC and PI3-K pathway 
induce de novo production of mediators (Ferry et al., 2001; Shefler et al., 1998). The 
inhibitory effects on histamine release by ELP and the individual herbs HEP, FLL and 
FP was seen in basic secretagogue activated mast cell. It is suspected that ELP and its 
herbal contents modulated mast cell activity through down-regulation on basic 
secretagogues activation pathway. Furthermore, anti-IgE induced histamine release 
after incubation with individual constituent herbs ofELP was not altered. It suggested 
that the exocytosis which mediated via activation ofPLCP signaling was not blocked 
in mast cells by the herbs and histamine release still occurred. PTX-sensitive Ig 
protein in mast cells is the major signaling molecule upstream ofthe PLCp signaling 
and it directly binds with basic secretagogues to initiate activation ofmast cells (Ferry 
et al, 2001). It was suspected that individual constituent herbs modulated the 
activation of Gi protein in mast cells and disturbed the activation by basic 
secretagogues. There are limited reports on discussing the mechanism of herbal 
medicines on degranulation of mast cells. Various herbal prescription and herbal 
medicines demonstrated inhibitory effect on histamine release but the mechanistic 
study on it was still unclear (Matsumoto et al., 1998; Wang et aL, 2006a). Studies 
with the use of inhibitors of signaling molecules are needed to further investigate the 
involvement ofELP and the herbal contents in mast cell exocytosis induced by basic 
secretagogues. 
It was found that ELP exerted dose-dependent inhibition on histamine release from 
anti-IgE activated mast cells, but similar observation was not seen in study with 
individual constituent herbs. It might suggest that the combination of herbs may 
I 
123 
Chapter 4. Effects of anti-osteoporosis Chinese 
. herbal medicines on activity of human mast cells 
trigger a synergistic effect on modulating immunological activation of human mast 
cells. The use of Chinese medicines always depends on the combination ofherbs. It is 
believed that the combination of herbs can enhance the therapeutic activity. The use 
of Chinese herbal medicine in treatment of diseases suggests a concept of enhancing 
self-healing capabilities of body to recover from imbalance. Therefore, the Chinese 
herbal formulation is always personalized and each herbs in the formulation contain 
certain concerted actions on body that are targeted to individual patients (Wang et al., 
2009). Lee (2000) has suggested an example of Chinese herbal formulation 
containing different herbal composition leaded to diverse actions. It was suggested 
that the therapeutic action of a Chinese herbal formulation is depended on its 
composition. The results in our study demonstrated that individual constituent herbs 
in ELP did not exert regulation on anti-IgE activated mast cells, but the mixture of 
them produced significant effect. The combination of active compounds in these 
herbs may effectively down-regulate the anti-IgE activation of mast cells. The 
observation may provide scientific explanation on the power of herbal formulation 
over individual herbs in treatment of disease. 
Herbal medicines were fractionated into different partitions by subjecting to various 
organic solvents. The chemical substances in herbs are soluble in different solvents 
with different solubility. The compounds contained in different fractions after solvent 
extraction require further separation and identification by high pressure liquid 
chromatography and mass spectrometry. The present data could only provide 
preliminary analysis to determine the fraction of herbal extracts that contain active 
chemicals involved in the regulation of mast cell degranulation. Crude HEP and FLL 
were extracted sequentially with dichloromethane (DCM), ethyl acetate (EA) and 
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n-butanol. Our study found that only DCM and EA partitions ofboth crude HEP and 
FLL reduced the level of histamine release from HCMC activated by anti-IgE. 
Butanol fractions of both herbal medicines promoted histamine release mediated by 
immunological stimulus. However, DCM, EA, butanol fractions of crude HEP and 
FLL and water residue obtained after solvent extraction of both herbal medicine 
induced dose-dependent inhibitory effect on histamine release from LAD2 cells 
induced by compound 48/80. Previous studies revealed icariin and oleanolic acid are 
the active components ofHEP and FLL respectively (Cheng et al., 2007; Liu, 1995). 
Icariin was found to have anti-osteoporosis and anti-inflammatory effect validated by 
in vivo and in vitro study (Nian e^  al., 2009; Xu et al., 2010). The solvent extraction 
ofHEP by ethyl acetate could recover highest amount of icariin (Cheng et al., 2007). 
We observed effective inhibitory effect by EA fraction ofHEP on induced histamine 
! 
release from human mast cells, which may be contributed by icariin. Since other 
fractions ofHEP also gave a positive inhibitory effect on mediator release form mast 
cells, it cannot exclude the possibility that other active compounds like flavonoids 
epimedin A, B and C isolated from HEP (Chen et aL, 2007) could also regulate 
degranulation of mast cells. Oleanolic acid from FLL could effectively inhibited the 
proliferation of leukemia cells through activation of caspase-mediated apoptosis 
(Zhang et al., 2007). The content of oleanolic acid was highest in chloroform extract 
ofFLL (Yim et al., 2001). Our study did not used chloroform for solvent extraction of 
FLL; it could not confirm the identity of active compound in regulating histamine 
release from human mast cells. The isolation of active compound from fractions of 
FLL is needed to identify the substance responsible for the regulatory events. It was 
demonstrated that crude FLL did not induce significant inhibitory effect on anti-IgE 
induced histamine release, but the effect of different fractions on regulation of 
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mediator release was obvious. This may be due to the condensation of active 
compounds in different fractions, which gave enough amount ofcompound to initiate 
the regulation. The effect ofvarious fractions on mast cell histamine release was more 
prominent when compared to the crude extract ofherbal medicines. 
Production and release of cytokine are the indications of late phase reaction of 
inflammation in immune system and also the regulation ofbone metabolism by bone 
cells (Bradding et al, 1996; Zheng et al” 1997). TNF-a is one of the cytokines 
produced by activated mast cells. The roles ofTNF-a in regulation of inflammation 
and bone metabolism was well-documented. TNF-a promotes inflammation by 
attracting lymphocytes to the site of actions (Mukhopadhyay et al., 2006). It is the 
major regulation of bone remodeling since it promotes differentiation of osteoclasts 
and induce apoptosis of osteoblasts (Lee et al., 2008). Our studies on the effect of 
TNF-a production from activated mast cells by the tested herbal medicines was 
consistent with various researches on the anti-inflammatory activity with the herbal 
medicines. Studies done by Xu et aL(20l0) demonstrated the suppression ofcytokine 
release including TNF-a from activated mast cells after treatment ofHEP. Xu et al. 
showed that icariin, the active compound isolated from HEP could effectively 
suppressed TNF-a production in mRNA and protein level in LPS-activated 
macrophages. The reduced production of cytokine was mediated through activation of 
PI3KMkt pathway and the inhibition ofNF-KB regulated gene expression. Treatment 
ofFLL on LPS-activated mouse PBMC also results in inhibition ofTNF-a production 
via the suppression on NF-KB activation (An et al, 2007). The study on FP about its 
role on inflammation was limited. The production of nitric oxide, an inflammatory 
mediator，was inhibited by treatment of FP with mouse macrophages activated by 
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LPS (Matsuda et aL, 2009). However, contrasting result was seen in similar study that 
macrophage was cultured with iaterferon-y (IFN-y). The production of nitric oxide 
and TNF-a was synergistically enhanced when treated with FP. However, it did not 
study the effect of cytokine production from macrophages without IFN-y co-culture 
(An et al., 2008). Based on the contrasting effect of FP on substance P induced 
cytokine release observed in other studies and from our studies, the role of FP in 
regulation ofcytokine production still requires further investigation. 
Production ofTNF-a is regulated by complex signaling on the transcription ofgenes, 
including NF-KB and AP-1. The involvement ofMEKK-regulated JNK pathway and 
PI3-K was reported to regulate TNF-a production by IgE-dependent activation of 
mast cell (Ishizuka et al, 1997). Azzolina et al. (2003) demonstrated that the 
production of TNF-a and IL-6 from substance P activated RPMC was mediated 
through the NF-KB pathway. The previous studies on HEP and FLL also suggested 
the involvement ofNF-KB signaling in the regulation ofTNF-a production. Therefore, 
the detailed mechanism study can be started with the signaling involved NF-KB and 
the signaling upstream of it, so as to understand how the herbal medicine can 
suppress cytokine production in human mast cells. 
Calcium mobilization in activated mast cells is crucial for granule exocytosis and the 
production of cytokines. It is observed that depletion ofcalcium lead to blockage of 
histamine release in both IgE dependent and IgE-independent activation ofmast cells 
(Aridor et al” 1990; Pearce, 1985). Recent study on HMC-1 demonstrated that 
increase intracellular Ca]+ stimulated p38 and ERKl/2 MAPK signaling cascades and 
result in activation ofNF-KB mediated up-regulation on IL-8 production (Kim et al, 
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2005). Influx of calcium into cytoplasm is under the regulation of calcium channels. 
Activation of PLC is initiated by G-protein coupled receptor or through engagement 
ofFcsRI by antigen in mast cells or other cells. PLC hydrolyzes phosphatidylinositol 
4,5-bisphosphate (PIP2) in membrane into inositol 1,4,5-trisphosphate (IP3) and 
diacylglycerol (DAG). DAG in tums activates PKC to trigger downstream signaling 
molecules, depends on the cells being activated. IP3 diffiises to the endoplasmic 
reticulum and bind to IP3 receptor to induce the release of Ca�+ from endoplasmic 
reticulum (Clapham, 2007). The depletion of Ca�+ store in cells subsequently induces 
the opening of Ca^^ release-activated Ca^^ (CRAC) channels on cell membrane 
(Parekh et aL, 1997). This substantial rise of calcium ions into cellular region is the 
major mediator to elicit exocytosis and the production of newly synthesized 
mediators in mast cell (Di Capite et aL, 2009). We demonstrated that 
anti-osteoporosis 500^g/ml herbal formulation ELP could suppress the calcium influx 
in compound 48/80 activated human mast cells significantly. Similar observations 
were seen in the treatments of mast cells with crude HEP and FLL. It suggested that 
the rate of calcium influx into the intracellular region of mast cells was reduced by 
the herbal medicines. Similar study was limited and it is only found that crude HEP 
could significantly blocked the influx of calcium in isolated rat aorta with the used of | 
radioisotope tracer technique (Yang et aL, 2006). The effect ofcrude HEP on rat aorta 
was similar to the inhibitory effect on human mast cells. Our study suggested that the 
reduction ofhistamine degranulation from activated human mast cells after treatment 
of HEP or FLL may be attributed by the reduction of calcium influx to the 
intracellular region. Effect of FP on calcium influx was not as obvious as other two 
herbal medicines. The inhibition of induced histamine release after FP may be 
resulted from mechanism other than reduction in calcium influx. Further study was 
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required to confirm the role of the herbal medicines on the regulation of calcium 
influx in mast cells. 
In the study of anti-osteoporosis Chinese herbal formulation ELP on activity ofmast 
cells, we found that ELP and the herbal constituents produced significant inhibitory 
effect on basic secretagogue induced histamine release from human mast cells. The 
difference response ofherbal constituents and ELP in the anti-IgE induced histamine 
release from mast cells may imply the importance of combination of herbs in 
regulating mast cell activity. The mixing of Chinese herbs may produce effect that 
was not produced by individual components. Histamine was one ofthe regulators in 
bone resorption (Biosse-Duplan et al., 2009; Fitzpatrick et a!., 2003) and mast cell 
activation was seen in the initial phase ofbone resorption (Lesclous et al., 2006), the 
inhibition of histamine release from human mast cells after the incubation with ELP 
suggested the action of ELP on protection of bone may be mediated through 
modulation of mast cell activity. The solvent extraction ofherbal constituents ofELP 
I 
did not isolate a particular fraction that could solely produce the inhibitory effect as 
the crude herbal products on basic secretagogue induced histamine release. A 
fme-tuming ofsolvent extraction to isolate single compound from herbal constituents 
of ELP is needed to identify the active compounds that are responsible for the 
regulation of mast cell activities. The significant suppression of TNF-a release from 
human mast cells by ELP and its herbal constituents suggested that the nuclear 
transcription was also modulated by the herbs. TNF-a is one of the bone resorbing 
cytokine that can promote osteoclastogenesis during bone remodeling (Lee et al” 
2008), the positive effect ofELP on regulating TNF-a release from human mast cells 
demonstrated another possible mechanism of anti-osteoporosis action ofELP through 
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the regulation of mast cell activity. Based on our study results, we provided 
preliminary observations on the effect of ELP and its herbal constituents on human 
mast cells activities. However, the detailed mechanism of the regulatory events was 
not fully studied. More mechanistic investigation is required to elucidate the detailed 
interaction between the anti-osteoporosis action of ELP on mast cells and the 
mediating action of mast cells on bone metabolism. 
.•‘ 
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Figure 4.1: Effect of 30 minutes incubation with ELP on basal histamine 
release from human mast cells, (a) HCMC and (b) LAD2 cells were treated with 
ELP formulation for 30 minutes to evaluate the basal activity of HCMC. All 
histamine releases were corrected to spontaneous release and all values are mean 士 
SEM for 3 experiments (sp: spontaneous release). 
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Figure 4.2: Effect of 30 minutes pre-incubation of ELP on anti-IgE-induced 
histamine release from HCMC. Sensitized HCMC were pre-treated with ELP 
formulation for 30 minutes before the challenge of anti-IgE for histamine release. All 
histamine releases were corrected to spontaneous release and all values are mean 士 
SEM for 3 experiments. Asterisk represents statistical significant difference (p<0.05) 
in histamine release when compared with that induced by anti-IgE (AE: anti-IgE 
control). 
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Figure 4.3: Effect of 30 minutes pre-incubation of ELP on histamine release 
induced by different secretagogues from LAD2 ceUs. Sensitized LAD2 cells were 
pre-incubated with ELP formulation for 30 minutes before the challenge of (a) 
anti-IgE or (b) compound 48/80 or (c) substance R All results were corrected with 
spontaneous release and values are mean 士 SEM for 3 experiments. Asterisks 
represent significant difference (at least p<0.05) in histamine release when compare 
with that induced by corresponding stimuli (AE: anti-IgE control; C48/80: compound 
48/80; sub P: substance P). 
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Figure 4.4: Effect of 30 minutes intubation of HEP on basal histamine release 
from human mast cells, (a) HCMC and (b) LAD2 cells were treated with HEP for 
30 minutes to evaluate the basal activity of the cells. All results were corrected with 
spontaneous release and values are mean 士 SEM for 3 一 5 experiments. 
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Figure 4.5: Effect of 30 minutes pre-incubation of HEP on anti-IgE induced 
histamine release from HCMC. Sensitized HCMC were pre-incubated with crude 
HEP solution for 30 minutes before the challenge of anti-IgE. All results were 
corrected with spontaneous release and values are mean 士 SEM for 4 experiments. 
Asterisks represent significant difference (at least p<0.05) in histamine release when 
compare with that induced by anti-IgE (AE: anti-IgE control). 
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Figure 4.6: Effect of 30 minutes pre-incubation of HEP on histamine release 
induced by different secretagogues from LAD2 ceUs. Sensitized LAD2 cells were 
pre-incubated with crude HEP solution for 30 minutes before the challenge of (a) 
anti-IgE, (b) compound 48/80 or (c) substance R All results were corrected with 
spontaneous release and values are mean 士 SEM for 3 experiments. Asterisks 
represent significant difference (at leaat p<0.05) in histamine release when compare 
with that induced by corresponding stimulus (AE: anti-IgE; C48/80: compound 48/80 
control; sub P: Substance P). 
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Figure 4.7: Effect of 30 minutes incubation of FFL on basal histamine release 
from human mast ceUs. (a) HCMC and (b) LAD2 cells were treated with FFL for 30 
minutes to evaluate the basal activity of the cells. All results were corrected with 
spontaneous release and values are mean 士 SEM for 3 一 5 experiments. 
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Figure 4.8: Effect of FLL on anti-IgE induced histamine release from HCMC. 
Sensitized HCMC were pre-incubated with crude FLL solution for 30 minutes before 
the challenge of anti-IgE. All results were corrected with spontaneous release and 
values are mean 士 SEM for 4 experiments (AE: anti-IgE control). 
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Figure 4.9: Effect of 30 minutes pre-incubation of FLL on histamine release 
induced by different secretagogues from LAD2 ceUs. Sensitized LAD2 cells were 
pre-incubated with crude FLL solution for 30 minutes before the challenge of (a) 
anti-IgE, (b) compound 48/80 or (c) substance R All results were corrected with 
spontaneous release and values are mean 士 SEM for 3 experiments. Asterisks 
represent significant difference (at least p<0.05) in histamine release when compare 
with that induced by corresponding stimulus (AE: anti-IgE; C48/80: compound 48/80 
control; sub P: Substance P). 
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Figure 4.10: Effect of 30 minutes incubation of FP on basal histamine release 
from human mast cells, (a) HCMC and (b) LAD2 cells were treated with crude FP 
solution for 30 minutes to evaluate the basal activity of cells. All results were 
corrected with spontaneous release and values are mean 士 SEM for 3 一 5 experiments. 
Asterisks represent significant difference (at least p<0.05) in histamine release when 
compare with that of cell alone (sp: spontaneous release) 
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Figure4.il: Effect of 30 minutes pre-incubation of FP on anti-IgE induced 
histamine release from HCMC. Sensitized HCMC were pre-treated with crude FP 
solution for 30 minutes before the challenged of anti-IgE. All results were corrected 
with spontaneous release and values are mean 士 SEM for 3 experiments. Asterisks 
represent significant difference (at least p<0.05) in histamine release when compare 
with that ofanti-IgE control (AE: anti-IgE control). 
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Figure 4.12: Effect of 30 minutes pre-incubation of FP on histamine release 
induced by different secretagogues from LAD2 ceUs. Sensitized LAD2 cells were 
pre-incubated with crude FP solution for 30 minutes before the challenge of (a) 
anti-IgE, (b) compound 48/80 or (c) substance P. All results were corrected with 
spontaneous release and values are mean 士 SEM for 3 - 4 experiments. Asterisks 
represent significant difference (at least p<0.05) in histamine release when compare 
with that induced by corresponding stimulus (AE: anti-IgE; C48/80: compound 48/80 
control; Sub P: substance P). 
142 
Chapter 4. Effects of anti-osteoporosis Chinese 
. herbal medicines on activity of human mast cells 
(a) iooi (b) 100-
80- 80-
E E 
I 6�_ I 60. 
0> 0> I 40- I 4�-
1 I 
20’ T 20-
• I ^^= 丁 pl T P ^ rj=n 亭 ff ff rTn o l r ^ P ^ i . i I , I 1：1 I . I 1丁1 
10 30 60 100 250 500 s p 10 30 60 100 250 500 s p 
HEP (DCM fraction) (^g/ml) HEP (EA fraction) (^g/ml) 
(C) 100i ( d ) 100-
80- 80-g g 
M ^^  S -^  s ®0" S 60' 2 S 
0) 0) 1 40. 1 40. iS Ji 
V) Ul 
I I 
20. 20-^ A r ^ r ^ o i + T>^==pn _ m _ m o i ^ 亭 _ p ^ 千亭 m 
10 30 60 100 250 500 sp 10 30 60 100 250 500 sp 
HEP (butanol fraction) (jig/ml) HEP (water residue) (^g/ml) 
Figure 4.13: Effect of 30 minutes incubation of different fractions of HEP on 
basal histamine release from human mast cells. LAD2 cells were treated with (a) 
dichloromethane, (b) ethyl acetate, (c) butanol fraction and (d) water residue of HEP 
to evaluate the basal activity of cells. All results were corrected with spontaneous 
release and values are mean 士 SEM for 3 一 4 experiments. 
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Figure 4.14: Effect of 30 minutes pre-incubation of different partitions of HEP 
on histamine release induced by anti-IgE from HCMC. Sensitized HCMC were 
treated with (a) dichloromethane, (b) ethyl acetate, (c) butanol fraction and (d) water 
residue of HEP for 30 minutes before the challenge of anti-IgE for 30 minutes. All 
results were corrected with spontaneous release and values are mean 士 SEM for 3 
experiments. Asterisks represent significant difference (at least p<0.05) in histamine 
release when compare with that induced by anti-IgE (AE: anti-IgE). 
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Figure 4.15: Effect of 30 minutes pre-incubation of different partitions of HEP 
on histamine release induced by anti-IgE from LAD2 cells. Sensitized LAD2 cells 
were treated with (a) dichloromethane, (b) ethyl acetate, (c) butanol fraction and (d) 
water residue ofHEP for 30 minutes before the challenge ofanti-IgE for 30 minutes. 
All results were corrected with spontaneous release and values are mean 士 SEM for 
4 - 5 experiments. Asterisks represent significant difference (at least p<0.05) in 
histamine release when compare with that induced by anti-IgE (AE: anti-IgE). 
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Figure 4.16: Effect of 30 minutes pre-incubation of different partitions of HEP 
on histamine release induced by compound 48/80 from LAD2 cells. LAD2 cells 
were treated with (a) dichloromethane, (b) ethyl acetate, (c) butanol fraction and (d) 
water residue ofHEP for 30 minutes before the challenge of compound 48/80 for 30 
minutes. All results were corrected with spontaneous release and values are mean ± 
SEM for 4 - 5 experiments. Asterisks represent significant difference (at least p<0.05) 
in histamine release when compare with that induced by compound 48/80 (C48/80: 
compound 48/80). 
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Figure 4.17: Effect of 30 minutes incubation of different fractions of FLL on 
basal histamine release from human mast cells. LAD2 cells were treated with (a) 
dichloromethane, (b) ethyl acetate, (c) butanol fraction and (d) water residue ofFLL 
to evaluate the basal activity of cells. All results were corrected with spontaneous 
release and values are mean 土 SEM for 3 - 4 experiments. 
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Figure 4.18: Effect of 30 minutes pre-incubation of different partitions of FLL 
on histamine release induced by anti-IgE from HCMC. Sensitized HCMC were 
treated with (a) dichloromethane，(b) ethyl acetate, (c) butanol fraction and (d) water 
residue of FLL for 30 minutes before the challenge of anti-IgE for 30 minutes. All 
results were corrected with sp0ntane9us release and values are mean 士 SEM for 3 
experiments. Asterisks represent significant difference (at least p<0.05) in histamine 
release when compare with that induced by anti-IgE (AE: anti-IgE). 
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Figure 4.19: Effect of 30 minutes pre-incubation of different partitions of FLL 
on histamine release induced by anti-IgE from LAD2 cells. Sensitized LAD2 cells 
were treated with (a) dichloromethane, (b) ethyl acetate, (c) butanol fraction and (d) 
water residue ofFLL for 30 minutes before the challenge of anti-IgE for 30 minutes. 
All results were corrected with spontaneous release and values are mean 士 SEM for 
4 - 5 experiments. Asterisks represent significant difference (at least p<0.05) in 
histamine release when compare with that induced by anti-IgE (AE: anti-IgE). 
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Figure 4.20: Effect of 30 minutes pre-incubation of different partitions of HEP 
on histamine release induced by compound 48/80 from LAD2 cells. LAD2 cells 
were treated with (a) dichloromethane, (b) ethyl acetate, (c) butanol fraction and (d) 
water residue ofHEP for 30 minutes before the challenge of compound 48/80 for 30 
minutes. All results were corrected with spontaneous release and values are mean 土 
SEM for 4 — 5 experiments. Asterisks represent significant difference (at least p<0.05) 
in histamine release when compare with that induced by compound 48/80 (C48/80: 
compound 48/80). 
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Figure 4.21: Effect of ELP on the release of TNF-a from human mast cells. 
LAD2 were pre-incubated with ELP and stimulated with substance R Supernatant 
was collect 8 hours afterward and TNF-a level was measured. All results were 
corrected with spontaneous release and values are mean 士 SEM for 3 experiments. 
Asterisks represent significant difference (at least p<0.05) in cytokine release when 
compare with that induced by substanCe P in control. 
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Figure 4.22: Effect of crude HEP on the release of TNF-a from human mast 
cells. LAD2 were pre-incubated with crude HEP and stimulated with substance P. 
Supernatant was collect 8 hours afterward and TNF-a level was measured. All results 
were corrected with spontaneous release and values are mean 士 SEM for 3 
experiments. Asterisks represent significant difference (at least p<0.05) in cytokine 
release when compare with that induced by substance P in control. 
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Figure 4.23: Effect of crude FLL on the release of TNF-a from human mast 
cells. LAD2 were pre-incubated with crude FLL and stimulated with substance R 
Supernatant was collect 8 hours afterward and TNF-a level was measured. All results 
were corrected with spontaneous release and values are mean 士 SEM for 3 
experiments. Asterisks represent significant difference (at least p<0.05) in cytokine 
release when compare with that induced by substance P in control. 
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Figure 4.24: Effect of crude FP on the release of TNF-a from human mast cells. 
LAD2 were pre-incubated with crude FP and stimulated with substance P. 
Supernatant was collect 8 hours afterward and TNF-a level was measured. All results 
were corrected with spontaneous release and values are mean 士 SEM for 3 
experiments. Asterisks represent significant difference (at least p<0.05) in cytokine 
release when compare with that induced by substance P in control. 
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Figure 4.25: Calcium mobiUzation of ELP-treated LAD2 cells activated by 
compound 48/80. LAD2 cells were pre-treated with ELP before the challenge of 
compound 48/80 and the calcium mobilization of cell was observed for 500s at 10s 
/*• 
intervals. Data was presented as relative fold change of [Ca ]i corrected to that at t = 
0 (a,b,c) and the arrow represents the addition of compound 48/80 to activate LAD2 
cells at t = 20s. The area under curves in (a), (b) and (c) were summarized (d). Values 
are mean 士 SEM for 5 experiments. Asterisks represent significant difference (p<0.05) 
in the response of intracellular calcium concentration in ELP-treated cells when 
compared with that in compound 48/80 control. 
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Figure 4.26: Calcium mobiUzation of HEP-treated LAD2 cells activated by 
compound 48/80. LAD2 cells were pre-treated with HEP before the challenge of 
compound 48/80 and the calcium mobilization of cell was observed for 500s at 10s 
intervals. Data was presented as relative fold change of [Ca^^]i corrected to that at t = 
0 (a,b,c) and the arrow represents the addition of compound 48/80 to activate LAD2 
cells at t = 20s. The area under curves in (a), (b) and (c) were summarized (d). Values 
are mean 士 SEM for 3 experiments. Asterisks represent significant difference (p<0.05) 
in the response of intracellular calcium concentration in HEP-treated cells when 
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Figure 4.27: Calcium mobiUzation of FLL-treated LAD2 cells activated by 
compound 48/80. LAD2 cells were pre-treated with FLL before the challenge of 
compound 48/80 and the calcium mobilization of cell was observed for 500s at 10s 
fy [ 
intervals. Data was presented as relative fold change of [Ca ]i corrected to that at t = 
0 (a,b,c) and the arrow represents the addition of compound 48/80 to activate LAD2 
cells at t = 20s. The area under curves in (a), (b) and (c) were summarized (d). Values 
are mean 士 SEM for 4 experiments. Asterisks represent significant difference ( at 
least p<0.05) in the response of intracellular calcium concentration in FLL-treated 
cells when compared with that in compound 48/80 control. 
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Figure 4.28: Calcium mobilization of FP-treated LAD2 cells activated by 
compound 48/80. LAD2 cells were pre-treated with FP before the challenge of 
compound 48/80 and the calcium mobilization of cell was observed for 500s at 10s 
<•> I 
intervals. Data was presented as relative fold change of [Ca ]i corrected to that at t = 
0 (a,b,c) and the arrow represents the addition of compound 48/80 to activate LAD2 
cells at t = 20s. The area under curves in (a), (b) and (c) were summarized (d). Values 
are mean 士 SEM for 3 experiments. 
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5 General discussion 
Various studies have demonstrated the involvement of mast cells in the development 
of osteoporosis and also in bone remodeling (Fallon et al, 1983; Fouilloux et al., 
2006). Histamine can actively mediate the differentiation of osteoclasts 
(Biosse-Duplan et al., 2009). Different pieces of evidence lead us to question whether 
estrogen, a mediator in bone remodeling, can exert its effects through regulating the 
mast cell activity. 
In our study, we have investigated the degranulation of human mast cells after 
treatment with estradiol and two SERMs, raloxifene and tamoxifen. The human mast 
cells were activated by both IgE-dependent and IgE-independent pathways. However, 
apart from the highest concentration tested, the drugs in general did not affect the 
histamine release from the human mast cells activated by either pathway. The results 
suggested that estradiol and the SERMs did not modulate degranulation in mast cells. 
Estrogen may not take up a role in regulating the degranulation of mast cells during 
the progression ofbone remodeling. 
We have found that estradiol did not affect TNF-a release from human mast cells 
activated by anti-IgE or polybasic secretagogues. The observation questioned if ERs 
could regulate production of TNF-a from human mast cells. However, we observed 
that the SERMs could significantly suppress TNF-a release induced by anti-IgE but 
not that induced by polybasic secretagogues. The effect of SERMs on regulating the 
cytokine production in human mast cells was more prominently observed than with 
degranulation. It suggested that the SERMs may be able to modulate the transcription 
ofTNF-a gene through regulating anti-IgE receptor associated signaling pathways. 
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From the results of the present study, we cannot conclude that the effect of estrogen 
on modulating degranulation or the effect of SERMs on regulating the cytokine 
production were mediated through the action of ERs. The use of ER antagonists can 
demonstrate whether the action is mediated by specific ERs or not. The role of 
estrogens in regulating the activity of mast cells cannot be clearly demonstrated in 
this study but our data still suggest that SERMs may exert their effect on regulating 
the cytokine release from human mast cells. Since TNF-a is a direct mediator in 
regulating bone resorption (Kobayashi et al., 2000), the suppression of the production 
of this cytokine from human mast cells can in tums control the rate ofbone resorption. 
This can be one of the possible mechanisms of the regulatory actions of SERMs on 
the bone remodeling process. Other cytokines such as IL-6 and TGF-p are also 
mediators involved in bone metabolism, the production of these cytokines from 
human mast cells can also be studied in order to obtain a better picture on the 
involvement of mast cells in the bone metabolism. 
Another piece of results in our study suggested that HCMC and LAD2 cells 
expressed different set ofERs. ER-a was only expressed in HCMC but not in LAD2 
cells. ER-a and ER-p only share around 50% amino acid homology in the ligand 
binding region (Katzenellenbogen et aL, 2000), which contribute to the difference in 
ligand binding properties and the subsequent transcriptional activities. The difference 
in ERs expression demonstrated in different subtypes of human mast cells may lead 
to variation in cellular activities. Differential expressions of ER in HeLa cells 
responded in different fashion when treated with estradiol and antiestrogens (Paech et 
al., 1997). The roles of estrogen and SERMs on regulating mast cells activity can also 
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be controlled by the expression of ERs. We observed that different responses in 
TNF-a production from different subtypes of human mast cells. The cellular 
distribution ofERs on bone cells are varied by the types ofbone; ER-a is dominantly 
expressed in cortical mineralized bone and high level of ER-p is expressed in 
trabecular bone (Bord et aL, 2001). The difference in the expression ofERs in bone 
tissue suggested that estrogen or SERMs may exert diverse effects on different types 
ofbone. The accumulation ofhuman mast cells in bone tissue during the development 
of osteoporosis gives addition complexity in determining the action of estrogens 
through the receptors. Apart from the ERs expressed on bone cells, ERs expressed on 
human mast cells can also be the target of estrogen. The expression level ofERs can 
affect the action of estrogen on regulating the bone metabolism. Moreover, the 
subtype ofhuman mast cells found in bone tissue is still under debate (Teodosio et al.’ 
2010), we cannot conclude the subtype ofhuman mast cells and also the phenotype of 
ER expression on the mast cells accumulated in bone tissue as observed in 
osteoporosis. The co-culture of different subtypes ofhuman mast cells with bone cells 
and the analysis of cellular contribution of ERs in the cellular system may help 
resolving the dominant ER phenotype in human mast cells which contributes to a 
regulating action on bone metabolism. 
We demonstrated the expression ofRANK and RANKL on human mast cells. RANK 
and RANKL are the major proteins that involved in bone resorption. The expressions 
of these two bone remodeling molecules suggest that human mast cells may also 
directly involve in bone resorption. Interaction between RANK and RANKL 
promotes the differentiation of osteoclast precursors and enhances the bone resorption 
process (Lemer, 2006). The expression of RANKL from human mast cells may 
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interact with RANK on osteoclast precursors, hence promote osteoclastogenesis. The 
direct interaction between human mast cells with osteoclasts still require further 
confirmation through analyzing the interaction between RANKL and RANK on these 
two types of different cells. 
The accumulation ofmast cells in bone marrow was observed in osteoporosis patient. 
It suggested that mast cells might mature rapidly in the bone regions ofpatients. The 
effects of estrogens and SERMs on the mature human mast cells were not very 
prominent. Since estrogen is a hormone controlling the differentiation and functions 
of various tissues, human mast cells differentiation may also be controlled by this 
steroid hormone. The growth and differentiation of human mast cells with the 
presence of estrogen can provide evidence on whether the accumulation of human 
mast cells is regulated by estrogen. By the changing of culture condition, it may be 
able to mimic the environment of mast cells in both premenopausal and 
postmenopausal patients, which in tums reveals the possible role ofhuman mast cells 
in the development of osteoporosis. 
The development of the simplified anti-osteoporosis Chinese herbal formulation ELP 
gave positive effects on preserving the mineral content in rat bones (Sun et a!., 2008). 
The mechanism of this herbal formulation on bone tissues was still unclear. We 
observed that ELP exerted prominent inhibitory effect on degranulation in human 
mast cells activated by either IgE-dependent or IgE-independent pathway. Effective 
inhibition of TNF-a production was resulted when human mast cells were treated 
with ELP. The outstanding effects of ELP on regulating human mast cells activities 
may suggest that ELP achieves its anti-osteoporosis action through modulating mast 
166 
Chapter 5. General discussion 
cells activities. 
We can see that the degranulation induced by immunological stimulant in human 
mast cells was more effectively suppressed by ELP than its herbal constituents. It 
implied that the combination of herbs may produce synergistic effect on the activity 
of human mast cells. ELP is consisted of three herbs in a specific weight ratio. The 
treatment ofhuman mast cells with varying ratios of individual herbs can demonstrate 
the contribution of single herbs. The study of different combinations of herbal 
extracts on regulating degranulation from human mast cells can reveal the interaction 
between the herbal extracts. The regulating effect produced by the combination of 
herbal extract can be additive, synergistic or antagonistic. The nature of effects 
produced by the various combinations of herbal extracts will be useful for studying 
the synergistic effect observed with ELP. The effect of a mixture consisted of HEP, 
FLL and FP extract can be compared with that of ELP in order to further analyze the 
interaction of the herbal constituents. The effect produced by simple mixing the 
herbal extracts on modulating mast cell activity only reflects the mixture ofchemical 
component in the mixture. However, during the preparation of the ELP concoction by 
boiling the crude herbs together, the chemical components in the extracts of the 
concoction may be altered with the production of new compounds. The regulating 
effect by ELP on human mast cell degranulation may be due to the interaction of 
these new unknown chemical components in the formulation with the activation 
pathways ofhuman mast cells. 
The solvent extraction of the two major constituent herbs, HEP and FLL, did not 
single out any partition which is responsible for the modulating effects on 
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degranulation. However, the active chemical compounds in HEP and FLL have been 
identified are well studied (Chen et al., 2007; Liu et al, 2003). In order to deduce the 
active components which exert regulating effect on degranulation, the experiment can 
be performed with these known active components, such as icariin from HEP and 
oleanolic acid from FLL, along with various partitions of the herbal extracts. The use 
of active components with known identity is useful for evaluating which partitions of 
HEP and FLL attribute to the effective modulating action on human mast cells. 
It was observed that the cytokine release was more effectively regulated by ELP and 
its herbal constituents in substance P activated human mast cells. The nuclear 
transcription of TNF-a gene was regulated by ELP, which suggested that the 
anti-osteoporosis action of ELP may work through the cytokine production from 
human mast cells after activation. In order to confirm the effect ofELP on regulating 
the production of TNF-a, it is necessary to study the pathway upstream of activation 
of gene transcription. The production of TNF-a from human mast cells can be 
mediated by activation of NF-KB and MAPK signaling (Lorentz et al, 2003). The 
response of signaling molecules after treatment with ELP can give direct evidence for 
proofing the interaction of ELP on regulating cytokine production from human mast 
cells. , 
Since the purpose ofELP is for the treatment of osteoporosis, the prominent effects of 
ELP and its herbal constituents on regulating mediators release from human mast 
cells implied that human mast cells may serve as a target of ELP in achieving its 
anti-osteoporosis effect. Since the action of ELP is working on the bone tissue and 
estrogen is a major regulator in bone remodeling, the effect ofELP may be mediated 
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through ER on bone cells. Recent in vitro studies demonstrated that HEP and FP 
exerted estrogenic effects through ERs (Mok et aL, 2010; Xin et aL, 2010). The 
herbal extracts may contain phytoestrogens and act on ERs. The obvious suppression 
on degranulation and cytokine production may be accounted by the ERs expressed on 
human mast cells. The use of ER antagonist can elucidate whether the action of ELP 
is mediated through ER or not. 
Furthermore, a co-culture model consists ofhuman mast cells and bone cells may be 
able to demonstrate a more detailed interaction between the two types of cells. The 
changes of various bone turnover markers such as the expressions ofRANKL, RANK 
and OPG in bone cells after the activation of mast cells in the co-culture system can 
possibly give support to the involvement of mast cells in bone metabolism. 
The use of estradiol and SERMs on treatment of osteoporosis has promising effect 
based on different clinical studies. In our study, we suggested that estrogen may not 
exert its osteoprotective effect through regulating the human mast cells activity. 
However, the SERMs may be useful to modulate the nuclear activity ofhuman mast 
cells and thus enhance their effects on the protection of bone. Further mechanistic 
study is needed to elucidate the detail regulation by SERMs on human mast cells. On 
the other hand, the anti-osteoporosis herbal formula, ELP, exerted prominent 
regulating effects on human mast cells activities. We cannot conclude if the action of 
ELP is mediated through ERs due to the lack of mechanistic study. However, we have 
demonstrated that this anti-osteoporosis herbal formulation processes 
anti-inflammatory effect through suppression of mast cell activation. It suggests that 
the suppression of inflammatory response will be a possible route in the management 
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ofosteoporosis. It ako indirectly reflects that the involvement ofhuman mast cells in 
development of osteoporosis would be mediated through the production of various 
mediators upon activation by yet to be indentified stimuli in bone. The focus of the 
study on mast cells involvement in the pathophysiology of osteoporosis can be 
targeted on how the bone mast cells are activated and how mediators from mast cells 
achieve their regulating effects on bone cells and also in bone remodeling. 
170 
Reference 
ACAR, D., CAYAN, S., AKTAS, S.，TEK, M. & AKBAY，E. (2007). The effect of 
tamoxifen on bladder functions and histology, and the role of estrogen 
receptor beta in a rat chemical cystitis model. Neurourol Urodyn, 26, 309-16. 
AKGUL, C., CANBAZ, M., VURAL, R, YCLDlRM, A. & GEREN, N. (1998). Hormone 
replacement therapy and urinary prostaglandins in postmenopausal women. 
Maturitas, 30，79-83. 
AN, HJ., JEONG, HJ., UM，J.Y., PARK, Y.J, PARK, R.K., KlM, E.C., NA, HJ., SfflN, 
T.Y., KM, H.M. & HONG，S.H. (2007). Fmctus Ligustmm lucidi inhibits 
inflammatory mediator release through inhibition of nuclear factor-kappaB in 
mouse peritoneal macrophages. JPharm Pharmacol, 59, 1279-85. 
AN, H.J.，SEO, MJ., CHOI, LY, PARK, R.K., JEONG, S., LEE, J.Y., KM, H.M, UM, J.Y. 
& HONG, S.H. (2008). Induction of nitric oxide & tumour necrosis 
factor-alpha by Psoralea corylifolia. Indian JMed Res, 128，752-8. 
ANDRADE, M.V.，HmAGUN, T. & BEAVEN，M.A. (2004). Dexamethasone suppresses 
antigen-induced activation of phosphatidylinositol 3-kinase and downstream 
responses in mast cells. JImmunol, 172, 7254-62. 
ARE)OR, M.，TRAUB, L.M. & SAGl-ElSENBERG, R. (1990). Exocytosis in mast cells by 
basic secretagogues: evidence for direct activation ofGTP-binding proteins. J 
CellBiol, 111，909-17. 
ARONlCA, S.M., KRAUS, W.L. & KATZENELLENBOGEN, B.S. (1994). Estrogen action 
via the cAMP signaling pathway: stimulation of adenylate cyclase and 
cAMP-regulated gene transcription. ProcNatlAcadSci USA, 91, 8517-21. 
AnONS, GJ., HAYNES, D.R., GEARY, S.M., LORIC, M., CROTTI, T.N. & FESTOLAY，D.M. 
(2000). Coordinated cytokine expression by stromal and hematopoietic cells 
during human osteoclast formation. Bone, 26, 653-61. 
AzzOLESfA, A., BONGlOVANNl, A. & LAMPIASI，N. (2003). Substance P induces 
TNF-alpha and IL-6 production through NF kappa B in peritoneal mast cells. 
Biochim BiophysActa, 1643，75-83. 
BAI, Z. & GUST, R. (2009). Breast cancer, estrogen receptor and ligands. Arch Pharm 
(Weinheim), 342，133-49. 
BARRETT-CONNOR, E.，SLONE, S., GREENDALE, G., KRITZ-SlLVERSTED J^, D., 
ESPELAND, M., JOHNSON, S.R., WACLAWIW, M. & FD^ BERG，S.E. (1997). The 
Postmenopausal Estrogen>'Progestin Interventions Study: primary outcomes in 
adherent women. Maturitas, 27，261-74. 
BASfflR，A., MAK, Y.T., SANKARAL^GAM, S.，CHEUNG, J., McGOWAN, N.W., 
GRIG0RIADIS, A.E., FOGELMAN, 1. & HAMPSON’ G. (2005). Changes in 
171 
RANKL/OPG/RANK gene expression in peripheral mononuclear cells 
following treatment with estrogen or raloxifene. Steroids, 70, 847-55. 
BENT, S. (2008). Herbal medicine in the United States: review ofefficacy, safety, and 
regulation: grand rounds at University of California, San Francisco Medical 
Center. J Gen Intem Med, 23，854-9. 
BEYAK, M. & VANNER，S. (1995). Histamine H1 and H3 vasodilator mechanisms in 
the guinea pig ileum. Gastroenterology, 108, 712-8. 
BlOSSE-DUPLAN, M., BAROUKH, B., DV, M , DE VERNEJOUL, M.C. & SAFFAR, J.L. 
(2009). Histamine promotes osteoclastogenesis through the differential 
expression ofhistamine receptors on osteoclasts and osteoblasts. Am J Pathol, 
174, 1426-34. 
BlSCHOFF, S.C. (2007). Role of mast cells in allergic and non-allergic immune 
responses: comparison of human and murine data. Nat Rev Immunol, 7, 
93-104. 
BlSMAR, H., DlEL, I.，ZffiGLER, R. & PFEH s^cfflFTER，J. (1995). Increased cytokine 
secretion by human bone marrow cells after menopause or discontinuation of 
estrogen replacement. J Clin Endocrinol Metab, 80，3351-5. 
BJORNSTROM, L. & SJOBERG，M. (2004). Estrogen receptor-dependent activation of 
AP-1 via non-genomic signalling. Nucl Recept, 2, 3. 
BJORNSTROM, L. & SJOBERG,M. (2005). Mechanisms ofestrogen receptor signaling: 
convergence of genomic and nongenomic actions on target genes. Mol 
Endocrinol, 19，833-42. 
BONDAR, G., KU0, J., HAMH), N. & MlCEVYCH, P. (2009). Estradiol-induced estrogen 
receptor-alpha trafficking. JNeurosci, 29，15323-30. 
BORD, S., HORNER, A., BEAVAN，S. & COMPSTON，J. (2001). Estrogen receptors alpha 
and beta are differentially expressed in developing human bone. J Clin 
EndocrinolMetab, 86，2309-14. 
BORGES, J.L. & Bn^EZlfaAN, J.R (2006). Update on osteoporosis therapy. Arq Bras 
Endocrinol Metabol, 50，755-63. 
BOYCE, J.A. (2005). Eicosanoid mediators of mast cells: receptors, regulation of 
synthesis, and pathobiologic implications. Chem ImmunolAllergy, 87, 59-79. 
BRADDE^ JG, P. & HOLGATE，S.T. (1996). The mast cell as a source of cytokines in 
asthma. Ann N YAcad Sci, 796, 272-81. 
BROADUS, A.E. (1996). Mineral balance and homeostasis. In Primer on the metabolic 
bone diseases and disorders of mineral metabolism, ed Favus, M.J. pp. 57-63. 
Philadelphia: Lippincott-Raven. 
BROWN, J.M., WlLSON, T.M. & METCALFE, D.D. (2008). The mast cell and allergic 
diseases: role in pathogenesis and implications for therapy. Clin Exp Allergy, 
172 
38, 4-18. 
CAULEY，J.A., ROBBmS, J.’ CHEN, Z., CUMMD^ GS, S.R., JACKSON, R.D., LACROIX, 
A.Z” LEBOFF, M , LEWIS, C.E., McGOWAN, J., NEUNER, J., PETTINGER, M., 
STEFANICK, M.L., WACTAWSKI-WENDE, J. & WATTS，N.B. (2003). EffectS of 
estrogen plus progestin on risk of fracture and bone mineral density: the 
Women's Health Initiative randomized trial. Jama, 290，1729-38. 
CHAHDI，A” pRAUNDORFER, P.F. & BEAVEN，M.A. (2000). Compound 48/80 activates 
mast cell phospholipase D via heterotrimeric GTP-binding proteins. J 
Pharmacol Exp Ther, 292, 122-30. 
CHEN, H., EMURA, S.，ISONO, H. & SHOUMURA, S. (2005). Effects of traditional 
Chinese medicine on bone loss in SAMP6: a murine model for senile 
osteoporosis. Biol Pharm Bull, 28, 865-9. 
CHEN, X J , Guo, B.L, Ll, S.P., ZHANG, Q.W., TU，RF. & WANG，Y.T. (2007). 
Simultaneous determination of 15 fIavonoids in Epimedium using pressurized 
liquid extraction and high-performance liquid chromatography. J Chromatogr 
A, 1163, 96-104. 
CHENG, S., Qm, R, WANG, S. & HE, J. (2007). HPLC analysis and pharmacokinetics 
oficariin in rats. JSep Sci, 30，1307-12. 
CHEUNG, J., MAK, Y.T., PAPAIOANNOU, S.，EVANS, B.A., FOGELMAN, 1. & HAMPSON， 
G. (2003). Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor 
kappaB ligand (RANKL) and osteoprotegerin production by human 
osteoblastic cells: comparison of the effects of 17-beta oestradiol and 
raloxifene. JEndocrinol, 177,423-33. 
CfflAPPETTA, N. & GRUBER, B. (2006). The role ofmast cells in osteoporosis. Semin 
Arthritis Rheum, 36, 32-6. 
CLAPHAM, D.E. (2007). Calcium signaling. Cell, 131，1047-58. 
COCCHIARA, R., ALBEGGIANI, G.，DlTRAPANI, G., AZZOUNA，A., LAMPL\SI, N.，REZO, 
F.，DiOTALLEVi，L., GlANAROLI, L. & GERACI，D. (1992). Oestradiol enhances 
in vitro the histamine release induced by embryonic histamine-releasing factor 
(EHRF) from uterine mast cells. Hum Reprod, 7, 1036-41. 
DAI, R., PfflLUPS，R.A. & AHMED，S.A. (2007). Despite inhibition of nuclear 
localization of NF-kappa B p65, c-Rel, and ReB, 17-beta estradiol 
up-regulates NF-kappa B signaling in mouse splenocytes: the potential role of 
Bcl-3. JImmunol, 179，1776-83. 
DATTA，H.K.，NG, W.F., WALKER, J.A., TUCK, S.P. & VARANASI，S.S. (2008). The cell 
biology ofbone metabolism. J Clin Pathol, 61, 577-87. 
DEYAMA, Y.，Kncumi, T, OHNISHI, G , FENG, Y.G., TAKEYAMA, S , HATTA, M , 
Y0SfflMURA, Y. & SuzuKi，K. (2002). Histamine stimulates production of 
173 
osteoclast differentiation factor/receptor activator of nuclear factor-kappaB 
ligand by osteoblasts. Biochem Biophys Res Commun, 298, 240-6. 
Dl CAPITE, J. & PAREKH，A.B. (2009). CRAC channels and Ca2+ signaling in mast 
cells. Immunol Rev, 231, 45-58. 
DOBlGNY, C. & SAFFAR，J.L. (1997). H1 and H2 histamine receptors modulate 
osteoclastic resorption by different pathways: evidence obtained by using 
receptor antagonists in a rat synchronized resorption model. J Cell Physiol, 
173, 10-8. 
DUFFY, S.M., LAWLEY, W.J., KAUR, D., YANG, W. & BRADDmG，P. (2003). Inhibition 
ofhuman mast cell proliferation and survival by tamoxifen in association with 
ion channel modulation. JAllergy Clin Immunol, 112，965-72. 
DUTERTRE, M. & SMiTH，C.L. (2000). Molecular mechanisms of selective estrogen 
receptor modulator (SERM) action. JPharmacol Exp Ther, 295, 431-7. 
ETONGER, B., BLACK, D.M., MlTLAK, B.H., KNICKERBOCKER, R.K., NlCKELSEN, T.， 
GENANT, H.K., CHRISTIANSEN, C.，DELMAS, P.D., ZANCHETTA, J.R., 
STAKKESTAD, J.，GLUER, C.C., KRUEGER, K.，COHEN, F.J” ECKERT, S., ENSRUD, 
K.E., AVI0LI, L.V., Ln>S, R & CUMMD S^，S.R. (1999). Reduction ofvertebral 
fracture risk in postmenopausal women with osteoporosis treated with 
raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes 
ofRaloxifene Evaluation (MORE) Investigators. Jama, 282，637-45. 
EVERTS, V., DELAISSE, J.M., KORPER, W., JANSEN, D.C., TlGCHELAAR-GUTTER, W., 
SAFUG, P. & BEERTSEN，W. (2002). The bone lining cell: its role in cleaning 
Howship's lacunae and initiating bone formation. J Bone Miner Res, 17, 
77-90. 
FALLON, M.D., WHYTE, M.R, CRAIG, R.B., jR. & TEITELBAUM，S.L. (1983). Mast-cell 
proliferation in postmenopausal osteoporosis. CalcifTissue Int, 35, 29-31. 
FARHAT, M.Y., LAVIGNE, M.C. & RAMWELL, RW. (1996). The vascular protective 
effects of estrogen. Faseb J, 10, 615-24. 
FERRY, X.，BREfflN, S.，KAMEL, R. & LANDRY，Y. (2002). G protem-dependent 
activation of mast cell by peptides and basic secretagogues. Peptides, 23, 
1507-15. 
FERRY, X., ElCHWALD, V” DAEFFLER, L. & LANDRY，Y. (2001). Activation of 
betaganmia subunits of G(i2) and G(i3) proteins by basic secretagogues 
induces exocytosis through phospholipase Cbeta and arachidonate release 
through phospholipase Cgamma in mast cells. JImmunol, 167，4805-13. 
FlSHER, B., COSTANTTNO，J.R，WlCKERHAM, Dl.，REDMOND, C.K., KAVANAH, M., 
CRONn>T, W.M., VOGEL, V., ROBH)OUX, A., DMITROV, N., AnONS，J., DALY, M., 




prevention of breast cancer: report of the National Surgical Adjuvant Breast 
and Bowel Project P-1 Study. JNatl CancerInst, 90，1371-88. 
FlTZPATRICK, L.A., BUZAS, E., GAGNE，TJ., NAGY, A.，HORVATH, C., FERENCZ, V., 
MESTER, A., KARI, B., RUAN, M., FALUS，A. & BARSONY，J. (2003). Targeted 
deletion ofhistidine decarboxylase gene in mice increases bone formation and 
protects against ovariectomy-induced bone loss. Proc Natl Acad Sci U S A, 
100，6027-32. 
FORSYTHE, P. & ENNIS，M. (2000). Clinical consequences ofmast cell heterogeneity. 
Inflamm Res, 49, 147-54. 
FOUILLOUX, I., DUPLAN, M.B., BAROUKH, B., CHERRUAU，M., SAFFAR, J.L. & 
LESCLOUS, P. (2006). Mast cell activation and degranulation occur early 
during induction of periosteal bone resorption. Bone, 38, 59-66. 
FRANCIS, R.M., SUTOJFFE,A.M. & SCANE,A.C. (1998). Pathogenesis ofosteoporosis. 
In Osteoporosis, eds Stevenson, J.C. & Lindsay，R. pp. 1-28. London: 
Chapman & Hall Medical. 
GALLI, SJ. & TSAl，M. (2008a). Mast cells: versatile regulators of inflammation, 
tissue remodeling, host defense and homeostasis. JDermatol Sci’ 49, 7-19. 
GALLI, SJ., TSAI, M. & PEJPONSKY，A.M. (2008b). The development of allergic 
inflammation. Nature, 454，445-54. 
GfflSLETTl, S., MEDA, C., MAGGI, A. & VEGETO, E. (2005). 17beta-estradiol inhibits 
inflammatory gene expression by controlling NF-kappaB intracellular 
localization. Mol Cell Biol, 25, 2957-68. 
GlANNI, W., RlCCI, A., GAZZANIGA，R，BRAMA, M., PlETROPAOLO, M., VOTANO, S., 
PATANE, R, AGUANO，A.M., SPERA, G., MARIGLIANO, V., AMMENDOLA, S., 
AGNUSDEI, D., MlGLlACCIO, S. & SCANDURRA, R. (2004). Raloxifene 
modulates interleukin-6 and tumor necrosis factor-alpha synthesis in vivo: 
results from a pilot clinical study. J Clin Endocrinol Metab, 89, 6097-9. 
GELFILLAN,A.M. & TKACZYK，C. (2006). Integrated signalling pathways for mast-cell 
activation. Nat Rev Immunol, 6, 218-30. 
GniASOLE, G., JlLKA, R.L., PASSERI, G., BOSWELL, S., BODER, G., WlLLIAMS, D.C. & 
MANOLAGAS, S.C. (1992). 17 beta-estradiol inhibits interleukin-6 production 
by bone marrow-derived stromal cells and osteoblasts in vitro: a potential 
mechanism for the antiosteoporotic effect of estrogens. J Clin Invest, 89， 
883-91. 
GURISH, M.F. & AuSTEN，K.F. (2001). The diverse roles ofmast cells. JExp Med’ 194， 
Fl-5. 
HADJE)AKIS, D.J. & ANDROULAKIS，II (2006). Bone remodeling. Ann N YAcad Sci, 
1092, 385-96. 
175 
HARNISH, D.C., ALBERT, L.M.，LEATHURBY, Y., ECKERT, A.M., ClARLETTA, A .， 
KASAIAN, M. & KEITH, J.C., JR. (2004). Beneficial effects of estrogen 
treatment in the HLA-B27 transgenic rat model of inflammatory bowel 
disease. Am JPhysiol Gastrointest Liver Physiol, 286，G118-25. 
HASEGAWA, T., YOSfflMURA, Y., KKUHU，T.，YAWAKA, Y., lAKEYAMA, S.，MATSUMOTO, 
A., OGUCHl, H. & SfflRAKAWA，T. (2002). Expression ofreceptor activator of 
NF-kappa B ligand and osteoprotegerin in culture of human periodontal 
ligament cells. JPeriodontalRes, 37,405-11. 
HAYNES, D.R., CROTTI, T.N., LORIC，M., BAlN, G.L, ATKESfS, G.J. & Fn^ DLAY，D.M. 
(2001). Osteoprotegerin and receptor activator of nuclear factor kappaB ligand 
(RANKL) regulate osteoclast formation by cells in the human rheumatoid 
arthritic joint. Rheumatology (Oxford), 40, 623-30. 
HEDQVIST, R, GAUTAM, N. & LE^BOM,L. (2000). Interactions between leukotrienes 
and other inflammatory mediators/modulators in the microvasculature. Am J 
Respir Crit Care Med, 161，S117-9. 
HroAKA, S., OKAMOTO, Y., YAMADA, Y., UWAZAKJL, K. & KMURA, T. (2000). 
Alterations in the periodontium after ovariectomy in rats: the effects of a 
Japanese herbal medicine, Chujo-to. Phytother Res, 14，527-33. 
Bmin, H., TAKATO, T., SHMIZU, T. & Isffll，S. (2008). The roles of prostanoids, 
leukotrienes, and platelet-activating factor in bone metabolism and disease. 
ProgLipidRes, 47, 107-26. 
HniAI, H., TANAKA, K.，YOSfflE, 0 ” OOAWA, K., KENMOTSU, K.，TAKAMORI, Y.， 
ICmMASA, M., SUGAMURA, K., NAKAMURA, M., TAKANO, S. & NAGATA, K. 
(2001). Prostaglandin D2 selectively induces chemotaxis in T helper type 2 
cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J 
ExpMed,m, 255-61. 
HOFBAUER, L.C., KHOSLA, S.，DUNSTAN, C.R., LACEY, D.L., SPELSBERG, T.C. & 
RlGGS, B.L. (1999). Estrogen stimulates gene expression and protein 
production of osteoprotegerin in human osteoblastic cells. Endocrinology’ 140， 
4367-70. 
HOFBAUER, L.C., KUHNE, C.A. & ViERECK，V. (2004). The OPG/RANKL/RANK 
system in metabolic bone diseases. J Musculoskelet Neuronal Interact, 4， 
268-75. 
Hsu, H.Y., YANG, J.J. & Ln^ ，C.C. (1997). Effects ofoleanolic acid and ul^ solic acid 
on inhibiting tumor growth and enhancing the recovery of hematopoietic 
system postirradiation in mice. Cancer Lett, 111，7-13. 
lKEDA, T.，UTSUYAMA, M. & ffiROKAWA, K. (2001). Expression profiles of receptor 
activator of nuclear factor kappaB ligand, receptor activator of nuclear factor 
176 
kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat 
bones. J Bone Miner Res, 16, 1416-25. 
lMPROTA-BREARS, T., WHORTON, A.R., CODAZZI, R，YORK, J.D., MEYER, T. & 
McDONNELL, D.P. (1999). Estrogen-induced activation of mitogen-activated 
protein kinase requires mobilization of intracellular calcium. Proc Natl Acad 
SciUSA,96,4686-91. 
IRANI,A.M. & SCHWARTZ, L.B. (1989). Mast cell heterogeneity. Clin Exp Allergy, 19, 
143-55. 
ISfflZUKA, T., TERADA, N., GERWn^ S, R，HAMELMANN, E., OSfflBA, A., FANGER, G.R., 
JOHNSON, G1 . & GELFAND, E.W. (1997). Mast cell tumor necrosis factor 
alpha production is regulated by MEK kinases. Proc Natl Acad Sci U SA, 94, 
6358-63. 
IZUMI, H., MAKESfO, Y.，SfflRAKAWA, K. & GARFIELD，R.E. (1995). Role of nitric 
oxide on vasorelaxation in human umbiHcal artery. Am J Obstet Gynecol, 172, 
1477-84. 
JACOB, J.，SEBASTIAN, K.S., DEVASSY, S., PRR^ ADARSE^ I, L , PAROOK, M.F., SHAMEEM, 
A.，MATHEW, D.，SREEJA, S. & THAMPAN, R.V. (2006). Membrane estrogen 
receptors: genomic actions and post transcriptional regulation. Mol Cell 
Endocrinol, 246, 34-41. 
JlLKA, R.L. (1998). Cytokines, bone remodeling, and estrogen deficiency: a 1998 
update. Bone, 23, 75-81. 
Jns[, U.H., KJM, D.L, LEE, T.K, LEE, D.N” Km, J.K., LEE, I.S. & KM, C.H. (2006). 
Herbal formulation, Yukmi-jihang-tang-Jahage, regulates bone resorption by 
inhibition of phosphorylation mediated by tyrosine kinase Src and 
cyclooxygenase expression. JEthnopharmacol, 106，333-43. 
KANG, O.H., CHAE, H.S., CHOI, J.H., CHOI, H.J., PARK, P.S., CHO, S.H., LEE, G.H., So, 
H.Y., CHOO, Y.K., KWEON, O.H. & KWON，D.Y. (2006). Effects of the 
Schisandra fructus water extract on cytokine release from a human mast cell 
line. JMedFood, 9，480-"6. 
KANIS, J.A. (1994). Pathogenesis of osteoporosis and fracture. In Osteoporosis, ed 
Kanis, J.A. pp. 22-55. Oxford ； Cambridge, Mass.: Blackwell Science. 
KANIS, J.A., BURLET,N., COOPER, C., DELMAS, RD., REGE S^TER, J.Y., BORGSTROM, F. 
& RLZZOLl, R. (2008). European guidance for the diagnosis and management 
ofosteoporosis in postmenopausal women. Osteoporos Int, 19，399-428. 
KARH ,^ M. (1995). The regulation of AP-1 activity by mitogen-activated protein 
kinases. JBiol Chem, 270, 16483-6. 
KATZENELLENBOGEN, B.S., CHOI, I., DELAGE-MOURROUX, R., EDIGER, T.R., MARTTNI’ 
RG., MONTANO, M., SUN, J., WEIS, K. & KATZENELLENBOGEN，J.A. (2000). 
177 
Molecular mechanisms of estrogen action: selective ligands and receptor 
pharmacology. JSteroid Biochem MolBiol, 74，279-85. 
KAWAGOE, J., OHMICHI, M., lAKAHASHI, T., OHSfflMA, C., MABUCHI, S., TAKAHASHI, 
K., lGARASHI, H., MORI-ABE, A” SAITOH, M” DU，B.，OHTA, T., KJMURA, A., 
KYO, S., lNOUE, M. & KURACHI，H. (2003). Raloxifene inhibits 
estrogen-induced up-regulation of telomerase activity in a human breast 
cancer cell line. JBiol Chem, 278, 43363-72. 
KHOSLA, S. (2001). Minireview: the OPG/RANKL/RANK system. Endocrinology, 
142，5050-5. 
KJM, M.S., CHAE, HJ., SmN, T.Y., KM, H.M. & KM，H.R. (2001). Estrogen regulates 
cytokine release in human mast cells. Immunopharmacol Immunotoxicol, 23， 
495-504. 
KM, M.S., LM, W.K., PARK, R.K., SfflN, T., Yoo,Y.H., HONG, S.H., AN, N.H. & KM， 
H.M. (2005). Involvement of mitogen-activated protein kinase and 
NF-kappaB activation in Ca2+-induced IL-8 production in human mast cells. 
Cytokine, 32，226-33. 
KmSHENBAUM, A.S., AKESf, C., WU, Y, ROTTEM, M.，GOFF, J.R, BEAVEN, M.A., RAO, 
V.K. & METCALFE，D.D. (2003). Characterization of novel stem cell factor 
responsive human mast cell lines LAD 1 and 2 established from a patient with 
mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI 
or FcgammaRI. Leuk Res, 27, 677-82. 
KOBAYASHI, K.，TAKAHASHI, N., JMI，E., UDAGAWA, N., TAKAMI, M., KOTAKE, S., 
NAKAGAWA, N.，KESfOSAKI, M., YAMAGUCHI, K., SfflMA, N., YASUDA, H .， 
MORn^ AGA, T.，HlGASfflO, K., MARTTN，T.J. & SUDA, T. (2000). Tumor 
necrosis factor alpha stimulates osteoclast differentiation by a mechanism 
independent ofthe ODF/RANKL-RANK interaction. JExpMed, 191，275-86. 
KONDO, T., KlTAZAWA, R.，YAMAGUCHI, A. & KTTAZAWA，S. (2008). Dexamethasone 
promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple 
\QYQ\s.JCellBiochem, 103, 335-45. 
KRUM, S.A., MmANDA-CARBONI, G.A., HAUSCHKA, P.V., CARROLL, J.S.，LANE, T.R, 
FREEDMAN, L.P. & BROWN，M. (2008). Estrogen protects bone by inducing 
Fas ligand in osteoblasts to regulate osteoclast survival. Embo J, 27, 535-45. 
LAGUNOFF, D., MAKHN, T.W. & READ, G. (1983). Agents that release histamine from 
mast cells. Annu Rev Pharmacol Toxicol, 23, 331-51. 
LE MELLAY, V.，GROSSE, B. & LlEBERHERR，M. (1997). Phospholipase C beta and 
membrane action of calcitriol and estradiol. JBiol Chem, 272, 11902-7. 
LEE, K.H. (2000). Research and future trends in the pharmaceutical development of 
medicinal herbs from Chinese medicine. Public Health Nutr, 3，515-22. 
178 
LEE, S.H., KJM, T.S., CHOI, Y. & LORENZO, J. (2008). Osteoimmunology: cytokines 
and the skeletal system. BMB Rep, 41,495-510. 
LEE, Y.R., PARK, J., Yu, H.N., KJM, J.S., Y0UN, H.J. & JUNG，S.H. (2005). 
Up-regulation ofPI3K7Akt signaling by 17beta-estradiol through activation of 
estrogen receptor-alpha, but not estrogen receptor-beta, and stimulates cell 
growth in breast cancer cells. Biochem Biophys Res Commun，336，1221-6. 
LENON, G.B., XUE, C.C., STORY, D.F.，TfflEN, RC., McPHEE, S. & Ll, C.G. (2007). 
Inhibition of release of inflammatory mediators in primary and cultured cells 
by a Chinese herbal medicine formula for allergic rhinitis. Chin Med, 2，2. 
LERNER, U.H. (2006). Bone remodeling in post-menopausal osteoporosis. JDent Res, 
85, 584-95. 
LESCLOUS, R, GUEZ, D., LLORENS, A. & SAFFAR, J.L. (2001). Time-course of mast 
cell accumulation in rat bone marrow after ovariectomy. Calcif Tissue Int, 68, 
297-303. 
LESCLOUS, R & SAFFAR, J.L. (1999). Mast cells accumulate in rat bone marrow after 
ovariectomy. Cells Tissues Organs, 164, 23-9. 
LESCLOUS, P., SCHRAMM, F.，GALUNA，S.，BAROUKH, B.，GUEZ, D. & SAFFAR, J.L. 
(2006). Histamine mediates osteoclastic resorption only during the acute 
phase ofbone loss in ovariectomized rats. Exp Physiol, 91, 561-70. 
LEvnsf, E.R. (2005). Integration of the extranuclear and nuclear actions of estrogen. 
MolEndocrinol, 19, 1951-9. 
LEWIECKI, E.M. (2009). Current and emerging pharmacologic therapies for the 
management of postmenopausal osteoporosis. J Womens Health (Larchmt), 18, 
1615-26. 
Ll, T., Ll, W., LU, J , LnJ, H., Ll, Y. & ZHAO, Y. (2009). SH2D4A regulates cell 
proliferation via the ERalpha/PLC-gammay^KC pathway. BMB Rep, 42, 
516-22. 
Ll, Y.C., AMUNG，M., PmRO, A.E., PRffiMEL, M., MEUSE, J., BARON, R.’ DELLESfG, G. 
& DEMAY, M.B. (1998). Normalization of mineral ion homeostasis by dietary 
means prevents hyperparathyroidism, rickets, and osteomalacia, but not 
alopecia in vitamin D receptor-ablated mice. Endocrinology, 139，4391-6. 
Ln^BERG, M.K., ERLANDSSON, M.，ALATALO, S.L., WrSfDAHL, S.，ANDERSSON, G., 
HALLEEN, J.M., CARLSTEN, H., GUSTAFSSON, J.A. & OHLSSON，C. (2001). 
Estrogen receptor alpha, but not estrogen receptor beta, is involved in the 
regulation of the OPG/RANKL (osteoprotegerin/receptor activator of 
NF-kappa B ligand) ratio and serum interleukin-6 in male mice. JEndocrinol, 
171，425-33. 
Ln>PERT, U., WELKER, P., KRUGER-KRASAGAKES, S., MOLLER, A. & HENZ，B.M. 
179 
(1996). Modulation of in vitro cytokine release from human leukemic mast 
cells (HMC-1) by glucocorticoids. Skin Pharmacol, 9, 93-8. 
Lnj, H.，Sffl, Y., WANG, D.，YANG, G., Yu, A. & ZHANG, H. (2003). MECC 
determination of oleanolic acid and ursolic acid isomers in Ligustmm lucidum 
Ait. JPharm BiomedAnal, 32,479-85. 
Lru，J. (1995). Pharmacology of oleanolic acid and ursolic acid. JEthnopharmacol, 
49，57-68. 
LnJ, J., Lm, Y., MADHU, C. & KLAASSEN, C.D. (1993). Protective effects ofoleanoUc 
acid on acetaminophen-induced hepatotoxicity in mice. J Pharmacol Exp 
Ther, 266，1607-13. 
LORENTZ, A.，KLOPP, 1” GEBHARDT, T.，MANNS, M.P. & BlSCHOFF, S.C. (2003). Role 
of activator protein 1，nuclear factor-kappaB, and nuclear factor of activated T 
cells in IgE receptor-mediated cytokine expression in mature human mast 
cells. JAllergy Clin Immunol;lll, 1062-8. 
LORENZO, I，HOROWlTZ, M. & CHOI, Y. (2008). Osteoimmunology: interactions of 
the bone and immune system. Endocr Rev, 29, 403-40. 
L0VE, R.R., CAMERON, L., CONNELL, B.L. & LEVENTHAL, H. (1991). Symptoms 
associated with tamoxifen treatment in postmenopausal women. Arch Intem 
Med, 151，1842-7. 
L0WMAN, M.A., BENYON, R.C. & CHURCH，M.K. (1988). Characterization of 
neuropeptide-induced histamine release from human dispersed skin mast cells. 
BrJPharmacol 95, 121-30. 
MANOLAGAS, S.C. & jDJCA，R.L. (1995). Bone marrow, cytokines, and bone 
remodeling. Emerging insights into the pathophysiology of osteoporosis. N 
EnglJMed,332, 305-11. 
MANOLAGAS, S.C. & WED S^TEns[, R.S. (1999). New developments in the pathogenesis 
and treatment ofsteroid-induced osteoporosis. JBoneMinerRes, 14, 1061-6. 
MARCELLI, C., YATES, A.I & MUNDY，G.R. (1990). In vivo effects of human 
recombinant transforming growth factor beta on bone turnover in normal mice. 
JBone Miner Res, 5，1087-96. 
MARmi, H., MnsaJTOLI, L., POLITO, R, BlTTO, A., ALTAVILLA, D., ATTERITANO, M., 
GAUDIO, A., MAZZAFERRO, S., pRISESTA, A., PRISESfA, N., LUBRANO, C., 
BONARJTO, M., D'ANNA, R., CAKNATA, Ml.，CORRADO, R, CANCELLIERI, R ， 
FARACI, M., MARn I^, R., ADAMO, E.B., W^SON, S. & SQUADRITO’ R (2008). 
OPG and sRANKL serum concentrations in osteopenic, postmenopausal 
women after 2-year genistein administration. JBone Miner Res, 23, 715-20. 
MARnsfO, M., GALLUZZO, P. & ASCENZI，R (2006). Estrogen signaling multiple 
pathways to impact gene transcription. Curr Genomics, 7，497-508. 
180 
MASnJKlEWlCZ, U.S., MlTNICK, M., GREY, A.B. & iNSOGNA，K.L. (2000). Estrogen 
modulates parathyroid hormone-induced interleukin-6 production in vivo and 
in vitro. Endocrinology, 141，2526-31. 
MATSUDA, H.，JQYOHARA, S., SUGIMOTO, S., ANDO, S., NAKAMURA, S. & YOSfflKAWA， 
M. (2009). Bioactive constituents from Chinese natural medicines. XXXIIL 
Inhibitors from the seeds of Psoralea corylifolia on production of nitric oxide 
in lipopolysaccharide-activated macrophages. Biol Pharm Bull, 32, 147-9. 
MATSUDA, H., SUGIMOTO, S., MORIKAWA, T., MATSUfflRA, K.，MEUGUCHI, E.， 
NAKAMURA, S. & YosfflKAWA, M. (2007). Bioactive constituents from 
Chinese natural medicines. XX. Inhibitors of antigen-induced degranulation in 
RBL-2H3 cells from the seeds of Psoralea corylifolia. Chem Pharm Bull 
(Tokyo), 55，106-10. 
MATSUMOTO, T. & SfflBATA，T. (1998). The ex vivo effect of the herbal medicine 
sho-saiko-to on histamine release from rat mast cells. Eur Arch 
Otorhinolaryngol, 255, 359-64. 
MATTHEWS, J. & GUSTAFSSON，J.A. (2003). Estrogen signaling: a subtle balance 
between ER alpha and ER beta. MolInterv, 3，281-92. 
McCARTHY, M.M. (2009). The two faces of estradiol: effects on the developing brain. 
Neuroscientist, 15, 599-610. 
McKAY, L.L & QDLOWSKI,J.A. (1999). Molecular control of immune/inflammatory 
responses: interactions between nuclear factor-kappa B and steroid 
receptor-signaling pathways. EndocrRev，20，435-59. 
McKENNA, M.J. & FRAME，B. (1985). The mast cell and bone. Clin Orthop RelatRes, 
226-33. 
METCALFE, D.D. (2008). Mast cells and mastocytosis. Blood, 112, 946-56. 
MlCHAELSSON, K., BARON, J.A., FARAHMAND, B.Y., JOHNELL, 0 ” MAGNUSSON, C., 
PERSSON, P.G., PERSSON, I. & LJUNGHALL，S. (1998). Hormone replacement 
therapy and risk of hip fracture: population based case-control study. The 
Swedish Hip Fracture Study Group. Bmj, 316，1858-63. 
Mn^ GYUE, W., UNG，G., BEI, X., JUNQE^ G^, C., PEIQD^G, Z. & JlE, H. (2005). Clinical 
observation on 96 cases of primary osteoporosis treated with kidney-tonifying 
and bone-strengthening mixture. J Tradit Chin Med, 25, 132-6. 
MEUNO, A., AMEUKA, N.，fiOE, K., MURAKAMI, A., FUJISE, N., KANNO, T., SATO, Y.， 
NAKAGAWA, N.，YASUDA, H.，MOCHIZUKI, S.，GOMIBUCffl, T., YANO, K” 
SmMA, N.，WASHK)A, N., TSUDA, E.，MORINAGA, T., HlGASfflO, K. & OZAWA, 
H. (1998). Severe osteoporosis in mice lacking osteoclastogenesis inhibitory 
factor/osteoprotegerin. Biochem Biophys Res Commun, 247，610-5. 
MOK, S.K., CHEN, W.F., LAI, W.R, LEUNG, RC., WANG, Xl.，YAO, X.S. & WONG， 
181 
M.S. (2010). Icariin protects against bone loss induced by oestrogen 
deficiency and activates oestrogen receptor-dependent osteoblastic functions 
inUMR 106 cells. BrJPharmacol, 159，939-49. 
MOLLER, A., GRABBE, J. & CZARNETZKI, B.M. (1991). Mast cells and their mediators 
in immediate and delayed immune reactions. Skin Pharmacol, 4 Suppl 1， 
56-63. 
MOLLER, A.，HENZ, B.M., GRUTZKAU, A., Ln>PERT, U., ARAGANE, Y., SCHWARZ, T. & 
KRUGER-KRASAGAKES, S. (1998). Comparative cytokine gene expression: 
regulation and release by human mast cells. Immunology, 93, 289-95. 
MOUSLI, M., BRONNER, C.，BUEB, J.L., TSCfflRHART, E., GlES, J.R & LANDRY，Y. 
(1989). Activation ofrat peritoneal mast cells by substance P and mastoparan. 
JPharmacol Exp Ther, 250, 329-35. 
MOUSLI, M., BRONNER, C., LANDRY, Y., BOCKAERT, J. & ROUOT，B. (1990). Direct 
activation of GTP-binding regulatory proteins (G-proteins) by substance P and 
compound 48/80. FEBSLett, 259，260-2. 
MUKHOPADHYAY, S., HoiDAL, J.R. & MUKHERJEE, T.K. (2006). Role ofTNFalpha in 
puknonary pathophysiology. Respir Res, 7, 125. 
NA, H.I , MOON, P.D., HONG, S.H.，SfflN, J.Y. & KM, H.M. (2004). Inhibitory effect 
of Yunbutang on mast cell-dependent allergic reactions. Immunopharmacol 
Immunotoxicol, 26, 233^2. 
NAKAE, S., SUTO, H., KAKURAI, M.，SEDGWICK, J.D., TSAI, M. & GALLI，S.J. (2005). 
Mast cells enhance T cell activation: Importance of mast cell-derived TNR 
ProcNatlAcadSci USA, 102, 6467-72. 
NlAN, H.，MA, M.H., NL\N, S.S. & Xu, L.L. (2009). Antiosteoporotic activity of 
icariin in ovariectomized rats. Phytomedicine, 16, 320-6. 
NlCOVANl, S. & RUDOLPH，M.I. (2002). Estrogen receptors in mast cells from arterial 
walls. Biocell, 26，15-24. 
MLSSON，S., MAKELA, S.，lREUTER, E., TUJAGUE, M.，THOMSEN, J., ANDERSSON, G., 
ENMARK, E., PETTERSSON, K.，WARNER, M. & GUSTAFSSON, J.A. (2001). 
Mechanisms of estrogen action. Physiol Rev, 81，1535-65. 
NOMURA, M., KORACH, K.S., PFAFF, D.W. & OGAWA，S. (2003). Estrogen receptor 
beta (ERbeta) protein levels in neurons depend on estrogen receptor alpha 
(ERalpha) gene expression and on its ligand in a brain region-specific manner. 
Brain Res MolBrain Res, 110, 7-14. 
OGAWA, Y. & CALHOUN，WJ. (2006). The role of leukotrienes in airway inflammation. 
JAllergy Clin Immunol, 118, 789-98; quiz 799-800. 
OKAYAMA, Y.，BENYON, R.C.，REES, P.H., LOWMAN, M.A., HELLIER, K. & CHURCH， 
M.K. (1992). Inhibition profiles of sodium cromoglycate and nedocromil 
182 
sodium on mediator release from mast cells of human skin, lung, tonsil, 
adenoid and intestine. Clin Exp Allergy, 22，401-9. 
0N0, K.，AKATSU, T., MURAKAMI, T., NlSfflKAWA, M., YAMAMOTO, M., KUGAI, N., 
MOTOYOSHl, K. & NAGATA, N. (1998). Important role of EP4, a subtype of 
prostaglandin (PG) E receptor, in osteoclast-like cell formation from mouse 
bone marrow cells induced by PGE2. JEndocrinol, 158，Rl-5. 
PAECH, K.，WEBB, p., KUIPER, G.G., NELSSON, S.，GUSTAFSSON, J., KUSHNER, PJ. & 
SCANLAN, T.S. (1997). Differential ligand activation of estrogen receptors 
ERalpha and ERbeta at API sites. Science, 277，1508-10. 
PAGEAU, S.C. (2009). Denosumab. MAbs, 1,210-5. 
PANG, X., COTREAU-BffiBO, M.M., SANT, G.R. & THEOHARroES, T.C. (1995). Bladder 
mast cell expression of high affmity oestrogen receptors in patients with 
interstitial cystitis. Br J Urol, 75, 154-61. 
PAREKH, A.B. & PENNER，R. (1997). Store depletion and calcium influx. PhysiolRev, 
77, 901-30. 
PASSERI, G., GniASOLE, G., JlLKA, R.L. & MANOLAGAS，S.C. (1993). Increased 
interleukin-6 production by murine bone marrow and bone cells after estrogen 
withdrawal. Endocrinology, 133，822-8. 
PEARCE, F.L. (1985). Calcium and mast cell activation. Br J Clin Pharmacol, 20 
Suppl2, 267S-274S. 
PETTWAY, GJ., MEGANCK, J.A., KOH, A.J., KELLER, E.T., GOLDSTEm, S.A. & 
McCAULEY, L.K. (2008). Parathyroid hormone mediates bone growth through 
the regulation of osteoblast proliferation and differentiation. Bone, 42，806-18. 
PFEDL^ SCmFTER，J., KODlTZ, R., PPOHL, M. & SCHATZ，H. (2002). Changes in 
proinflammatory cytokine activity after menopause. EndocrRev, 23, 90-119. 
PlCOTTO, G., VAZQUEZ, G. & BOLAND，R. (1999). 17beta-oestradiol increases 
intracellular Ca2+ concentration in rat enterocytes. Potential role of 
phospholipase C-dependent store-operated Ca2+ influx. Biochem J, 339 ( Pt 
1)，71-7. 
Prs[K, J.J. & JORDAN，V.C. (1996). Models of estrogen receptor regulation by 
estrogens and antiestrogens in breast cancer cell lines. Cancer Res, 56, 
2321-30. 
PRESS, M.R, N0USEK-G0EBL, N.A., BUR, M. & GREENE，G1. (1986). Estrogen 
receptor localization in the female genital tract. Am JPathol, 123，280-92. 
PRUSSm, C. & METCALFE，D.D. (2003). 4. IgE, mast cells, basophils, and eosinophils. 
JAllergy Clin Immunol, 111，S486-94. 
PUNDDl, P. & KULKA，M. The role of G protein-coupled receptors in mast cell 
activation by antimicrobial peptides: is there a connection? Immunol Cell Biol. 
183 
PUTNAM, S.E., SCUTT, A.M., BlCKNELL, K., PRIESTLEY, C.M. & WnXIAMSON, E.M. 
(2007). Natural products as alternative treatments for metabolic bone 
disorders and for maintenance ofbone health. Phytother Res, 21, 99-112. 
RAISZ, L.G. (2005). Pathogenesis of osteoporosis: concepts, conflicts, and prospects. 
JClinInvest, 115, 3318-25. 
RAISZ, L.G. (1999a). Physiology and pathophysiology of bone remodeling. Clin 
Chem, 45，1353-8. 
RAISZ, L.G. (1999b). Prostaglandins and bone: physiology and pathophysiology. 
Osteoarthritis Cartilage, 7, 419-21. 
RAPHAEL, T.J. & KUTTAN，G. (2003). Effect of naturally occurring triterpenoids 
glycyrrhizic acid, ursolic acid, oleanolic acid and nomilin on the immune 
system. Phytomedicine，10, 483-9. 
RAUD, J., THORLACnJS, H., XlE, X., LES[DBOM, L. & HEDQVIST, P. (1994). Interactions 
between histamine and leukotrienes in the microcirculation. Aspects of 
relevance to acute allergic inflammation. Ann N YAcad Sci, 744, 191-8. 
RAZANDI, M., PEDRAM, A. & LEVK^，E.R. (2000). Plasma membrane estrogen 
receptors signal to antiapoptosis in breast cancer. Mol Endocrinol, 14， 
1434-47. 
RlGGS, B 1 . & HARTMANN, L.C. (2003). Selective estrogen-receptor modulators ~ 
mechanisms of action and application to clinical practice. NEnglJMed, 348， 
618-29. 
RlZZOLl, R. & BONJOUR，J.R (1999). Determinants of peak bone mass and 
mechanisms of bone loss. Osteoporos Int, 9 Suppl 2, S17-23. 
ROBDs[SON, J.A., HARRIS, S.A., RlGGS, B.L. & SPELSBERG，T.C. (1997). Estrogen 
regulation of human osteoblastic cell proliferation and differentiation. 
Endocrinology, 138，2919-27. 
ROBUNG，A.G., CASTILLO, A.B. & TURNER，C.H. (2006). Biomechanical and 
molecular regulation ofbone remodeling. Annu Rev Biomed Eng, 8，455-98. 
ROMASHKOVA, J.A. & MAKA^ iCT^ ，S.S. (1999). NF-kappaB is a target of AKT in 
anti-apoptotic PDGF signalling. Nature, 401, 86-90. 
ROZNIECKI, JJ., DMITFOADOU, V., LAMBRACHT-HALL, M., PANG, X. & THEOHARTOES, 
T.C. (1999). Morphological and functional demonstration of rat dura mater 
mast cell-neuron interactions in vitro and in vivo. Brain Res, 849, 1-15. 
RUMN，M.R., C0SMAN, F., Lns[DSAY, R. & Bni^ EZnciAN，J.R (2002). The anabolic 
effects of parathyroid hormone. Osteoporos Int, 13，267-77. 
SAITO, H., EBISAWA, M.，SAKAGUCHI, N., ONDA, T.，lKURA, Y., YANAGE)A, M .， 
UZUMAKI, H. & NAKAHATA, T. (1995). Characterization of cord-blood-derived 
human mast cells cultured in the presence of Steel factor and interleukin-6. Int 
184 
Arch Allergy Immunol, 107, 63-5. 
SAKAMOTO, S., SASSA, S., KUDO, H., SUZUKI, S.，MlTAMURA, T. & SfflNODA, H. 
(2000). Preventive effects of a herbal medicine on bone loss in rats treated 
with a GnRH agonist. EurJEndocrinol, 143，139-42. 
SALLUSTO, F.，LANZAVECCfflA，A. & MACKAY, C.R. (1998). Chemokines and 
chemokine receptors in T-cell priming and Thl/Th2-mediated responses. 
Immunol Today, 19, 568-74. 
SANCHEZ, C.，GABAY, 0., SALVAT, C., HENROTESf, Y.E. & BERENBAUM, F. (2009). 
Mechanical loading highly increases IL-6 production and decreases OPG 
expression by osteoblasts. Osteoarthritis Cartilage, 17, 473-81. 
SATO, M., RPPY, M.K. & BRYANT，H.U. (1996). Raloxifene, tamoxifen, nafoxidine, or 
estrogen effects on reproductive and nonreproductive tissues in 
ovariectomized rats. Faseb J, 10, 905-12. 
SECRETO, FJ., GROVER, A., PACURARI, M., RlCE, M.B., KANTOROW, M., BK)WAI, A.P., 
BLAHA, J.D. & KEETTNG, RE. (2003). Estrogen potentiates the combined 
effects of transforming growth factor-beta and tumor necrosis factor-alpha on 
adult human osteoblast-Uke cell prostaglandin E2 biosynthesis. Calcif Tissue 
Int, 73, 565-74. 
SEEMAN, E. (2003). Invited Review: Pathogenesis of osteoporosis. JAppl Physiol, 95, 
2142-51. 
SENKUS-KONEFKA, E., KONEFKA, T. & JASSEM, J. (2004). The effects of tamoxifen on 
the female genital tract. Cancer Treat Rev, 30，291-301. 
SHEFLER, 1.，TAUBE, Z., MEDALIA, 0 . & SAGI-ElSENBERG, R. (1998). Basic 
secretagogues activate protein tyrosine phosphorylation and release of 
arachidonic acid in mast cells via a novel protein kinase C and 
phosphatidylinositol 3 -kinase-dependent mechanism. Eur J Immunol, 28， 
3468-78. 
SHEN, R，GUO, B.L., GONG, Y., HONG, D.Y., HONG, Y. & YONG, E l . (2007). 
Taxonomic, genetic, chemical and estrogenic characteristics of Epimedium 
species. Phytochemistry, 68，1448-58. 
SHU, L., GUAN, S.M., Fu, S.M., Guo, T., CAO, M. & Dn^G, Y. (2008). Estrogen 
modulates cytokine expression in human periodontal ligament cells. J Dent 
Res, 87,142-7. 
Sn^ BERSTEn^ , R., MELNICK，M., GREENBERG, G. & MDOTN，C. (1991). Bone 
remodeling in W/Wv mast cell deficient mice. Bone, 12, 227-36. 
SMMONDS, R.E. & F0XWELL, B.M. (2008). Signalling, inflammation and arthritis: 
NF-kappaB and its relevance to arthritis and inflammation. Rheumatology 
(Oxford), 47，584-90. 
185 
SMONS, F.E. (2003). H1 - Antihistamines: more relevant than ever in the treatment of 
allergic disorders. JAllergy Clin Immunol, 112, S42-52. 
Smis, E., ADACHI, J.D., LU,Y., FUERST, T., CRANS, G.G., WONG, M.，HARPER, K.D. & 
GENANT, H.K. (2002). Effects of raloxifene on fracture severity in 
postmenopausal women with osteoporosis: results from the MORE study. 
Multiple Outcomes ofRaloxifene Evaluation. Osteoporos Int, 13，907-13. 
SOLOMON, RR., ADAMS, R, SDJVER, A.，ZMMER, J. & DEVEAUX，R. (2002). Ginkgo 
for memory enhancement: a randomized controlled trial. Jama, 288, 835-40. 
STOCH, S.A., ZAJIC, S., STONE, J., MnXER，Dl.，VANDYCK, K., GUTIERREZ, M.J., DE 
DECKER, M., LRJ, L., Lnj, Q., SCOTT, B.B., PANEBIANCO, D., ]JN, B., DUONG， 
L.T., GOTTESDIENER, K. & WAGNER，J.A. (2009). Effect of the cathepsin K 
inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal 
women: two double-blind, randomized, placebo-controlled phase I studies. 
Clin Pharmacol Ther, 86，175-82. 
SUGANXJMA, M.，OKABE, S., SUEOKA, E., lE)A, N., KOMORI, A., KM, SJ. & FUHKI，H. 
(1996). A new process of cancer prevention mediated through inhibition of 
tumor necrosis factor alpha expression. Cancer Res, 56, 3711-5. 
SUN, Y., LEE, S.M., WONG, Y.M., LAU, C.R, SHAW, RC., QES[, L., LEUNG, RC. & FUNG, 
K.P. (2008). Dosing effects of an antiosteoporosis herbal formula--a 
preclinical investigation using a rat model. Phytother Res, 22，267-73. 
SUURONEN, T., NwnNEN, T., HUUSKONEN, J., OJALA, J., THORNELL, A. & SALMmEN， 
A. (2005). Anti-inflammatory effect of selective estrogen receptor modulators 
(SERMs) in microglial cells. Inflamm Res, 54，194-203. 
SUZUKI, A.，SEKIGUCHI, S., ASANO, S. & lTOH, M. (2008). Pharmacological topics of 
bone metabolism: recent advances in pharmacological management of 
osteoporosis. JPharmacol Sci, 106, 530-5. 
TAKAYANAGI, H. (2009). Osteoimmunology and the effects of the immune system on 
bone. Nat Rev Rheumatol, 5，667-76. 
TEODOSIO, C., GARCIA-MONTERO, A.C., JARA-ACEVEDO, M.，SANCHEZ-MUNOZ, L., 
ALVAREZ-TWOSE, I., NUNEZ, R., SCHWARTZ, L.B., WALLS, A.F., ESCRIBANO,L. 
& ORFAO，A. (2010). Mast cells from different molecular and prognostic 
subtypes of systemic mastocytosis display distinct inununophenotypes. J 
Allergy Clin Immunol, 125，719-26，726 el-726 e4. 
THOMPSON, D.D.，SMMONS, H.A., PRIE, C.M. & KE，H.Z. (1995). FDA Guidelines 
and animal models for osteoporosis. Bone, 17, 125S-133S. 
TniTNEN，A., NnCANDER, E., HlETANEN, R，METSA-HEIKKILA, M, & YUKORKALA, 0. 
(2004). Changes in bone mineral density during and after 3 years' use of 
tamoxifen or toremifene. Maturitas, 48，321-7. 
186 
TODOROVA, V.K., KAUFMANN, Y., Luo, S. & SUZANNE KLIMBERG, V. Tamoxifen and 
raloxifene suppress the proliferation of estrogen receptor-negative cells 
through inhibition of glutamine uptake. Cancer Chemother Pharmacol 
VENDEUN，J.，LAmNEN, C., VAmiO, RJ., NlSSE^N, E., MAKI, T. & EKLUND, K.K. 
(2005). Novel sulfliydryl-reactive compounds orazipone and OR-1958 inhibit 
cytokine production and histamine release in rat and human mast cells. Int 
Immunopharmacol, 5，177-84. 
VLIAGOFTIS, H.，DMITRIADOU, V., BOUCHER, W., ROZNIECKI, J.J., CORREIA, I., RAAM, 
S. & THEOHARroES，T.C. (1992). Estradiol augments while tamoxifen inhibits 
rat mast cell secretion. Int Arch Allergy Immunol 98, 398-409. 
WAGNER, E.M. (2000). TNF-alpha induced bronchial vasoconstriction. Am J Physiol 
Heart Circ Physiol, 279, H946-51. 
WALSH, B.W, Cox, D.A., SASHEGYI, A , DEAN, R.A., TRACY, R.R & ANDERSON，RW. 
(2001). Role oftumor necrosis factor-alpha and interleukin-6 in the effects of 
hormone replacement therapy and raloxifene on C-reactive protein in 
postmenopausal women. Am J Cardiol, 88, 825-8. 
WANG, J., VAN DER HEIJDEN, R., SPRUIT, S., HANKERMEIER, T., CHAN, K.，VAN DER 
GREEF，J.，Xu, G. & WANG，M. (2009). Quality and safety of Chinese herbal 
medicines guided by a systems biology perspective. JEthnopharmacol, 126， 
31-41. 
WANG, J., WANG, N.L., YAO，X.S., ISHII, R. & KlTANAKA, S. (2006a). Inhibitory 
activity ofChinese herbal medicines toward histamine release from mast cells 
and nitric oxide production by macrophage-like cell line, RAW 264.7. J Nat 
Med, 60, 73-77. 
WANG, X.S.，Yn>, K.H., SAM, S.W. & LAU, H.Y. (2006b). Buffy coat preparation is a 
convenient source of progenitors for culturing mature human mast cells. J 
Immunol Methods, 309, 69-74. 
WANG, Y.K. & HUANG,Z.Q. (2005). Protective effects oficariin on human umbilical 
vein endothelial cell injury induced by H202 in vitro. Pharmacol Res, 52, 
174-82. 
WELLE, M. (1997). Development, significance, and heterogeneity of mast cells with 
particular regard to the mast cell-specific proteases chymase and tryptase. J 
Leukoc Biol, 61, 233-45. 
WHO (2004). Overview. In WHO scientific group on the assessment ofosteoporosis. 
Brussels, Belgium: World Health Organization. 
WlLLlAMS, C.M. & COLEMAN，J.W. (1995). Induced expression of mRNA for IL-5, 
IL-6, TNF-alpha, MIP-2 and IFN-gamma in immunologically activated rat 
peritoneal mast cells: inhibition by dexamethasone and cyclosporin A. 
187 
Immunology, 86, 244-9. 
Wn^ SLOW, L.C. & KROLL, D.J. (1998). Herbs as medicines. Arch Intern Med, 158, 
2192-9. 
WONG, R.W. & RABIE, A.B. (2009). Effect of Buguzhi (Psoralea corylifolia fruit) 
extract on bone formation. Phytother Res. 
W00DffiL, F.N., FALL, P.M. & RAISZ,L.G. (1996). Anabolic effects ofprostaglandins 
in cultured fetal rat calvariae: structure-activity relations and signal 
transduction pathway. JBone Miner Res, 11, 1249-55. 
WRIGHT, D.H., METTERS, K.M., ABRAMOVITZ, M. & FORD-HUTCfflNSON，A.W. 
(1998). Characterization of the recombinant human prostanoid DP receptor 
and identification ofL-644,698, a novel selective DP agonist. BrJPharmacol, 
123，1317-24. 
Wu, H., LlEN, E.J. & LlEN，L.L. (2003). Chemical and pharmacological investigations 
ofEpimedium species: a survey. Prog Drug Res, 60, 1-57. 
XlE，R, Wu, C.R, LAI, W.R, YANG, X.J., CHEUNG, RY., YAO, X.S., LEUNG, RC. & 
WONG, M.S. (2005). The osteoprotective effect of Herba epimedii (HEP) 
extract in vivo and in vitro. Evid Based Complement Altemat Med, 2, 353-61. 
XJN, D.，WANG, H.，YANG, J.，Su, Y.R, FAN, G.W., WANG, Y.F., ZHU, Y. & GAO, X.M. 
(2010). Phytoestrogens from Psoralea corylifolia reveal estrogen 
receptor-subtype selectivity. Phytomedicine, 17，126-31. 
Xu, C.Q.，Lm, BJ., WU, J.R, Xu, Y.C., DUAN, X.H., CAO, YX. & DONG，J.C. (2010). 
Icariin attenuates LPS-induced acute inflammatory responses: Involvement of 
PI3K/Akt and NF-kappaB signaling pathway. Eur JPharmacoL 
YAN, F.R, LnJ, Y., LDJ, Y.F. & ZHAO，Y.X. (2008). Herba Epimedii water extract 
elevates estrogen level and improves lipid metabolism in postmenopausal 
women. PhytotherRes, 22，1224-8. 
YANG, Y.，Lm, N., Mo, Z.，XlE, J., LlAO, J. & Mo，S. (2006). Influence of a Chinese 
crude drug on Ca2+ influx and efflux in rat visceral organs: investigation and 
evaluation by45Ca. Appl 'Radiat Isot, 64，241-6. 
Ym, T.K., Wu, W.K., PAK, W.R & Ko，K.M. (2001). Hepatoprotective action ofan 
oleanolic acid-enriched extract of Ligustmm lucidum fruits is mediated 
through an enhancement on hepatic glutathione regeneration capacity in mice. 
PhytotherRes, 15, 589-92. 
ZAITSU, M., NARITA, S., LAMBERT, K.C., GRADY, J.J., ESTES, D.M., CURRAN, E.M., 
BROOKS, E.G., WATSON, C.S., GOLDBLUM, R.M. & MH)ORO-HORKJTI, T. 
(2007). Estradiol activates mast cells via a non-genomic estrogen 
receptor-alpha and calcium influx. Mol Immunol, 44，1977-85. 
ZHANG, C.Z., WANG, S.X., ZHANG, Y., CHEN, J.P. & LlANG，X.M. (2005). In vitro 
188 
estrogenic activities of Chinese medicinal plants traditionally used for the 
management of menopausal symptoms. JEthnopharmacol, 98，295-300. 
ZHANG, J.R, Ll, G., MENG, C.L., DONG, Q., CHAN, C.Y., HE, M . L.，L E U N G , P.C., 
ZHANG, Y.0. & KUNG，H.R (2009). Total flavonoids of Herba Epimedii 
improves osteogenesis and inhibits osteoclastogenesis ofhuman mesenchymal 
stem cells. Phytomedicine, 16，521-9. 
ZHANG, P., Ll, H., CHEN, D., Nl, J., KANG, Y. & WANG，S . (2007). Oleanolic acid 
induces apoptosis in human leukemia cells through caspase activation and 
poly(ADP-ribose) polymerase cleavage. Acta Biochim Biophys Sin (Shanghai), 
39，803-9. 
ZHANG, Y., LAI, W.R, LEUNG, P.C., Wu, C.R, YAO, X.S. & WONG, M.S. (2006). 
Effects of Fructus Ligustri Lucidi extract on bone tumover and calcium 
balance in ovariectomized rats. Biol Pharm Bull, 29, 291-6. 
ZHANG, Y., LEUNG, P.C., CHE, C.T.，CHOW, H.K., WU, C.F. & WONG, M.S. (2008). 
Improvement of bone properties and enhancement of mineralization by 
ethanol extract ofFructus Ligustri Lucidi. BrJNutr, 99，494-502. 
ZHAO, F., TANG, Y.Z. & Lru，Z.Q. (2007a). Protective effect of icariin on DNA against 
radical-induced oxidative damage. JPharm Pharmacol, 59, 1729-32. 
ZHAO, G., Ll, S., QlN, G.W., FEI, J. & GUO，L.H. (2007b). Inhibitive effects ofFructus 
Psoraleae extract on dopamine transporter and noradrenaline transporter. J 
Ethnopharmacol, 112，498-506. 
ZHAO, X J . , MCKERR, G., DONG, Z., HKKHNS，C.A., CARSON, J.，YANG, Z.Q. & 
HANNIGAN, B.M. (2001). Expression o f oestrogen and progesterone receptors 
by mast cells alone, but not lymphocytes, macrophages or other immune cells 
in human upper airways. Thorax, 56, 205-11. 
ZHENG, S.X., VRJNDTS, Y.，LOPEZ, M., DE GROOTE, D., ZANGERLE, R R , COLLETTE, J., 
FRANCHMONT, N., GEENEN, V.’ ALBERT, A. & REGESTSTER，J.Y. (1997). 
Increase in cytokine production (IL-1 beta, IL-6, TNF-alpha but not 
IFN-garmna, GM-CSF or LIF) by stimulated whole blood cells in 
postmenopausal osteoporosis. Maturitas, 26，63-71. 
ZUCKERMAN, S.H.，BRYAN-POOLE, N., EVANS, G.R, SHORT, L. & GLASEBROOK，八丄. 
(1995). Li vivo modulation of murine serum tumour necrosis factor and 
interleukin-6 levels during endotoxemia by oestrogen agonists and antagonists. 
Immunology, 86, 18-24. 
189 
―聊:_l^ ^ 
. 界‘1 '^  / 广 7 . ^ : ' * V � h , i t � \ > / > : � , 
^ ‘ ^ * ‘^^  \ " : ; . � ‘ i , < . . , � 
• H « ^ ^ .^^ '1 ^ � � � “ 
•• - -i. . • •. 、..… ,.’..、 、、-..,> ,：• „ .,}•••' .•.•：一的凡礼,.‘一".-”:八4* '.•，） . " * .>/_^-'V.-,,. . .,,¾ ^ “ 1^ ^ 。 ； ‘ r - - ： � , ^  
,. = •, . . • . '.. ' , - . , . . , : , . : •. - - - _T*': 、，、.：^...;>"i: ;;-.. 、‘,， i � .； 
....:. ,) , ‘‘. . • ：• ' r - r ‘ ‘ C < 
.. . ‘ - 心 " 丨 、 ‘” ： 
‘ - ^ ^ ‘ � 
, t • • ‘ ， / l e — '•• •- • - - .. f . - . 
M- j • - I , '1 ‘ • i'"j - «• 
. :..,' . �L , . I'i , , ‘ . ；• • V 片•兄 ..•‘ ‘ • j :r ... 
... .. ‘.. . - . . . , . . . ^ . r i � "• . •• <:^ i^ .:..:.4 
• . • . •: ： . .....A � ：:..H. :.X“.（.：. . ... . i 
•• • +•“ •"/•. _ "- 、. ’ 'I '.二." •-, 、 ‘ . ：  '.! •‘ : . .,.: ； . ‘ • : 
• . . . • ‘ :-. . , . “： ‘ > - ： ‘^ . -: ..•‘ 』， ‘ V . - •卢‘ .• ." ， 
•0: . '• • • _, ‘一 ‘ 二严,..• _ ‘ 
• -'、• .  . , . - • .' .• . ’ ;, [. ：： ... • r '• ‘ 1, / 1 一 ’ 
• . . - . ‘ 、， . .： ••• . w I ， 〜 . . 1 
. ‘ . «‘ . . ‘ .v •-' , •‘ Y.-.、 ； . 
•资 -
” • , . • . , :,>• . . "I ’•: '• . . •�: ..'� � . • � . , :• “ -. . t ‘ • . . ‘ � .. :l � - “ • ‘ . 
t .‘丨 一 i , , ‘ 
‘ - - : . .、 . . . . . . . > ； • ‘.. ： ‘ • • . , ‘ 』 . 
� ‘- -. � • “ 
. ‘ •_ ‘ (• .. • . , • .,. . � 
‘ • •； 
‘ • •“ , ’ : • ^ ‘ .i ,, . .y ‘ •• • ‘ • -. ,. : t : 
, • 子 •’ . •务. ‘ •> . J . •‘ 
•-、 ‘ . . .J - ‘ . • 二 •  V -1 S«| 
. . .、-、•." • -••：' 
“ ....> 
. ：， .. •'.' • :‘ : • • ., , ,' ‘ . ： . • . . • _ - > .‘ '.. � i 
. . . . . . - • ,. . < • �� 
, \ . : . . .. .• • ‘ ： 
’ .， ) 
- .‘： ，. . ， ‘ ^ 
•: ‘ � • - -, . , 
• • ！、 • 
_ . - - .. . •： .. � , . ； - •,•：' i ‘ - • , • • , r - ： . •-： 1 . ’ 
- -• _ • ‘ ^ • . , 二 . .• • '^  . I 
'••• ， ^ ‘ 丨. .i 
• ： • 、：：. 
..-'“ ‘ , • , . _ -- .. 
- • : ‘:. !• 
-.. 、 ‘ .‘ • • .1 ；： 
- ‘ • . : 、 、 . ‘ , . . ‘ ‘ ., - • : ‘ .^ 
, ‘ - � ‘‘ 
• “‘ _ . '. . , ‘ ‘ . I 
• 、 , , ‘ - ,:. , J 
. ‘ . . . “ ‘ . . ; . V . 4 j 
• “ . ‘ 
- ？ • . . • „• I. 
• - . '• • . - - ； � • , • . . . ‘. .w, : "- . • - , • I L ‘ , . - _ 
. ‘ .• - 丁 ： . . 
. � ,•', ... V ... . — • : . • l' . • • - ^： . r ..: 
‘ . • . - ._ ••‘‘‘ . •- ‘ . . - . _ ••丨 J 
- • . ‘ •:。，‘ � - •' . V. > 
• - •• • -. • ‘ ‘ I 1 
• -1 • ^‘ : 
‘ .. , : • . 
. - - • • - < . . . i  
: ‘ - . . . • • , : 
. ‘ • , •- . “^  : . � . . • • ,: • , ; . . . •• . •• • ‘ ‘ ‘‘ • ‘ _ I' ,. ,. ., I 介 •• ' • • _, ., V 1 
‘ . ‘1 _. 'I •.:‘— • ,j 
• j . •• • ‘ 
•• _ , ‘ • • • ‘ . ..' •'： -、 _. • ‘. •  .、； 't ,-. L-• , •-• ‘ . T '. •. . v  • •• y• . ^ • . - ^ . . . • . ‘ • I ‘ . i - • . • ： • . . I . ：」 . ,.- - . - . . - . • - • •‘ . . • � .. • , .. I I •‘ •• , .—  • ‘ 1丨  .... '- ^ ’ ’ - ,. 广•-•• • .= ：•'.,‘ . ,.. - , '  : ‘ ^ ^ : “ . ^ . ’, ‘ - • - > ‘ :‘ ""•..’. > [-  1• .. U^-^ •• J ‘ . . ,.li- ‘I I • . . ‘ ‘ - . . ! - , • .. :,-i  , ：： i' •> . '• >* . •:‘ \• ,. • .：： . . • . ' r^ | ‘ , .'?. : •.  .••..' ‘ ‘ - . _ , ？…I .. . • { 5,  -'*.-•• • . • • . . . . • . . ‘ •^ 广 ‘ ”. . . ‘‘ - . ‘ .• '• .. . ,  :.： :' .. 丨丨 l'  . - -. 'Tj  •‘ ‘ ‘ '• ^ •「 • :、：- ,..i, , 拉 ^- ‘ 厂 ^ :‘ , .: |:_ ..... ”  > +. • ‘ '^  V : • . • ...-. •. - '- ''- , ， .  V- .. ‘ ？. . L 广 J �‘ , , '• M^  ^ ^‘ . , •' • - . %" . �i. ‘ . �f ‘ i ^ . ， ^i .• . - - . -• •,  • • ••••'/ , it> �^ u “ �p 1• ‘ .• - '•.... . .  ‘？：， ，,, • :7><- ' :^ :tf: V H i H <f *- . . . ‘ ,. “ ‘ . . ^ v , ‘ r ^ i , ^- . , ..• - • : • • - ( , ^ — »  ^ ' » ... ,• .,. :: I 'V :.•'   ‘ - ； , ' ” ^ ^ : f 1，， ，她 ";& :fc^ S^^ tf
CUHK L i b r a r i e s 
____l I 004779138 | 
j “ 
.i 
3 
